=> fil reg
FILE 'REGISTRY' ENTERED AT 10:34:13 ON 24 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 APR 2003 HIGHEST RN 504385-01-7
DICTIONARY FILE UPDATES: 23 APR 2003 HIGHEST RN 504385-01-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN **175175-73-2** REGISTRY
CN L-Aspartic acid, L-phenylalanyl-L-isoleucyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Aspartic acid, N-(N-L-phenylalanyl-L-isoleucyl)-
OTHER NAMES:
CN 56: PN: WO9958679 SEQID: 13 claimed sequence
FS STEREOSEARCH
MF **C19 H27 N3 O6**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 131:350265

REFERENCE 2: 124:257898

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:34:26 ON 24 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 24 Apr 2003  VOL 138 ISS 17
FILE LAST UPDATED: 23 Apr 2003  (20030423/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d all hitstr tot l25

L25  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2003 ACS
AN   1999:736930  HCAPLUS
DN   131:350265
TI   Antibodies to CD23
IN   Bonnefoy, Jean-Yves Marcel Paul; Crowe, Scott James; Ellis,
     Jonathan Henry; Rapson, Nicholas Timothy; Shearin,
     Jean
PA   Glaxo Group Limited, UK
SO   PCT Int. Appl., 81 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  C12N015-13
     ICS  C07K016-28; A61K039-395; C12N015-62
CC   15-3 (Immunochemistry)
     Section cross-reference(s): 3
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 9958679         A1   19991118      WO 1999-GB1434   19990507
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
             MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2328606          AA   19991118      CA 1999-2328606  19990507
     AU 9938367          A1   19991129      AU 1999-38367    19990507
     BR 9910327          A    20010130      BR 1999-10327    19990507
     EP 1076701          A1   20010221      EP 1999-920991   19990507
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     EE 200000658        A    20020415      EE 2000-20000065819990507
```

	NO 2000005632	A	20010108	NO 2000-5632	20001108
PRAI	GB 1998-9839	A	19980509		
	WO 1999-GB1434	W	19990507		

AB The authors disclose the prepn. and characterization of murine monoclonal and humanized antibodies which bind to the CD23 (Fc.epsilon.RII receptor) antigen. In one example, humanized IgG1, with mutations to eliminate C1q and Fc binding, was shown to bind to CD23 with assocn. rates of the order of 1.5-1.85 x 106 M-1 s-1 and to not exhibit complement activation or ADCC. The authors suggest these antibodies may find use in the treatment of autoimmune and inflammatory disorders.

ST antibody CD23 antigen; FcepsilonRII receptor antibody

IT Antitumor agents
(B-cell leukemia; anti-CD23 antibodies as)

IT Antitumor agents
(B-cell lymphoma; anti-CD23 antibodies as)

IT Intestine, disease
(Crohn's; anti-CD23 antibodies in treatment of)

IT Immunoglobulin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IgE type II, sol.; prepn. and characterization of antibodies to)

IT Immunoglobulin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IgE type II; prepn. and characterization of antibodies to)

IT Allergy inhibitors
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
(anti-CD23 antibodies as)

IT Dermatitis
Eczema
Psoriasis
Sjogren's syndrome
Urticaria
(anti-CD23 antibodies in treatment of)

IT Thyroid gland, disease
(autoimmune thyroiditis; anti-CD23 antibodies in treatment of)

IT Bronchi
(bronchitis; anti-CD23 antibodies in treatment of)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric; to CD23 on hematopoietic cells)

IT Lung, disease
(chronic obstructive; anti-CD23 antibodies in treatment of)

IT Kidney, disease
(glomerulonephritis; anti-CD23 antibodies in treatment of)

IT Transplant and Transplantation
(graft-vs.-host reaction; anti-CD23 antibodies in treatment of)

IT Immunoglobulins
RL: PRP (Properties)
(heavy chains, CDR; of antibodies to CD23)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized; to CD23 on hematopoietic cells)

Intestine, disease
(inflammatory; anti-CD23 antibodies in treatment of)

Pancreatic islet of Langerhans

(insulitis; anti-CD23 antibodies in treatment of)
IT Immunoglobulins
RL: PRP (Properties)
(light chains, CDR; of antibodies to CD23)
IT Kidney, disease
(nephrotic syndrome; anti-CD23 antibodies in treatment of)
IT Protein sequences
cDNA sequences
(of antibody fragments to CD23)
IT Blood cell
(prepn. and characterization of antibodies to CD23 of)
IT Nose
(rhinitis; anti-CD23 antibodies in treatment of)
IT Lupus erythematosus
(systemic; anti-CD23 antibodies in treatment of)
IT Multiple sclerosis
(therapeutic agents; anti-CD23 antibodies as)
IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(to CD23 on hematopoietic cells)
IT Intestine, disease
(ulcerative colitis; anti-CD23 antibodies in treatment of)
IT Eye, disease
(uveitis; anti-CD23 antibodies in treatment of)
IT 250332-00-4 250332-01-5 250332-02-6 250332-03-7
RL: PRP (Properties)
(amino acid sequence; anti-CD23 antibodies as)
IT 250332-04-8 250332-05-9 250332-06-0 250332-07-1
RL: PRP (Properties)
(nucleotide sequence; anti-CD23 antibodies as)
IT **175175-73-2** 201468-24-8, LMSTRAS 250143-97-6, RSSKSLLYKDGKTYLN 250143-98-7, QQLVEYPFT 250143-99-8, GYWMS 250144-00-4, EIRLKSDNYATHYAESVKG
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(of antibodies to CD23)
IT 250242-61-6, CGCTCGAGTAAGAGTCTCCTGTATAAGGATGGGAAGACATACTTGAAT 250242-63-8, TTGATGTCCACCCGGGCATCA 250242-65-0, CAACAGCTGGTAGAGTATCCATTCACG 250242-67-2, GGCTACTGGATGTCC 250242-69-4, GAAATTAGATTGAAATCTGATAATTATGCAACACATTATGCGGAGTCT 250242-71-8, TTCATAGAC
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(of nucleic acid encoding antibodies to CD23)
IT 162565-25-5, GenBank A18463 162565-71-1, GenBank A18479 162565-72-2, GenBank A18480 250332-75-3 250382-76-4 250382-77-5 250382-78-6 250382-79-7 250382-81-1 250382-82-2 250382-83-3 250382-84-4 250382-85-5 250382-88-8 250382-89-9 250382-90-2 250382-91-3 250382-92-4 250382-93-5 250382-94-6 250382-95-7 250382-96-8
RL: PRP (Properties)
(unclaimed nucleotide sequence; antibodies to CD23)
IT 247166-37-6 250253-00-0 250253-04-4 250253-05-5 250253-06-6 250253-07-7
RL: PRP (Properties)
(unclaimed sequence; antibodies to CD23)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Bonnefoy, J; The Journal of Immunology 1987, V138(9), P2970 HCAPLUS
Flores-Romo, L; Science 1993, V261(5124), P1038 HCAPLUS
Glaxo Group Ltd; WO 9612741 A 1996 HCAPLUS
Idec Pharmaceuticals; WO 9302108 A 1993 HCAPLUS
Idec Pharmaceuticals Corp; WO 9837099 A 1998 HCAPLUS

(6) Plater-Zyberk, C; Nature Medicine 1995, V1(8), P781 HCAPLUS

IT **175175-73-2**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(of antibodies to CD23)

RN 175175-73-2 HCAPLUS

CN L-Aspartic acid, L-phenylalanyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS

AN 1996:188211 HCAPLUS

DN 124:257898

TI Structural aspects of antibody-antigen interaction revealed through small random peptide libraries

AU Slootstra, Jerry W.; Puijk, Wouter C.; Ligtvoet, Gerard; Langeveld, Jan P. M.; Meloen, Rob H.

CS Dep. Molecular Recognition, Institute Animal Science Health, Lelystad, 8200 AB, Neth.

SO Molecular Diversity (1996), 1(2), 87-96
CODEN: MODIF4; ISSN: 1381-1991

PB ESCOM

DT Journal

LA English

CC 15-2 (Immunochemistry)

AB Two small random peptide libraries, one composed of 4550 dodecapeptides and one of 8000 tripeptides, were synthesized in newly developed credit-card format miniPEPSCAN cards (miniPEPSCAN libraries). Each peptide was synthesized in a discrete well (455 peptides/card). The 2 miniPEPSCAN libraries were screened with 3 different monoclonal antibodies (Mabs). Two other random peptide libraries, expressed on the wall of bacteria (recombinant libraries) and composed of 107 hexa- and octapeptides, were screened with the same 3 Mabs. The aim here was to compare the amino acid sequence of peptides selected from small and large pools of random peptides and, in this way, investigate the potential of small random peptide libraries. The screening of the 2 miniPEPSCAN libraries resulted in the identification of a surprisingly large no. of antibody-binding peptides, while the screening of the large recombinant libraries, using the same Mabs, resulted in the identification of only a small no. of peptides. The large no. of peptides derived from the small random peptide libraries allowed the detn. of consensus sequences. These consensus sequences could be related to small linear and nonlinear parts of the resp. epitopes. The small no. of peptides derived from the large random peptide libraries could only be related to linear epitopes that were previously mapped using small libraries of overlapping peptides covering the antigenic protein. Thus, with respect to the cost and speed of identifying peptides that resemble linear and nonlinear parts of epitopes, small diversity libraries based on synthetic peptides appear to be superior to large diversity libraries based on expression systems.

ST antibody antigen random peptide library

IT Combinatorial library
(structural aspects of antibody-antigen interaction revealed through small random peptide libraries)

IT Antibodies
Antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(structural aspects of antibody-antigen interaction revealed through small random peptide libraries)

IT 6403-09-4 19240-46-1 21658-46-8 28130-14-5 28782-83-4 28836-80-8
34337-48-9 35039-58-8 41961-61-9 42061-45-0 50842-15-4
55024-00-5 61756-30-7 65148-40-5 66438-40-2 70902-10-2
73717-26-7 74075-24-4 82261-72-1 85051-47-4 85530-41-2
85530-73-0 85530-96-7 85775-46-8 85806-89-9 85807-04-1
85807-09-6 85807-25-6 85807-26-7 85807-28-9 85807-30-3
88872-13-3 90236-06-9 92172-16-2 95034-41-6 101269-37-8
102610-64-0 105219-98-5 105803-00-7 108885-18-3 108885-48-9
109656-19-1 115945-15-8 116685-16-6 116685-23-5 116720-17-3
117439-87-9 121998-03-6 122061-62-5 122605-96-3 123195-97-1
123195-99-3 123462-67-9 124234-69-1 126705-31-5 127103-07-5
130050-12-3 130535-12-5 130535-13-6 130535-14-7 130535-21-6
130535-22-7 130535-23-8 130535-28-3 130944-63-7 132105-45-4
138168-51-1 140716-03-6 140716-06-9 140716-07-0 140716-10-5
141892-46-8 147049-30-7 147637-66-9 148696-80-4 149095-93-2
149756-66-1 151937-82-5 151937-97-2 155893-12-2 156039-60-0
157535-06-3 158754-37-1 159718-11-3 159954-37-7 160112-37-8
163217-42-3 164288-87-3 166891-94-7 169199-75-1 172781-49-6
173923-64-3 175172-72-2 175172-73-3 175172-74-4 175172-75-5
175172-76-6 175172-77-7 175172-78-8 175172-79-9 175172-80-2
175172-81-3 175172-82-4 175172-83-5 175172-84-6 175172-85-7
175172-86-8 175172-87-9 175172-88-0 175172-89-1 175172-90-4
175172-91-5 175172-92-6 175172-93-7 175172-94-8 175172-95-9
175172-96-0 175172-97-1 175172-98-2 175172-99-3 175173-00-9
175173-01-0 175173-02-1 175173-03-2 175173-04-3 175173-05-4
175173-06-5 175173-07-6 175173-08-7 175173-09-8 175173-10-1
175173-11-2 175173-12-3 175173-13-4 175173-14-5 175173-15-6
175173-16-7 175173-17-8 175173-18-9 175173-19-0 175173-20-3
175173-21-4 175173-22-5 175173-23-6 175173-24-7 175173-25-8
175173-26-9 175173-27-0 175173-28-1 175173-29-2 175173-30-5
175173-31-6 175173-32-7 175173-33-8 175173-34-9 175173-35-0
175173-36-1 175173-37-2 175173-38-3 175173-39-4 175173-40-7
175173-41-8 175173-42-9 175173-43-0 175173-44-1 175173-45-2
175173-46-3 175173-47-4 175173-48-5 175173-49-6 175173-50-9
175173-51-0 175173-52-1 175173-53-2 175173-54-3 175173-55-4
175173-56-5 175173-57-6 175173-58-7 175173-59-8 175173-60-1
175173-61-2 175173-62-3 175173-63-4 175173-64-5 175173-65-6
175173-66-7 175173-67-8 175173-68-9 175173-69-0 175173-70-3
175173-71-4 175173-72-5 175173-73-6 175173-74-7 175173-75-8
175173-76-9 175173-77-0 175173-78-1 175173-79-2 175173-80-5
175173-81-6 175173-82-7 175173-83-8 175173-84-9 175173-85-0
175173-86-1 175173-87-2 175173-88-3 175173-89-4 175173-90-7
175173-91-8 175173-92-9 175173-93-0 175173-94-1 175173-95-2
175173-96-3 175173-97-4 175173-98-5 175173-99-6 175174-00-2
175174-01-3 175174-02-4 175174-03-5 175174-04-6 175174-05-7
175174-06-8 175174-07-9 175174-08-0 175174-09-1 175174-10-4
175174-11-5 175174-12-6 175174-13-7 175174-14-8 175174-15-9
175174-16-0
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(structural aspects of antibody-antigen interaction revealed through small random peptide libraries)

IT 175174-17-1 175174-18-2 175174-19-3 175174-20-6 175174-21-7

175174-22-8 175174-23-9 175174-24-0 175174-25-1 175174-26-2
175174-27-3 175174-28-4 175174-29-5 175174-30-8 175174-31-9
175174-32-0 175174-33-1 175174-34-2 175174-35-3 175174-36-4
175174-37-5 175174-38-6 175174-39-7 175174-40-0 175174-41-1
175174-42-2 175174-43-3 175174-44-4 175174-45-5 175174-46-6
175174-47-7 175174-48-8 175174-49-9 175174-50-2 175174-51-3
175174-52-4 175174-53-5 175174-54-6 175174-55-7 175174-56-8
175174-57-9 175174-58-0 175174-59-1 175174-60-4 175174-61-5
175174-62-6 175174-63-7 175174-64-8 175174-65-9 175174-66-0
175174-67-1 175174-68-2 175174-69-3 175174-70-6 175174-71-7
175174-72-8 175174-73-9 175174-74-0 175174-75-1 175174-76-2
175174-77-3 175174-78-4 175174-79-5 175174-80-8 175174-81-9
175174-82-0 175174-83-1 175174-84-2 175174-85-3 175174-86-4
175174-87-5 175174-88-6 175174-89-7 175174-90-0 175174-91-1
175174-92-2 175174-93-3 175174-94-4 175174-95-5 175174-96-6
175174-97-7 175174-98-8 175174-99-9 175175-00-5 175175-01-6
175175-02-7 175175-03-8 175175-04-9 175175-05-0 175175-06-1
175175-07-2 175175-08-3 175175-09-4 175175-10-7 175175-11-8
175175-12-9 175175-13-0 175175-14-1 175175-15-2 175175-16-3
175175-17-4 175175-18-5 175175-19-6 175175-20-9 175175-21-0
175175-22-1 175175-23-2 175175-24-3 175175-25-4 175175-26-5
175175-27-6 175175-28-7 175175-29-8 175175-30-1 175175-31-2
175175-32-3 175175-33-4 175175-34-5 175175-35-6 175175-36-7
175175-37-8 175175-38-9 175175-39-0 175175-40-3 175175-41-4
175175-42-5 175175-43-6 175175-44-7 175175-45-8 175175-46-9
175175-47-0 175175-48-1 175175-49-2 175175-50-5 175175-51-6
175175-52-7 175175-53-8 175175-54-9 175175-55-0 175175-56-1
175175-57-2 175175-58-3 175175-59-4 175175-60-7 175175-61-8
175175-62-9 175175-63-0 175175-64-1 175175-65-2 175175-66-3
175175-67-4 175175-68-5 175175-69-6 175175-70-9 175175-71-0
175175-72-1 **175175-73-2** 175175-74-3 175175-75-4
175175-76-5 175175-77-6 175175-78-7 175175-79-8 175175-80-1
175175-81-2 175175-82-3 175175-83-4 175175-84-5 175175-85-6
175175-86-7 175175-87-8 175175-88-9 175175-89-0 175175-90-3
175175-91-4 175175-92-5 175175-93-6 175175-94-7 175175-95-8
175175-96-9 175175-97-0 175175-98-1 175175-99-2 175176-00-8
175176-01-9 175176-02-0 175176-03-1 175176-04-2 175176-05-3
175176-06-4 175176-07-5 175176-08-6 175176-09-7 175176-10-0
175176-11-1 175176-12-2 175176-13-3 175176-14-4 175176-15-5
175176-16-6 175176-17-7 175176-18-8 175176-19-9 175176-20-2
175176-21-3 175176-22-4 175176-23-5 175176-24-6 175176-25-7
175176-26-8 175176-27-9 175176-28-0 175176-29-1 175176-30-4
175176-31-5 175176-32-6 175176-33-7 175176-34-8 175176-35-9
175176-36-0 175176-37-1 175176-38-2 175176-39-3 175176-40-6
175176-41-7 175176-42-8 175176-43-9 175176-44-0 175176-45-1
175176-46-2 175176-47-3 175176-48-4 175176-49-5 175176-50-8
175176-51-9 175176-52-0 175176-53-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(structural aspects of antibody-antigen interaction revealed through small random peptide libraries)

IT 175176-54-2 175176-55-3 175176-56-4 175176-57-5 175176-58-6
175176-59-7 175176-60-0 175176-61-1 175176-62-2 175176-63-3
175176-64-4 175176-65-5 175176-66-6 175176-67-7 175176-68-8
175176-69-9 175176-70-2 175176-71-3 175176-72-4 175176-73-5
175176-74-6 175176-75-7 175176-76-8 175176-77-9 175176-78-0
175176-79-1 175176-80-4 175176-81-5 175176-82-6 175176-83-7
175176-84-8 175176-85-9 175176-86-0 175176-87-1 175176-88-2
175176-89-3 175176-90-6 175176-91-7 175176-92-8 175176-93-9
175176-94-0 175176-95-1 175176-96-2 175176-97-3 175176-98-4
175176-99-5 175177-00-1 175177-01-2 175177-02-3 175177-03-4
175177-04-5 175177-05-6 175177-06-7 175177-07-8 175177-08-9
175177-09-0 175177-10-3 175177-11-4 175177-12-5 175177-13-6

175177-14-7 175177-15-8 175177-16-9 175177-17-0 175177-18-1
175177-19-2 175177-20-5 175177-21-6 175177-22-7 175177-23-8
175177-24-9 175177-25-0 175177-26-1 175177-27-2 175177-28-3
175177-29-4 175177-30-7 175177-31-8 175177-32-9 175177-33-0
175177-34-1 175177-35-2 175177-36-3 175177-37-4 175177-38-5
175177-39-6 175177-40-9 175177-41-0 175177-42-1 175177-43-2
175177-44-3 175177-45-4 175177-46-5 175177-47-6 175177-48-7
175177-49-8 175177-50-1 175177-51-2 175177-52-3 175177-53-4
175177-54-5 175177-55-6 175177-56-7 175177-57-8 175177-58-9
175177-59-0 175177-60-3 175177-61-4 175177-62-5 175177-63-6
175177-64-7 175177-65-8 175177-66-9 175177-67-0 175177-68-1
175177-69-2 175177-70-5 175177-71-6 175177-72-7 175177-73-8
175177-74-9 175177-75-0 175177-76-1 175177-77-2 175177-78-3
175177-79-4 175177-80-7 175177-81-8 175276-10-5
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(structural aspects of antibody-antigen interaction revealed through small random peptide libraries)

IT **175175-73-2**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(structural aspects of antibody-antigen interaction revealed through small random peptide libraries)

RN 175175-73-2 HCAPLUS
CN L-Aspartic acid, L-phenylalanyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg
FILE 'REGISTRY' ENTERED AT 10:34:38 ON 24 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 APR 2003 HIGHEST RN 504385-01-7
DICTIONARY FILE UPDATES: 23 APR 2003 HIGHEST RN 504385-01-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP

PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l11
L6 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L8 583 SEA FILE=REGISTRY SSS FUL L6
L9 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

Offer search on Seq # 3

```
STEREO ATTRIBUTES: NONE
L10          294 SEA FILE=REGISTRY SUB=L8 SSS FUL L9
L11          289 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 NOT L10


=> d his

     (FILE 'HOME' ENTERED AT 10:00:55 ON 24 APR 2003)
                SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 10:01:07 ON 24 APR 2003
                E WO99-GB1434/AP,PRN
L1             1 S E3,E4
                SEL RN

     FILE 'REGISTRY' ENTERED AT 10:01:33 ON 24 APR 2003
L2            48 S E1-E48
L3             1 S L2 AND C19H27N3O6
L4           254 S C19H27N3O6/MF AND 46.150.18/RID
L5             5 S L4 AND ASPART? AND ISOLEUC?
L6               STR
L7             2 S L6
L8           583 S L6 FUL
                SAV L8 NEON674/A
L9               STR L6
L10          294 S L9 FUL SUB=L8
L11          289 S L8 NOT L10
L12          288 S L11 NOT L3

     FILE 'HCAPLUS' ENTERED AT 10:07:45 ON 24 APR 2003
L13            2 S L3
L14          280 S L12
L15          255 S L10
                E BONNEFOY J/AU
L16          194 S E3,E6,E11,E12
                E CROWE J/AU
L17           45 S E3,E15,E16,E24
                E ELLIS J/AU
L18          321 S E3,E16,E17
                E ELLIS JON/AU
L19           20 S E3,E4,E6,E7
                E RAPSON N/AU
L20           12 S E3-E7
                E SHEARIN J/AU
L21            3 S E4
                E GLAXO/PA,CS
                E GLAX/PA,CS
L22         6631 S E5-E20
L23         7920 S GLAXO?/PA,CS
L24            1 S L13 AND L16-L23
L25            2 S L13,L24
L26            0 S L14,L15 AND L16-L23
L27          124 S (PD<=19980509 OR PRD<=19980509 OR AD<=19980509) AND L14
L28          138 S (PD<=19980509 OR PRD<=19980509 OR AD<=19980509) AND L15
L29            0 S L27 AND CD23
L30            0 S L28 AND CD23
L31            0 S FC(L)RII? AND L14,L15
L32           69 S IMMUNOGLOB? AND L14,L15
L33           11 S IGG? AND L14,L15
L34            0 S C1Q AND L14,L15
L35           52 S (?INFLAM? OR AUTOIMMUN?) AND L14,L15
L36          178 S ANTIBOD? AND L14,L15
```

```
                E IMMUNOGLOBULIN RECEPTOR/CT
                E E4+ALL
L37          2  S L14,L15 AND E10-E12,E9+NT
                E IMMUNOGLOBULINS/CT
                E E3+ALL
L38         64  S L14,L15 AND E7,E6+NT
                E ALLERGY INHIBITOR/CT
                E E4+ALL
L39          8  S E2+NT AND L14,L15
L40         11  S E10+NT AND L14,L15
                E ANTI-INFLAM/CT
                E E5+ALL
L41         15  S E4,E5,E3+NT AND L14,L15
                E E18+ALL
L42          4  S L14,L15 AND E6,E5+NT
                E E10+ALL
L43          4  S L14,L15 AND E2+NT
                E INFLAMMATION/CT
                E E3+ALL
L44         24  S L14,L15 AND E2+NT
                E ANTIDIABET/CT
                E E5+ALL
L45         12  S L14,L15 AND E4,E5,E3+NT
                E E13+ALL
L46         10  S L14,L15 AND E5,E4+NT
                E DERMATITIS/CT
                E E3+ALL
L47          4  S E6+NT AND L14,L15
                E ECZEMA/CT
                E E3+ALL
L48          2  S E7+NT AND L14,L15
                E PSORIASIS/CT
                E E3+ALL
L49          8  S L14,L15 AND E4+NT
                E SJOGREN/CT
                E E6+ALL
L50          0  S L14,L15 AND E7,E6+NT
                E URTICARIA/CT
                E E3+ALL
L51          1  S L14,L15 AND E4+NT
                E THYROID DISEASE/CT
                E E4+ALL
                E E2+ALL
L52          7  S L14,L15 AND E4,E5,E3+NT
                E BRONCHI/CT
                E E3+ALL
L53          2  S L14,L15 AND E6+NT
                E LUNG, DISEASE/CT
                E E3+ALL
L54         22  S L14,L15 AND E4,E5,E3+NT
                E KIDNEY DISEASE/CT
                E E4+ALL
                E E2+ALL
L55         12  S L14,L15 AND E4,E5,E3+NT
                E TRANSPLANT/CT
                E E5+ALL
L56          4  S L14,L15 AND E7-E12,E6+NT
                E E38+ALL
L57          5  S L14,L15 AND E2
                E INTESTINE, DISEASE/CT
                E E3+ALL
L58         21  S L14,L15 AND E4,E5,E3+NT
                E  PANCREA/CT
```

```
                E E108+ALL
L59           5 S L14,L15 AND E11,E10+NT
                E NOSE/CT
                E E3+ALL
L60           1 S L14,L15 AND E8
                E LUPUS/CT
                E E7+ALL
L61           4 S L14,L15 AND E5,E4+NT
                E MULTIPLE SCLEROSIS/CT
                E E3+ALL
L62           7 S L14,L15 AND E3
                E EYE DISEASE/CT
                E E4+ALL
                E E2+ALL
L63          15 S L14,L15 AND E4,E5,E3+NT
                E ANTITUMOR/CT
                E E5+ALL
L64          73 S L14,L15 AND E4,E3+NT
L65          58 S L27,L28 AND L37-L64
L66          27 S L65 AND ANTIBOD?
L67          34 S L65 AND 15/SC,SX
L68          19 S L66 AND L67
L69          22 S L67 AND P/DT
L70          16 S L65 NOT L66-L69
L71          42 S L65 AND P/DT
L72          30 S L71 AND L66-L68
L73          27 S L66 AND L67-L72
L74          15 S L67 NOT L73
L75          54 S L73,L74,L71
L76          32 S L65-L75 AND US/PC
L77          33 S L65-L75 AND US/PRC
L78          32 S L65-L75 AND US/AC
L79          37 S L76-L78
L80          21 S L65 NOT L79
L81          58 S L79,L80
L82         220 S L32,L33,L35,L36
L83          90 S L82 AND L27,L28
L84          37 S L81 AND L83
L85          53 S L83 NOT L81
L86          58 S L81,L84
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 10:31:53 ON 24 APR 2003
L87          75 S E1-E75
L88          37 S L87 AND L12
L89          38 S L87 NOT L88

     FILE 'HCAPLUS' ENTERED AT 10:34:00 ON 24 APR 2003
L90          32 S L88 AND L86

     FILE 'REGISTRY' ENTERED AT 10:34:13 ON 24 APR 2003

     FILE 'HCAPLUS' ENTERED AT 10:34:26 ON 24 APR 2003

     FILE 'REGISTRY' ENTERED AT 10:34:38 ON 24 APR 2003

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:35:32 ON 24 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 24 Apr 2003 VOL 138 ISS 17
FILE LAST UPDATED: 23 Apr 2003 (20030423/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot l90 hitstr

L90 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:466536 HCAPLUS
DN 137:46056
TI Human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis
IN Steinman, Lawrence; Zamvil, Scott
PA USA
SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 125,407, abandoned.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K038-00
ICS A61K039-38; A01N025-00
NCL 424184100
CC **15-2** (Immunochemistry)
Section cross-reference(s): 63
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002076412	A1	20020620	US 1995-484409	19950607 <--
	WO 9117268	A1	19911114	WO 1991-US2991	19910501 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	EP 725277	A2	19960807	EP 1996-100852	19910501 <--
	EP 725277	A3	19961204		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5667967	A	19970916	US 1993-66325	19930521 <--
PRAI	US 1987-86694	B2	19870817 <--		
	US 1989-379500	B2	19890712 <--		
	US 1990-517245	B2	19900501 <--		
	WO 1991-US2991	A2	19910501 <--		
	US 1992-877444	B1	19920430 <--		
	US 1993-66325	A2	19930521 <--		
	US 1993-125407	B2	19930922 <--		
	EP 1991-909565	A3	19910501 <--		

AB Methods for modulating the immune system of an animal, as well as tolerating such an immune system through the administration of one or more polypeptides derived from human myelin basic protein (hMBP), are provided. Such polypeptides include residues 87-99 of hMBP, as well as residues His-Phe-Phe-Lys and/or Lys-Ile-Phe-Lys of hMBP. The method is esp. useful for treating multiple sclerosis.
ST immunomodulator immune tolerance myelin basic protein; human myelin basic protein epitope multiple sclerosis

IT Structure-activity relationship
(antigen-binding; human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT Drug delivery systems
(carriers; human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT DNA sequences
Epitopes
Human
Immunomodulators
Multiple sclerosis
Protein sequences
(human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT Myelin basic protein
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT Immune tolerance
(inducer; human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT 438070-01-0, Myelin basic protein (human precursor)
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT 60998-20-1 115306-15-5 118506-26-6 124470-31-1 124470-32-2
158401-73-1 158401-74-2 163350-44-5 438002-44-9 438002-47-2
438002-49-4 438002-51-8 438002-53-0 438002-55-2 438002-57-4
438002-59-6 438002-63-2 438002-65-4 438002-66-5 438002-67-6
438002-68-7 438002-69-8 438002-71-2 438002-72-3 438002-73-4
438002-75-6 438002-77-8 438002-79-0 438002-83-6 438002-85-8
438002-87-0 438002-89-2 438002-91-6 438002-93-8 438002-95-0
438002-96-1 438002-97-2 438069-09-1 438069-10-4
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT 438070-02-1, DNA (human myelin basic protein cDNA)
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT 158401-69-5 158401-70-8 158401-71-9 158401-72-0 158401-75-3
158401-76-4 158401-77-5 158401-78-6 158401-79-7 158401-80-0
158401-81-1
RL: PRP (Properties)
(unclaimed sequence; human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
IT **438002-96-1**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human myelin basic protein epitopes for modulating immune system and for treating multiple sclerosis)
RN 438002-96-1 HCAPLUS
CN L-Aspartic acid, L-lysyl-L-valyl-L-phenylalanyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L90 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:136063 HCAPLUS
DN 136:162348
TI Methods of preparing corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof
IN Redei, Eva; Aird, Fraser
PA Northwestern University, USA; The Trustees of the University of Pennsylvania
SO U.S., 48 pp., Cont.-in-part of U.S. 6,039,956.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM C07K004-12
ICS C07K005-00; C07K007-06; C07K007-08; C07K014-435
NCL 530330000
CC 3-2 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 13
FAN.CNT 5

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 6348571	B1	20020219		US 1999-366627	19990803	<--
	US 5830866	A	19981103		US 1995-523125	19950908	<--
	US 6039956	A	20000321		US 1996-660561	19960607	<--
	US 2002137885	A1	20020926		US 2002-78777	20020219	<--
PRAI	US 1994-304383	B2	19940912	<--			
	US 1995-523125	A2	19950908	<--			
	US 1996-660561	A2	19960607	<--			
	US 1999-366627	A3	19990803	<--			

AB The invention provides a substantially pure prepn. of a corticotropin release inhibiting factor (CRIF) peptide having from three to twenty one or to twenty five contiguous amino acids contained within the amino acid sequence positioned between the fourth and fifth TRH sequence on a prepro-TRH protein. The invention also provides a kit comprising a CRIF peptide and methods for using the peptide.

ST rat corticotropin release inhibiting factor CRIF
IT Stress, animal
(CRIF concn. varing with; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT **Rheumatoid arthritis**
(CRIF contributing development of; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT Rat
(CRIF from; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT Antidepressants
(CRIF with effect of; methods of prepg. corticotropin release

inhibiting factor (CRIF) and therapeutic uses thereof)
IT Protein sequences
(homol., of rat, mouse and human CRIF; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT Genetic engineering
Test kits
(methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT Protein sequences
(of CRIF of rat; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT 9002-62-4, Prolactin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CRIF affecting secretion of; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT 9002-60-2, Acth, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CRIF regulating prodn. of; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT 316357-54-7P 396717-05-8P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT 148937-30-8P, Corticotropin release inhibiting factor
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(of rat, human; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT 100469-84-9, Prepro-trh
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(of rat, human; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT 396834-41-6, 7: PN: US6348571 SEQID: 7 unclaimed DNA 396834-42-7, 8: PN: US6348571 SEQID: 8 unclaimed DNA 396834-43-8, 9: PN: US6348571 SEQID: 9 unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
IT **122018-92-2** 147023-71-0 257865-46-6 **396717-04-7**
RL: PRP (Properties)
(unclaimed sequence; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Bird; Science 1988, V42, P423
(2) Bonsen; US 4265874 A 1981 HCAPLUS
(3) Bowie; Science 1990, V247(4948), P1306 HCAPLUS
(4) Bulant; J Biol Chem 1988, V263(32), P17189 HCAPLUS
(5) Greene; US 5334702 A 1994 HCAPLUS
(6) Grossman; J Endocrinology 1989, V123, P169 HCAPLUS
(7) Huston; Proc Natl Acad Sci USA 1988, V85, P5879 HCAPLUS
(8) Kakucska; Endocrinology 1992, V130, P2845 HCAPLUS
(9) Karalis; Science 1991, V254, P421 HCAPLUS
(10) Lechan; Science 1986, V231, P159 HCAPLUS
(11) Lee; J Biol Chem 1988, V263, P16604 HCAPLUS
(12) McGivern; J Neurosci 1997, V17, P4886 HCAPLUS
(13) Ngo; The Protein Folding Problem and Tertiary Structure Prediction 1994, P433 HCAPLUS
(14) Nillni; Endocrinology 1993, V132, P1260 HCAPLUS
(15) Palermo; Acta Eur Fertilitatis 1994, V25, P161 MEDLINE

(16) Pare; J Physiol 1993, V87, P229 MEDLINE
(17) Plotsky; J Neuroendocrinol 1991, V3, P1 HCAPLUS
(18) Prystowsky; Immunomethods 1994, V5, P49 HCAPLUS
(19) Redei; US 5830866 A 1998 HCAPLUS
(20) Redei; US 6039956 A 2000 HCAPLUS
(21) Redei; Am J Physiol 1994, V266, PR353 HCAPLUS
(22) Redei; Endocrinology 1988, V123, P2736 HCAPLUS
(23) Redei; Endocrinology 1993, V133, P452 MEDLINE
(24) Redei; Integrative Neurohormonal Mechanism Developments in Neuroscience 1984, P377
(25) Redei; Neuroendocrinology 1994, V60, P113 HCAPLUS
(26) Redei; Neuropeptides and Stress 1989, V6, P62
(27) Sabol; Arch Biochem Biophys 1980, V203, P37 HCAPLUS
(28) Satoh; Brain Res Mol Brain Res 1992, 1-2, P131 HCAPLUS
(29) Segerson; Science 1987, V238, P78 HCAPLUS
(30) Sevarino; J Biol Chem 1989, V264, P215229
(31) Silman; APMIS 1994, V102, P721 MEDLINE
(32) Sternberg; Proc Natl Acad Sci USA 1989, V86, P2374 HCAPLUS
(33) Theeuwes; US 4160452 A 1979 HCAPLUS
(34) Theeuwes; US 4256108 A 1981
(35) Uhler; J Biol Chem 1983, V258, P257 HCAPLUS
(36) Walker; Lupus 1995, V4, P3 MEDLINE
(37) Yamada; Molec Endocrinol 1990, V4, P551 HCAPLUS
(38) Zumoff; Ob & Gyn Clinics of N Am 1994, V21, P751 MEDLINE

IT **122018-92-2 396717-04-7**
RL: PRP (Properties)
(unclaimed sequence; methods of prepg. corticotropin release inhibiting factor (CRIF) and therapeutic uses thereof)

RN 122018-92-2 HCAPLUS

CN L-Glutamic acid, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-tryptophyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-lysyl-L-.alpha.-glutamylglycyl-L-.alpha.-glutamylglycyl-L-valyl-L-leucyl-L-methionyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

CO_2H

RN 396717-04-7 HCAPLUS
CN L-Glutamic acid, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-tryptophyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-threonyl-L-.alpha.-glutamylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



L90 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:352237 HCAPLUS
DN 134:371749
TI Treatment and prevention of immune rejection reactions
IN Franklin, Richard L.; St. Pierre, Yves
PA Phairson Medical, Inc., USA
SO U.S., 27 pp., Cont.-in-part of U.S. 5,958,406.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM C12Q001-34
ICS C12N005-16; C12N005-10
NCL 435018000
CC 63-3 (Pharmaceuticals)
Section cross-reference(s): 9
FAN.CNT 5

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 6232088	B1	20010515		US 1998-220731	19981224	<--
	US 5945102	A	19990831		US 1995-385540	19950208	<--
	US 6030612	A	20000229		US 1995-486820	19950607	<--
	US 5958406	A	19990928		US 1996-600273	19960208	<--
PRAI	US 1995-385540	A2	19950208	<--			
	US 1995-486820	A2	19950607	<--			
	US 1996-600273	A2	19960208	<--			
	US 1994-338501	B2	19941122	<--			

AB Provided, among other things, is a method of preventing or ameliorating transplantation rejection reactions comprising treating the donor tissue with a rejection reaction-preventing or ameliorating effective amt. of a hydrolase that is effective to reduce the amt. of one or more cell surface adhesion mols. Hydrolases may be obtained from cod, krill, Penaeus vannamei, P. monodon, Uca pugilator, and Kamchatka crab.
ST hydrolase transplant rejection immunosuppressant adhesin removal
IT Cell adhesion molecules

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); REM (Removal or disposal); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(ICAM-1 (intercellular adhesion mol. 1); hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT Crab
(Kamchatka; hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT Polyacrylamide gel electrophoresis
(SDS; hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT Immunosuppressants
Molecular weight distribution
Penaeus vannamei
Protein sequences
Transplant rejection
Uca pugilator
(hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT Adhesins
CD28 (antigen)
CD4 (antigen)
CD8 (antigen)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); REM (Removal or disposal); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT Cod
Crayfish
Euphausia superba
Krill
Penaeus monodon
Salmon
(hydrolases of; hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT 151-21-3, Sds, uses
RL: NUU (Other use, unclassified); USES (Uses)
(PAGE; hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT 204529-30-6 204529-31-7 204529-33-9 204529-37-3 204529-38-4 204529-39-5
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT 9002-07-7, Trypsin
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(cod; hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT 182238-43-3 **244097-30-1 244097-31-2 244097-32-3** 244097-33-4 244097-34-5 244097-35-6 **244097-36-7** 244097-37-8 244097-38-9 244097-39-0 244097-40-3 244097-41-4 244097-42-5 290812-90-7 290812-91-8 339315-95-6 339540-58-8 339540-61-3 339540-64-6
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(hydrolases from marine animals for treatment and prevention of immune rejection reactions)

IT 9001-12-1, Collagenase 9001-92-7, Proteinase 9004-06-2, Elastase
9004-07-3, Chymotrypsin 9027-41-2, Hydrolase 9031-96-3, Exopeptidase
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(hydrolases from marine animals for treatment and prevention of immune rejection reactions)

RE.CNT 107 THERE ARE 107 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) -Pierre; J Immunol 1991, V147(9), P2875
(2) Abraham; J Immunol 1992, V148(12), P3746 HCAPLUS
(3) Al-Mohanna; J Mar Biol Ass U K 1985, V65, P901
(4) Anheller; Archives of Dermatology Research 1989, V281, P105 HCAPLUS
(5) Anheller; Dermatol, Res 1989, V281, P105 HCAPLUS
(6) Anon; EP 170115 A1 1985 HCAPLUS
(7) Anon; JP 6168419 1986
(8) Anon; WO 9319732 1993 HCAPLUS
(9) Anon; WO 9324142 1993 HCAPLUS
(10) Anon; WO 9419005 1994 HCAPLUS
(11) Anon; WO 9507686 1995 HCAPLUS
(12) Anon; WO 9507688 1995 HCAPLUS
(13) Anon; WO 9533470 1995 HCAPLUS
(14) Anon; WO 9624371 1996 HCAPLUS
(15) Anon; WO 9808863 1998 HCAPLUS
(16) Anon; Dialog Search relating to cysteine protease
(17) Anon; Dialog Search relating to enzyme-based therapeutics
(18) Arthur, Z; Biochemistry 1973, V12(9), P1814
(19) Asuncion, O; Biochimica et Biophysica Acta 1978, V523, P181
(20) Athie; Medicina (Mex) 1965, V45(961), P145 MEDLINE
(21) Bachmann; Immunity 1997, V7, P549 HCAPLUS
(22) Bar; Lille Med 1970, V15(5), P827 HCAPLUS
(23) Bazerque; Medicina (B Aires) 1972, V32(4), P357 MEDLINE
(24) Bazil; Proc Natl Acad Sci USA 1993, V90, P3792 HCAPLUS
(25) Berenshtein; Antibiotiki 1978, V23(11), P1002 HCAPLUS
(26) Blazar; Blood 1995, V85(9), P2607 HCAPLUS
(27) Blazar; Immunol Rev 1997, V157, P79 HCAPLUS
(28) Bluestone; J Immunol 1998, V158(5), P1989
(29) Bucht, A; Biol Chem Hoppe Sryler, Abstract 06.03.55 1986, V367, P366
(30) Cavazzana-Calvo; Br J Haematol 1996, V93(I), P131
(31) Chen; US 4677069 1987 HCAPLUS
(32) Chen; Journal of Food Biochemistry 1978, V2, P349
(33) Chuchnova, T; 1990, 10, P52
(34) Chudakov; Kirurgiia (Mosk) 1973, V49(2), P87
(35) Cobbold; Curr Opin Immunol 1998, V10(5), P518 HCAPLUS
(36) Coblentz; J Am Geriatr Soc 1968, V16(9), P1039 MEDLINE
(37) Daniushchenkova; Antibiotiki 1978, V23(4), P330 MEDLINE
(38) Del Pozo; Eur J Immunol 1994, V24, P2586 HCAPLUS
(39) Demianiuk; Klin Khir 1972, V8, P56 MEDLINE
(40) Dimarco; Clin Pediatr 1970, V52(1), P34
(41) Doring; J Immunol 1995, V154(9), P4842 MEDLINE
(42) Dustin; Annu Rev Immunmol 1991, V9, P27 HCAPLUS
(43) D'Arrigo, C; Minerva Medica 1969, V60(87), P4327 MEDLINE
(44) Gacon; Lyon Med 1969, V222(43), P997 MEDLINE
(45) Gastshchev; Sovetskaia Meditsina 1980, 9, P52
(46) Gates; Shrimp Trypsin 1969, V8(11), P4483 HCAPLUS
(47) Geller; Khirurgiia (Mosk) 1973, V49(2), P64
(48) Glozman, V; 1990, 10, P57
(49) Goodfriend; J Am Podiatry Assoc 1965, V55(9), P667 MEDLINE
(50) Gordillo, F; Medicina (Mex) 1965, V45(973), P490
(51) Gotishchev; Sovetskaia Meditsina 1978, 5, P80
(52) Grant; Biochemistry 1980, V19, P4653 HCAPLUS
(53) Grant; Biochemistry 1980, V19, P6089 HCAPLUS
(54) Grant; Biochemistry 1983, V22, P354 HCAPLUS

(55) Grant; Methods in Enzymology 1980, V80, P722
(56) Grigorian; Klin Khir 1971, V9, P1 MEDLINE
(57) Gudmundsodottir; Eur J Biochem 1993, V217, P1091
(58) Hellgren; US 4801451 1989 HCAPLUS
(59) Hellgren; US 4963491 1990 HCAPLUS
(60) Jacobs; J Am Podiatry Assoc 1965, V55(11), P743 MEDLINE
(61) Johansson, B; Biol Chem Hoppe Sryler, Abstract 06.03.56 1986, V367, P366
(62) Karlstam; Biol Chem Hoppe Seyler 1986, V367, P339
(63) Kimoto; Agric Biol Chem 1983, V47(3), P529 HCAPLUS
(64) Kimoto; Agric Biol Chem 1985, V49(6), P1599 HCAPLUS
(65) Kimoto; Journal of Food Science 1981, V46, P1881 HCAPLUS
(66) Klimova; Biochemical and Biophysical Research Communications 1990, V166(3), P1411 HCAPLUS
(67) Knut, K; Comp Biochem Physiol 1955, V82B(4), P607
(68) Knut, K; Comp Biochem Physiol 1985, V82B(4), P599
(69) Knut, K; Comp Biochem Physiol 1986, V83B(2), P445
(70) Knut, K; Comp Biochem Physiol 1986, V83B(4), P801
(71) Kraft; Biol Chem Hoppe Seyler 1972, V353, P1540
(72) Lezdey; US 5134119 1992 HCAPLUS
(73) Lipman; Science 1985, V227, P1435 HCAPLUS
(74) Lopez, R; Medicina (Mex) 1965, V45(964), P221
(75) Lu; Biol Chem Hoppe-Seyler 1990, V371, P851 HCAPLUS
(76) Mazza, V; Folia Med 1969, V52(9), P565 MEDLINE
(77) Melrose, J; Arch Orthop Trauma Surg 1995, V114, P145 MEDLINE
(78) Olav, S; Comp Biochem Physical 1987, V88B(1), P165
(79) Perez; Immunity 1997, V6(4), P411 HCAPLUS
(80) Poul, K; Nordisk Medicin 1966, V75(14), P390
(81) Rathgeber, W; S Afr Med J 1971, 457, P181
(82) Rawlings; US 5439935 1995 HCAPLUS
(83) Riffat; Lyon Med 1971, V226(13), P103 MEDLINE
(84) Sakharov; Comp Biochem Physiol 1994, V108B, P561 HCAPLUS
(85) Sakharov, Y; Arch Dermatol Res 1993, V285, P32
(86) Schwartz; Curr Opin Immunol 1997, V9(3), P351 HCAPLUS
(87) Sellos; FEBS 1992, V309(3), P219 HCAPLUS
(88) Spindler; Polar Biology 1988, V9, P115
(89) Stoddart; J Immunol 1996, V157(12), P5653 HCAPLUS
(90) Sykes; Blood 1995, V86(6), P2429 HCAPLUS
(91) Sykes; Proc Natl Acad Sci USA 1990, V87(15), P5633 HCAPLUS
(92) Szeghy; Klin Monatshl Augenheilkd 1968, V153(6), P827 MEDLINE
(93) Theodor, N; Hautarz 1967, V18(1), P31
(94) Tokuda; Nippon Ganka Kiyo 1968, V19(10), P993 MEDLINE
(95) Tsai; Biochimica et Biophysica Acta 1991, V1080, P59 HCAPLUS
(96) Tsu; The Journal of Biochemical Chemistry 1994, V269(30), P19565 HCAPLUS
(97) Turkiewicz; Acta Biochimica Polonica 1986, V33(2), P87 HCAPLUS
(98) Turkiewicz; Comp Biochem Physiol 1991, V99B, P359 HCAPLUS
(99) Ushiyama; J Immunol 1995, V154(6), P2687 HCAPLUS
(100) Von Billigmann, P; Fortschrr Med 1995, V113(4), P43
(101) Weber; Immunobiol 1997, V197(1), P82 HCAPLUS
(102) Welgus; Biochemistry 1982, V21, P5183 HCAPLUS
(103) Welgus; Biochemistry 1983, V22, P2228 HCAPLUS
(104) Woodward; Transplantation 1996, V62(7), P1011 HCAPLUS
(105) Wormhoudt; Comp Biochem Physiol 1992, V103B(3), P675
(106) Yi-Qun; J Immunol 1997, V158(10), P4734 HCAPLUS
(107) Zhailiev, D; Khirurgiia (Mosk) 1984, 1, P67 MEDLINE

IT **244097-30-1 244097-31-2 244097-32-3 244097-36-7**
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(hydrolases from marine animals for treatment and prevention of immune rejection reactions)

RN 244097-30-1 HCAPLUS

CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-asparaginyl-L-.alpha.-

glutamyl-L-valyl-L-threonyl-L-prolyl-L-histidyl-L-alanyl-L-tyrosyl-L-prolyl-L-tryptophyl-L-glutaminyl-L-valylglycyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





PAGE 2-B



PAGE 3-A



PAGE 4-A

RN 244097-31-2 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-methionyl-L-.alpha.-glutamyl-L-valyl-L-threonyl-L-prolyl-L-histidyl-L-alanyl-L-tyrosyl-L-prolyl-L-tryptophyl-L-glutaminyl-L-valylglycyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





PAGE 2-B



PAGE 3-A



PAGE 4-A

RN 244097-32-3 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-valyl-L-.alpha.-glutamyl-L-alanyl-L-threonyl-L-prolyl-L-histidyl-L-seryl-L-tryptophyl-L-prolyl-L-histidyl-L-glutaminyl-L-alanyl-L-alanyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 244097-36-7 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-valyl-L-.alpha.-glutamyl-L-alanyl-L-valyl-L-prolyl-L-asparaginyl-L-seryl-L-tryptophyl-L-prolyl-L-histidyl-L-glutaminyl-L-alanyl-L-alanyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



L90 ANSWER 4 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:645832 HCAPLUS
DN 133:256752
TI Microparticles for delivery of nucleic acid
IN Lunsford, Lynn B.; Putnam, David; Hedley, Mary Lynne
PA Zycos Inc., USA
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K009-16
ICS A61K048-00
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 3
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000053161	A2	20000914	WO 2000-US6578	20000310 <--
	WO 2000053161	A3	20010201		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1161227	A2	20011212	EP 2000-919403	20000310 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002538196	T2	20021112	JP 2000-603650	20000310 <--
	US 2002182258	A1	20021205	US 2001-909460	20010718 <--
PRAI	US 1999-266463	A2	19990311 <--		
	US 1999-321346	A2	19990527 <--		
	US 1997-35983P	P	19970122 <--		

US 1998-3253 B2 19980106 <--
WO 1998-US1499 A2 19980122 <--
WO 2000-US6578 W 20000310

AB A prepn. of microparticles made up of a polymeric matrix, a nucleic acid expression vector, and a lipid is disclosed. The polymeric matrix includes one or more synthetic polymers having a soly. in water of less than about 1 mg/L. At least 90 % of the microparticles have a diam. less than about 100 .mu.. The nucleic acid is either RNA, at least 50 % of which is in the form of closed circles, or circular DNA plasmid mols., at least 50 % of which are supercoiled.

ST microparticle drug delivery nucleic acid

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MHC (major histocompatibility complex), class I, -binding mols.; microparticles for delivery of nucleic acid)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MHC (major histocompatibility complex), class II; microparticles for delivery of nucleic acid)

IT Bacteria (Eubacteria)
Chlamydia
Hepatitis B virus
Hepatitis C virus
Human herpesvirus
Human immunodeficiency virus
Human papillomavirus
Mycobacterium
Parasite
Plasmodium (malarial genus)
Virus
(antigenic fragments; microparticles for delivery of nucleic acid)

IT **Pancreatic islet of Langerhans**
(antigens; microparticles for delivery of nucleic acid)

IT Drug delivery systems
(carriers; microparticles for delivery of nucleic acid)

IT DNA
Nucleic acids
RL: DEV (Device component use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(circular; microparticles for delivery of nucleic acid)

IT Glycoproteins, specific or class
RL: PRP (Properties)
(desmogleins; microparticles for delivery of nucleic acid)

IT **Immunoglobulins**
RL: PRP (Properties)
(invariant chain; microparticles for delivery of nucleic acid)

IT Vagina
(microparticle delivery to; microparticles for delivery of nucleic acid)

IT Biological transport
Drug targeting
Emulsification
Freeze drying
Gene therapy
Particle size distribution
Plasmid vectors
Polar solvents
Protein sequences
Stabilizing agents
Surfactants
(microparticles for delivery of nucleic acid)

IT Antigens

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(microparticles for delivery of nucleic acid)

IT Carbohydrates, biological studies
RL: DEV (Device component use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(microparticles for delivery of nucleic acid)

IT Nucleic acids
Phosphatidylethanolamines, processes
Phosphatidylinositols
Phosphatidylserines
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(microparticles for delivery of nucleic acid)

IT Lipoproteins
RL: PRP (Properties)
(microparticles for delivery of nucleic acid)

IT Myelin basic protein
RL: PRP (Properties)
(microparticles for delivery of nucleic acid)

IT Drug delivery systems
(microparticles; microparticles for delivery of nucleic acid)

IT Supercoiled structure
(nucleic acids; microparticles for delivery of nucleic acid)

IT Solvents
(org.; microparticles for delivery of nucleic acid)

IT Nucleic acids
Phosphatidylcholines, biological studies
Phospholipids, biological studies
RL: DEV (Device component use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(particle component; microparticles for delivery of nucleic acid)

IT Lipids, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particle component; microparticles for delivery of nucleic acid)

IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particle matrix; microparticles for delivery of nucleic acid)

IT T cell (lymphocyte)
(peptide recognition by; microparticles for delivery of nucleic acid)

IT Cell nucleus
Endoplasmic reticulum
Endosome
Lysosome
(trafficking to; microparticles for delivery of nucleic acid)

IT Antigens
RL: PRP (Properties)
(tumor-assocd.; microparticles for delivery of nucleic acid)

IT Organelle
(vesicle, trafficking to; microparticles for delivery of nucleic acid)

IT Crystallins
RL: PRP (Properties)
(.alpha.-; microparticles for delivery of nucleic acid)

IT Crystallins
RL: PRP (Properties)
(.beta.-; microparticles for delivery of nucleic acid)

IT 115505-57-2 **115505-63-0** 115505-64-1 115521-13-6
119261-00-6 119401-82-0 124470-29-7 127424-82-2 133209-09-3
133295-51-9 136182-67-7 136494-37-6 137354-10-0 137354-11-1

145151-52-6 146554-61-2 148305-84-4 148305-88-8
148305-93-5 149383-25-5 152015-90-2 152074-99-2 **152244-23-0**
152846-82-7 158563-18-9 167319-80-4 182620-15-1 182620-16-2
192066-10-7 210629-19-9 210629-20-2 292633-18-2 292633-19-3
292633-20-6 292633-21-7 292633-22-8 292633-23-9 292633-24-0
292633-25-1 292633-26-2 292633-27-3 292633-28-4 292633-29-5
292633-30-8 292633-31-9 294178-78-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(microparticles for delivery of nucleic acid)

IT 26780-50-7, Polylactide co glycolide
RL: DEV (Device component use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(microparticles for delivery of nucleic acid)

IT 6899-10-1
RL: DEV (Device component use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(particle component; microparticles for delivery of nucleic acid)

IT 144449-86-5 147820-47-1 147934-24-5 151423-78-8 151423-83-5
151456-29-0 151808-57-0 151808-59-2 153607-10-4 153607-19-3
153607-20-6 153607-21-7 153607-23-9 154330-44-6 154330-45-7
154427-29-9 154652-68-3 155970-24-4 157048-07-2 160040-01-7
160040-02-8 160040-10-8 160040-16-4 160040-20-0 160040-28-8
160040-31-3 160212-35-1 160212-76-0 160212-93-1 160214-77-7
160216-13-7 160216-22-8 160216-59-1 160216-60-4 160983-12-0
162558-08-9 162558-10-3 162558-12-5 163816-00-0 166188-11-0
167319-68-8 170173-06-5 170294-35-6 223413-45-4 264120-60-7
292859-32-6 292859-33-7 292859-34-8 292859-35-9 292859-36-0
292859-37-1 292859-38-2 292859-39-3 292859-40-6 292859-41-7
292859-42-8 292859-43-9 292859-44-0 292859-45-1 292859-46-2
292859-47-3 292859-48-4 292859-49-5 292859-50-8 292859-51-9
RL: PRP (Properties)
(unclaimed sequence; microparticles for delivery of nucleic acid)

IT **115505-63-0 145151-52-6 152244-23-0**
292633-30-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(microparticles for delivery of nucleic acid)

RN 115505-63-0 HCAPLUS
CN L-Asparagine, L-seryl-L-threonyl-L-histidyl-L-valyl-L-methionyl-L-prolyl-L-asparaginyl-L-tryptophyl-L-valyl-L-arginyl-L-lysyl-L-valyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-isoleucyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 145151-52-6 HCAPLUS
CN L-Tryptophan, glycyl-L-glutaminyl-L-threonyl-L-isoleucyl-L-.alpha.-glutamyl-L-tryptophyl-L-isoleucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-alanyl-L-phenylalanyl-L-threonyl-L-.alpha.-glutamyl-L-asparaginylglycyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-C

RN 152244-23-0 HCAPLUS

CN L-Serine, L-asparaginyl-L-tryptophyl-L-valyl-L-arginyl-L-lysyl-L-valyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-isoleucyl-L-prolyl-L-asparaginyl-L-isoleucyl-L-methionyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 292633-30-8 HCAPLUS

CN L-Lysine, L-leucyl-L-methionyl-L-glutaminyl-L-tyrosyl-L-isoleucyl-L-.alpha.-aspartyl-L-alanyl-L-asparaginyl-L-seryl-L-lysyl-L-phenylalanyl-L-isoleucylglycyl-L-isoleucyl-L-threonyl-L-.alpha.-glutamyl-L-leucyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L90 ANSWER 5 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:141480 HCAPLUS
DN 132:189685
TI Krill-derived multifunctional enzyme and its medical uses
IN De Faire, Johan R.; Franklin, Richard L.; Kay, John; Lindblom, Ragnvald
PA Phairson Medical Inc., UK
SO U.S., 41 pp., Cont.-in-part of U.S. Ser. No. 385,450.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K038-48
ICS A61K038-46; C12N009-64; D06M016-00
NCL 424094630
CC 1-12 (Pharmacology)
Section cross-reference(s): 7, 12, **15**, 63
FAN.CNT 5

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 6030612	A	20000229		US 1995-486820	19950607	<--
	US 5945102	A	19990831		US 1995-385540	19950208	<--
	CA 2212533	AA	19960815		CA 1996-2212533	19960208	<--
	WO 9624371	A1	19960815		WO 1996-US1650	19960208	<--
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM						
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG						
	AU 9649170	A1	19960827		AU 1996-49170	19960208	<--
	AU 718220	B2	20000413				
	EP 810875	A1	19971210		EP 1996-905398	19960208	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV						
	BR 9607506	A	19971223		BR 1996-7506	19960208	<--
	CN 1181018	A	19980506		CN 1996-193103	19960208	<--
	CN 1090505	B	20020911				
	JP 11502102	T2	19990223		JP 1996-524401	19960208	<--
	US 5958406	A	19990928		US 1996-600273	19960208	<--
	NZ 302984	A	20010126		NZ 1996-302984	19960208	<--
	NZ 503162	A	20011130		NZ 1996-503162	19960208	<--
	NO 9703627	A	19971007		NO 1997-3627	19970806	<--
	US 6232088	B1	20010515		US 1998-220731	19981224	<--
PRAI	US 1994-338501	B2	19941122	<--			
	US 1995-385540	A2	19950208	<--			
	US 1995-486820	A	19950607	<--			
	NZ 1996-302984	A1	19960208	<--			
	US 1996-600273	A2	19960208	<--			
	WO 1996-US1650	W	19960208	<--			

AB The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a mol. wt. between about 20 kDa and about 40 kDa as detd. by SDS-PAGE. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homol. with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including **autoimmune** disease and cancer. Addnl., the invention relates to a method of purifying the multifunctional enzyme, and to a prepn. of essentially purified multifunctional enzyme.

ST multifunctional enzyme krill medical treatment; proteinase multifunctional krill pharmaceutical

IT CD antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CD49, enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ICAM-1 (intercellular adhesion mol. 1), enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ICAM-2 (intercellular adhesion mol. 2), enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)

IT Selectins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(L-, enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PECAM-1, enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(VCAM-1, enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)

IT Skin, disease
(aging, wrinkles, redn. of; krill-derived multifunctional enzyme and its medical uses)

IT Skin preparations (pharmaceutical)
Skin preparations (pharmaceutical)
(antiulcer agents; krill-derived multifunctional enzyme and its medical uses)

IT Skin, disease
(boils, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT **Bronchi**
(bronchitis, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Keloid
(decompn. of; krill-derived multifunctional enzyme and its medical uses)

IT Antiulcer agents

Antiulcer agents
(decubitus ulcer inhibitors; krill-derived multifunctional enzyme and its medical uses)

IT Joint, anatomical
(disease, wrist, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Immunity
(disorder, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(enzyme removal or inactivation of, of cell surface; krill-derived multifunctional enzyme and its medical uses)

IT CD28 (antigen)
CD4 (antigen)
CD44 (antigen)
CD8 (antigen)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)

IT Disease, animal
(fistula, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Vein
(hemorrhoid, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Human herpesvirus 2
(herpes genitalis from, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Drug delivery systems
(hydrogels; krill-derived multifunctional enzyme and its medical uses)

IT Candida
(infection by, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Haemophilus influenzae
Human herpesvirus
Human herpesvirus 3
Human immunodeficiency virus
Influenza virus
Mycoplasma
(infection with, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Mouth
(infection, gum, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT **Eye, disease**
Urinary tract
Vagina
(**infection**, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Joint, anatomical
(**inflammation**, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Ovary, neoplasm
Ovary, neoplasm
(inhibitors; krill-derived multifunctional enzyme and its medical uses)

IT Cell adhesion
(krill hydrolase inhibition of; krill-derived multifunctional enzyme and its medical uses)

IT **Allergy inhibitors**
Anti-AIDS agents

Anti-infective agents
Antibacterial agents
Antidiarrheals
Antiglaucoma agents
Antiulcer agents
Antiviral agents
Fungicides
Krill
Parasiticides
Protein sequences
Thrombolytics
Wound healing promoters
(krill-derived multifunctional enzyme and its medical uses)

IT Mouth
(lichen planus, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Drug delivery systems
(lozenges; krill-derived multifunctional enzyme and its medical uses)

IT Enzymes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multifunctional; krill-derived multifunctional enzyme and its medical uses)

IT **Antitumor agents**
Antitumor agents
(ovary; krill-derived multifunctional enzyme and its medical uses)

IT Tooth
(plaque, removal of; krill-derived multifunctional enzyme and its medical uses)

IT **Intestine, neoplasm**
(**polyp**, removal of; krill-derived multifunctional enzyme and its medical uses)

IT Penis
(prepuce, infection of, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Newborn
(prevention and treatment of infection in navel of; krill-derived multifunctional enzyme and its medical uses)

IT Prostate gland
(prostatitis, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Skin, disease
(rash, allergic, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Wart
(removal of; krill-derived multifunctional enzyme and its medical uses)

IT **Antitumor agents**
(sarcoma; krill-derived multifunctional enzyme and its medical uses)

IT Skin, disease
(scar, decompn. of; krill-derived multifunctional enzyme and its medical uses)

IT Connective tissue
(scleroderma, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Respiratory tract
(sinusitis, treatment of; krill-derived multifunctional enzyme and its medical uses)

IT Drug delivery systems
(solns., ophthalmic; krill-derived multifunctional enzyme and its medical uses)

IT Drug delivery systems

(topical; krill-derived multifunctional enzyme and its medical uses)
IT **Abscess**
Acne
Alopecia
Athlete's foot
Cataract
Common cold
Eczema
Leprosy
Mastitis
Psoriasis
Seborrhea
(treatment of; krill-derived multifunctional enzyme and its medical uses)
IT **Intestine, disease**
(**ulcerative colitis**, treatment of; krill-derived multifunctional enzyme and its medical uses)
IT Infection
(viral, treatment of; krill-derived multifunctional enzyme and its medical uses)
IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.1, enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)
IT 71012-19-6, Asialoganglioside GM1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(enzyme removal or inactivation of; krill-derived multifunctional enzyme and its medical uses)
IT 9001-12-1P, Collagenase 9001-92-7P, Proteinase 9002-07-7P, Trypsin 9004-06-2P, Elastase 9004-07-3P, Chymotrypsin 9031-96-3P, Exopeptidase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(krill-derived multifunctional enzyme and its medical uses)
IT 182238-43-3
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(peptide sequence; krill-derived multifunctional enzyme and its medical uses)
IT 244097-41-4 260058-17-1 260058-18-2 260058-19-3 260058-20-6
RL: PRP (Properties)
(unclaimed protein sequence; krill-derived multifunctional enzyme and its medical uses)
IT **244097-30-1 244097-31-2 244097-32-3**
244097-33-4 244097-34-5 244097-35-6 **244097-36-7**
244097-37-8 244097-38-9 244097-39-0 244097-40-3 244097-42-5
244097-43-6 259881-54-4
RL: PRP (Properties)
(unclaimed sequence; krill-derived multifunctional enzyme and its medical uses)
RE.CNT 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Al-Mohanna; J Mar Biol Ass U K 1985, V65, P901
(2) Anheller; Archives of Dermatology Research 1989, V281, P105 HCAPLUS
(3) Anon; EP 170115 A1 1985 HCAPLUS
(4) Anon; JP 6168419 1986
(5) Anon; WO 9319732 1993 HCAPLUS
(6) Anon; WO 9324142 1993 HCAPLUS
(7) Anon; WO 9419005 1994 HCAPLUS
(8) Anon; WO 9507686 1995 HCAPLUS

(9) Anon; WO 9507688 1995 HCAPLUS
(10) Arthur, Z; Biochemistry 1973, V12(9), P1814
(11) Athie; Medicina 1965, V45(961), P145 MEDLINE
(12) Bar; Lille Med 1970, V15(5), P827 HCAPLUS
(13) Bazerque; Medicina 1972, V32(4), P357 MEDLINE
(14) Berenshtein; Antibiotiki 1978, V23(11), P1002 HCAPLUS
(15) Bucht, A; Biol Chem Hoppe Sryler Abstract 06.03.55 1986, V367, P366
(16) Chen; US 4677069 1987 HCAPLUS
(17) Chen; Journal of Food Biochemistry 1978, V2, P349
(18) Chuchnova, T; 1990, 10, P52
(19) Chudakov; Kirurgiia 1973, V49(2), P87
(20) Coblentz; J Am Geriatr Soc 1968, V16(9), P1039 MEDLINE
(21) Daniushchenkova; Antibiotiki 1978, V23(4), P330 MEDLINE
(22) Demianiuk; Klin Khir 1972, V8, P56 MEDLINE
(23) Dimarco; Clin Pediatr 1970, V52(1), P34
(24) D'Arrigo, C; Minerva Medica 1969, V60(87), P4327 MEDLINE
(25) Fernandez, G; Medicina 1965, V45(973), P490
(26) Gacon; Lyon Med 1969, V222(43), P997 MEDLINE
(27) Gastshchev; Sovetskaia Meditsina 1980, 9, P52
(28) Gates; Shrimp Trypsin 1969, V8(11), P4483 HCAPLUS
(29) Geller; Khirurgiia 1973, V49(2), P64
(30) Glozman, V; 1990, 10, P57
(31) Goodfriend; J Am Podiatry Assoc 1965, V55(9), P667 MEDLINE
(32) Gotishchev; Sovetskaia Meditsina 1978, 5, P80
(33) Grant; Biochemistry 1980, V19, P6089 HCAPLUS
(34) Grant; Biochemistry 1983, V22, P354 HCAPLUS
(35) Grant; Methods in Enzymology 1980, V80, P722
(36) Grant; UCA Pugilator, Biochemistry 1980, V19, P4653 HCAPLUS
(37) Grigorian; Klin Khir 1971, V9, P1 MEDLINE
(38) Gudmundsodottir; Eur J Biochem 1993, V217, P1091
(39) Hellgren; US 4801451 1989 HCAPLUS
(40) Hellgren; US 4963491 1990 HCAPLUS
(41) Jacobs; J Am Podiatry Assoc 1965, V55(11), P743 MEDLINE
(42) Johansson, B; Biol Chem Hoppe Sryler, Abstract 1986, V367, P366
(43) Karlstam; Biol Chem Hoppe Seyler 1986, V367, P339
(44) Kimoto; Agric Biol Chem 1983, V47(3), P529 HCAPLUS
(45) Kimoto; Agric Biol Chem 1985, V49(6), P1599 HCAPLUS
(46) Kimoto; Journal of Food Science 1981, V46, P1881 HCAPLUS
(47) Kjer, P; Nordisk Medicin 1966, V75(14), P390 MEDLINE
(48) Klimova; Biochemical and Biophysical Research Communications 1990, V166(3), P1411 HCAPLUS
(49) Kraft; Biol Chem Hoppe Seyler 1972, V353, P1540
(50) Lezdey John; US 5134119 1992 HCAPLUS
(51) Lipman; Science 1985, V227, P1435 HCAPLUS
(52) Lu; Biol Chem Hoppe-Seyler 1990, V371, P851 HCAPLUS
(53) Mazza, V; Folia Med 1969, V52(9), P565 MEDLINE
(54) Melrose, J; Arch Orthop Trauma Surg 1995, V114, P145 MEDLINE
(55) Nasemann, T; Hautarz 1967, V18(1), P31 MEDLINE
(56) Olalla, A; Biochimica et Biophysica Acta 1978, V523, P181 HCAPLUS
(57) Osnes, K; Comp Biochem Physiol 1985, V82B(4), P599 HCAPLUS
(58) Osnes, K; Comp Biochem Physiol 1986, V83B(2), P445 HCAPLUS
(59) Osnes, K; Comp Biochem Physiol 1986, V83B(4), P801 HCAPLUS
(60) Osnes, K; Comp Biochem Physiol 1995, V82B(4), P607
(61) Rathgeber, W; S Afr Med J 1971, V45(7), P181 MEDLINE
(62) Rawlings; US 5439935 1995 HCAPLUS
(63) Reyes, L; Medicina 1965, V45(964), P221
(64) Riffat; Lyon Med 1971, V226(13), P103 MEDLINE
(65) Sakharov; Comp Biochem Physiol 1994, V108B, P561 HCAPLUS
(66) Sakharov, Y; Arch Dermatol Res 1993, V285, P32
(67) Seather, O; Comp Biochem Physical 1987, V88B(1), P165
(68) Sellos; FEBS 1992, V309(3), P219 HCAPLUS
(69) Spindler; Polar Biology 1988, V9, P115
(70) Szeghy; Klin Monatshl Augenheilkd 1968, V153(6), P827 MEDLINE

(71) Tokuda; Nippon Ganka Kiyo 1968, V19(10), P993 MEDLINE
(72) Tsai; Biochimica et Biophysica Acta 1991, V1080, P59 HCAPLUS
(73) Tsu; The Journal of Biochemical Chemistry 1994, V269(30), P19565 HCAPLUS
(74) Turkiewicz; Acta Biochimica Polonica 1986, V33(2), P87 HCAPLUS
(75) Turkiewicz; Comp Biochem Physiol 1991, V99B, P359 HCAPLUS
(76) Von, P; Fortschrr Med 1995, V113(4), P43
(77) Welgus; Biochemistry 1982, V21, P5183 HCAPLUS
(78) Welgus; Biochemistry 1983, V22, P2228 HCAPLUS
(79) Wormhoudt; Comp Biochem Physiol 1992, V103B(3), P675
(80) Zhailiev, D; Khirurgiia 1984, 1, P67 MEDLINE

IT **244097-30-1 244097-31-2 244097-32-3**
244097-36-7
RL: PRP (Properties)
(unclaimed sequence; krill-derived multifunctional enzyme and its medical uses)

RN 244097-30-1 HCAPLUS

CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-asparaginyl-L-.alpha.-glutamyl-L-valyl-L-threonyl-L-prolyl-L-histidyl-L-alanyl-L-tyrosyl-L-prolyl-L-tryptophyl-L-glutaminyl-L-valylglycyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





PAGE 2-B



PAGE 3-A



PAGE 4-A

RN 244097-31-2 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-methionyl-L-.alpha.-glutamyl-L-valyl-L-threonyl-L-prolyl-L-histidyl-L-alanyl-L-tyrosyl-L-prolyl-L-tryptophyl-L-glutaminyl-L-valylglycyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





PAGE 2-B



PAGE 3-A



PAGE 4-A

RN 244097-32-3 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-valyl-L-.alpha.-glutamyl-L-alanyl-L-threonyl-L-prolyl-L-histidyl-L-seryl-L-tryptophyl-L-prolyl-L-histidyl-L-glutaminyl-L-alanyl-L-alanyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 244097-36-7 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-valyl-L-.alpha.-glutamyl-L-alanyl-L-valyl-L-prolyl-L-asparaginyl-L-seryl-L-tryptophyl-L-prolyl-L-histidyl-L-glutaminyl-L-alanyl-L-alanyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



L90 ANSWER 6 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:795998 HCAPLUS
DN 132:31798
TI Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
IN An, Gang; O'Hara, S. Mark; Ralph, David; Veltri, Robert W.
PA Urocor, Inc., USA
SO PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C12Q001-68
ICS C07H021-04; C07K014-435; C07K016-00; A61K038-17; A61K048-00
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 14, 63
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9964631	A1	19991216	WO 1999-US13151	19990611	<--
	W: AU, CA, JP					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	US 6218529	B1	20010417	US 1998-97199	19980612	<--
	AU 9945604	A1	19991230	AU 1999-45604	19990611	<--
	EP 1086246	A1	20010328	EP 1999-928561	19990611	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					

PRAI US 1998-97199 A 19980612 <--
US 1995-1655P P 19950731 <--
US 1996-13611P P 19960111 <--
US 1996-692787 A2 19960731 <--
WO 1999-US13151 W 19990611

AB Disclosed are diagnostic techniques for the detection of human prostate, bladder and breast cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate, bladder and breast cancer are described. The invention relates particularly to probes and

methods for evaluating the presence of 26 mRNA species (identified by RNA fingerprinting or quant. RT-PCR) that are differentially expressed in prostate, bladder and breast cancer compared to normal human prostate, benign prostatic hyperplasia, or normal bladder or breast tissue. Three of the markers were identified as cyclin A, fibronectin, and a truncated Her2/neu. The gene for UC28 protein was mapped to chromosome 6q23-24 by FISH chromosome mapping.

ST prostate bladder breast cancer genetic marker; sequence cDNA marker prostate bladder breast cancer marker; hybridization probe genetic marker cancer; amplification primer genetic marker cancer

IT Cyclins
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(A; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT PCR (polymerase chain reaction)
(RT-PCR (reverse transcription-PCR); biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT Genetic mapping
(UC28 gene mapping on human chromosome 6q23-24; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT Immunoassay
Nucleic acid hybridization
PCR (polymerase chain reaction)
Protein sequences
Tumor markers
cDNA sequences
(biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT Fibronectins
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT **Antibodies**
Primers (nucleic acid)
Probes (nucleic acid)
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT Antisense DNA
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT **Antitumor agents**
(bladder carcinoma; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT Diagnosis
(cancer; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT Bladder
Bladder
(carcinoma, inhibitors; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT Chromosome
(human 6, UC28 gene mapping on human chromosome 6q23-24; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT **Antitumor agents**
(mammary gland; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT Mammary gland
Mammary gland
Prostate gland
Prostate gland
(neoplasm, inhibitors; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT Bladder
Mammary gland
Prostate gland
(neoplasm; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT **Antitumor agents**
(prostate gland; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT neu (receptor)
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(truncated; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT 203266-57-3
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for NEU; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT 203266-70-0 203266-71-1
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC201; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT 203266-72-2 203266-73-3
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC204; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT 203266-74-4 203266-75-5
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC205; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT 203266-76-6
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC207; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT 203266-77-7 203266-78-8
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC209; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT 203266-79-9 203266-80-2
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC210; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)
IT 203266-81-3 203266-82-4
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC211; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)



IT 203266-83-5 203266-84-6
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC212; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-85-7 203266-86-8
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC213; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 252565-29-0 252565-30-3
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC214; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 252565-31-4 252565-32-5
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC215; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-41-5 203266-42-6
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC25; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-43-7 203266-44-8
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC27; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 252565-36-9
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC28/2.5; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-45-9 203266-46-0 252565-33-6 252565-34-7
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC28; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-47-1 203266-48-2
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC31; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-49-3 203266-50-6
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC32; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-51-7 203266-52-8
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC33; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-58-4 203266-59-5
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC38; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-60-8 203266-61-9
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(PCR primer for UC40; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-62-0 203266-63-1
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC41; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-66-4 203266-67-5
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC43; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-68-6 203266-69-7
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for UC47; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-39-1 203266-40-4
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for cyclin A; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-87-9 233266-27-8
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for prostate-specific antigen; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 203266-53-9 203266-54-0 233266-28-9
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PCR primer for .beta.-actin; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT **252370-14-2**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(UC28 antigenic peptide; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 135316-30-2 252565-38-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 252565-35-8
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(in situ hybridization probe for UC28; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

IT 140033-77-8 140068-52-6 203267-72-5 203267-73-6 203267-74-7
203267-75-8 203267-76-9 203267-78-1 203267-79-2 203267-80-5
203267-81-6 203267-82-7 203267-83-8 203267-84-9 203267-85-0
203267-86-1 203267-87-2 203267-89-4 203267-90-7 203267-91-8
203267-92-9 203267-93-0 203267-94-1 203267-95-2 252565-37-0
252565-39-2
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(nucleotide sequence; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Adam; Proceedings of the American Association for Cancer Research 1995,

V36, P25
(2) Chen; Journal of Urology 1995, V153(Supplement 4), P267
(3) Eberlein; US 5550214 A 1996 HCAPLUS
(4) Mcclelland; US 5487985 A 1996 HCAPLUS
(5) Mosher; US 5342762 A 1994 HCAPLUS
(6) Shyjan, A; US 5633161 A 1997 HCAPLUS

IT **252370-14-2**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(UC28 antigenic peptide; biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer)

RN 252370-14-2 HCAPLUS

CN L-Glutamic acid, L-arginyl-L-lysyl-L-lysyl-L-.alpha.-glutamyl-L-lysyl-L-valyl-L-lysyl-L-arginyl-L-seryl-L-glutaminyl-L-lysyl-L-alanyl-L-threonyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B

L90 ANSWER 7 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:622175 HCAPLUS
DN 131:237988
TI Acne treatment with krill-derived multifunctional enzyme
IN De Faire, Johan R.; Franklin, Richard L.; Kay, John; Lindblom, Ragnvald
PA Phairson Medical Inc., UK
SO U.S., 42 pp., Cont.-in-part of U.S. Ser. No. 486,820.
CODEN: USXXAM
DT **Patent**
LA English
IC A61K038-48; C12N009-64; D06M016-00
NCL 424094630
CC 1-12 (Pharmacology)
Section cross-reference(s): 7, 12, **15**, 63
FAN.CNT 5

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 5958406	A	19990928		US 1996-600273	19960208	<--
	US 5945102	A	19990831		US 1995-385540	19950208	<--
	US 6030612	A	20000229		US 1995-486820	19950607	<--
	US 6232088	B1	20010515		US 1998-220731	19981224	<--
PRAI	US 1994-338501	B2	19941122	<--			
	US 1995-385540	A2	19950208	<--			
	US 1995-486820	A2	19950607	<--			
	US 1996-600273	A2	19960208	<--			

AB The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a mol. wt. between about 20 kd and about 40 kd as detd. by SDS PAGE. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homol. with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including **autoimmune** disease and cancer. Addnl., the invention relates to a method of purifying the multifunctional enzyme, and to a prepn. of essentially purified multifunctional enzyme. Women with facial acne were treated with 0.1 mg of krill multifunctional hydrolase prepn. several times a day for 4-6 days.

ST multifunctional enzyme krill acne treatment; proteinase multifunctional krill acne pharmaceutical

IT CD antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CD28, enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)

IT CD antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CD29D, enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)

IT CD antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CD49, enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)
IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ICAM-1 (intercellular adhesion mol. 1), enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)
IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ICAM-2 (intercellular adhesion mol. 2), enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)
IT Selectins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(L-, enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)
IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PECAM-1, enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)
IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(VCAM-1, enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)
IT Acne
Allergy inhibitors
Anti-infective agents
Antibacterial agents
Antidiarrheals
Antiglaucoma agents
Antiulcer agents
Antiviral agents
Fungicides
Krill
Parasiticides
Protein sequences
Thrombolytics
Wound healing promoters
(acne treatment with krill-derived multifunctional enzyme)
IT Skin, disease
(aging, wrinkles, redn. of; acne treatment with krill-derived multifunctional enzyme)
IT Skin preparations (pharmaceutical)
Skin preparations (pharmaceutical)
(antiulcer agents; acne treatment with krill-derived multifunctional enzyme)
IT Intestine
(anus, polyps, removal of; acne treatment with krill-derived multifunctional enzyme)
IT Skin, disease
(boils, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT **Bronchi**
(bronchitis, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Keloid
(decompn. of; acne treatment with krill-derived multifunctional enzyme)

IT Antiulcer agents
Antiulcer agents
(decubitus ulcer inhibitors; acne treatment with krill-derived multifunctional enzyme)
IT Joint, anatomical
(disease, wrist, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(enzyme removal or inactivation of, of cell surface; acne treatment with krill-derived multifunctional enzyme)
IT CD4 (antigen)
CD44 (antigen)
CD8 (antigen)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)
IT Disease, animal
(fistula, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Vein
(hemorrhoid, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Human herpesvirus 2
(herpes genitalis from, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Drug delivery systems
(hydrogels; acne treatment with krill-derived multifunctional enzyme)
IT Haemophilus influenzae
Human herpesvirus
Human herpesvirus 3
Human immunodeficiency virus
Influenza virus
Mycoplasma
(infection with, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Mouth
(infection, gum, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT **Eye, disease**
Urinary tract
(**infection**, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Joint, anatomical
(**inflammation**, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Ovary, neoplasm
Ovary, neoplasm
(inhibitors; acne treatment with krill-derived multifunctional enzyme)
IT Cell adhesion
(krill hydrolase inhibition of; acne treatment with krill-derived multifunctional enzyme)
IT Mouth
(lichen planus, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Drug delivery systems
(lozenges; acne treatment with krill-derived multifunctional enzyme)
IT Enzymes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(multifunctional; acne treatment with krill-derived multifunctional enzyme)
IT **Antitumor agents**
Antitumor agents
(ovary; acne treatment with krill-derived multifunctional enzyme)
IT Tooth
(plaque, removal of; acne treatment with krill-derived multifunctional enzyme)
IT Penis
(prepuce, infection of, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Newborn
(prevention and treatment of infection in navel of; acne treatment with krill-derived multifunctional enzyme)
IT Prostate gland
(prostatitis, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Skin, disease
(rash, allergic, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Wart
(removal of; acne treatment with krill-derived multifunctional enzyme)
IT **Antitumor agents**
(sarcoma; acne treatment with krill-derived multifunctional enzyme)
IT Skin, disease
(scar, decompn. of; acne treatment with krill-derived multifunctional enzyme)
IT Connective tissue
(scleroderma, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Respiratory tract
(sinusitis, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Drug delivery systems
(solns., ophthalmic; acne treatment with krill-derived multifunctional enzyme)
IT Drug delivery systems
(topical; acne treatment with krill-derived multifunctional enzyme)
IT **Abscess**
Alopecia
Athlete's foot
Cataract
Common cold
Eczema
Mastitis
Psoriasis
Seborrhea
(treatment of; acne treatment with krill-derived multifunctional enzyme)
IT **Intestine, disease**
(**ulcerative colitis**, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT Infection
(viral, treatment of; acne treatment with krill-derived multifunctional enzyme)
IT 182238-43-3
RL: PRP (Properties)
(N-terminal sequence, for krill-derived multifunctional enzyme; acne treatment with krill-derived multifunctional enzyme)
IT **244097-30-1 244097-31-2 244097-32-3**
244097-33-4 244097-34-5 244097-35-6 **244097-36-7**
244097-37-8 244097-38-9 244097-39-0 244097-40-3 244097-41-4

244097-42-5 244097-43-6
RL: PRP (Properties)
(Unclaimed; acne treatment with krill-derived multifunctional enzyme)
IT 9001-12-1, Collagenase 9001-92-7, Endopeptidase 9002-07-7, Trypsin
9004-06-2, Elastase 9004-07-3, Chymotrypsin 9031-96-3, Exopeptidase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acne treatment with krill-derived multifunctional enzyme)
IT 71012-19-6
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(enzyme removal or inactivation of; acne treatment with krill-derived multifunctional enzyme)
IT 244145-79-7, PN: US5958406 SEQID: 4 unclaimed protein 244145-80-0
244145-91-3 244145-92-4
RL: PRP (Properties)
(unclaimed protein sequence; acne treatment with krill-derived multifunctional enzyme)
RE.CNT 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Al-Mohanna; J Mar Biol Ass U K 1985, V65, P901
(2) Anheller; Arch Dermatol Res 1989, V281, P105 HCAPLUS
(3) Anheller; Archives of Dermatology Research 1989, V281, P105 HCAPLUS
(4) Anon; EP 0170115 A1 1985 HCAPLUS
(5) Anon; JP 6168419 1986
(6) Anon; WO 9319732 1993 HCAPLUS
(7) Anon; WO 9324142 1993 HCAPLUS
(8) Anon; WO 9419005 1994 HCAPLUS
(9) Anon; WO 9507686 1995 HCAPLUS
(10) Anon; WO 9507688 1995 HCAPLUS
(11) Athie; Medicina (Mex) 1965, V45(961), P145 MEDLINE
(12) Bar; Lille Med 1970, V15(5), P827 HCAPLUS
(13) Bazerque; Medicina (B Aires) 1972, V32(4), P357 MEDLINE
(14) Berenshtein; Antibiotiki 1978, V23(11), P1002 HCAPLUS
(15) Billigmann, V; Fortschrr Med 1995, V113(4), P43
(16) Bucht, A; Biol Chem Hoppe Sryler 1986, V367, P366
(17) Chen; US 4677069 1987 HCAPLUS
(18) Chen; Journal of Food Biochemistry 1978, V2, P349
(19) Chudakov; Kirurgiia (Mosk) 1973, V49(2), P87
(20) Coblentz; J Am Geriatr Soc 1968, V16(9), P1039 MEDLINE
(21) Daniushchenkova; Antibiotiki 1978, V23(4), P330 MEDLINE
(22) Demianiuk; Klin Khir 1972, V8, P56 MEDLINE
(23) Dimarco; Clin Pediatr, (Bologna) 1970, V52(1), P34
(24) D'Arrigo, C; Minerva Medica 1969, V60(87), P4327 MEDLINE
(25) Eisen, A; Biochemistry 1973, V12(9), P1814 HCAPLUS
(26) Gacon; Lyon Med 1969, V222(43), P997 MEDLINE
(27) Gastschev; Sovetskaia Meditsina 1980, 9, P52
(28) Gates; Shrimp Trypsin 1969, V8(11), P4483 HCAPLUS
(29) Geller; Khirurgiia (Mosk) 1973, V49(2), P64
(30) Goodfriend; J Am Podiatry Assoc 1965, V55(9), P667 MEDLINE
(31) Gordillo, F; Medicina (Mex) 1965, V45(973), P490
(32) Gotishchev; Sovetskaia Meditsina 1978, 5, P80
(33) Grant; Biochemistry 1980, V19, P4653 HCAPLUS
(34) Grant; Biochemistry 1983, V22, P354 HCAPLUS
(35) Grant; Methods in Enzymology 1980, V80, P722
(36) Grant And Eisen; Biochemistry 1980, V19, P6089
(37) Grigorian; Klin Khir 1971, V9, P1 MEDLINE
(38) Gudmundsodottir; Eur J Biochem 1993, V217, P1091
(39) Hellgren; US 4801451 1989 HCAPLUS
(40) Hellgren; US 4963491 1990 HCAPLUS
(41) Jacobs; J Am Podiatry Assoc 1965, V55(11), P743 MEDLINE
(42) Johansson, B; Biol Chem Hoppe Sryler 1986, V367, P366

(43) Karlstam And Ljunglof; Biol Chem Hoppe Seyler 1986, V367, P339
(44) Kimoto; Agric Biol Chem 1983, V47(3), P529 HCAPLUS
(45) Kimoto; Agric Biol Chem 1985, V49(6), P1599 HCAPLUS
(46) Kimoto; Journal of Food Science 1981, V46, P1881 HCAPLUS
(47) Kjer, P; Nordisk Medicin 1966, V75(14), P390 MEDLINE
(48) Klimova; Biochemical and Biophysical Research Communications 1990, V166(3), P1411 HCAPLUS
(49) Kraft And Falkenberg; Biol Chem Hoppe Seyler 1972, V353, P1540
(50) Lezdey; US 5134119 1992 HCAPLUS
(51) Lipman And Pearson; Science 1985, V227, P1435
(52) Lu; Biol Chem Hoppe-Seyler 1990, V371, P851 HCAPLUS
(53) Mazza, V; Folia Med 1969, V52(9), P565 MEDLINE
(54) Melrose, J; Arch Orthop Trauma Surg 1995, V114, P145 MEDLINE
(55) Nasemann, T; Hautarz 1967, V18(1), P31 MEDLINE
(56) Olalla, A; Biochimica et Biophysica Acta 1978, V523, P181 HCAPLUS
(57) Osnes, K; Comp Biochem Physiol 1985, V82B(4), P599 HCAPLUS
(58) Osnes, K; Comp Biochem Physiol 1986, V83B(2), P445 HCAPLUS
(59) Osnes, K; Comp Biochem Physiol 1986, V83B(4), P801 HCAPLUS
(60) Osnes, K; Comp Biochem Physiol 1995, V82B(4), P607
(61) Rathgeber, W; S Afr Med J 1971, V45(7), P181 MEDLINE
(62) Rawlings; US 5439935 1995 HCAPLUS
(63) Reyes, L; Medicina (Mex) 1965, V45(964), P221
(64) Riffat; Lyon Med 1971, V226(13), P103 MEDLINE
(65) Sakharov; Comp Biochem Physiol 1994, V108B, P561 HCAPLUS
(66) Sakharov, Y; Arch Dermatol Res 1993, V285, P32
(67) Seather, O; Comp Biochem Physical 1987, V88B(1), P165
(68) Sellos And Wormhoudt; FEBS 1992, V309(3), P219
(69) Spindler; Polar Biology 1988, V9, P115
(70) Szeghy; Klin Monatshl Augenheilkd 1968, V153(6), P827 MEDLINE
(71) Tokuda; Nippon Ganka Kiyo 1968, V19(10), P993 MEDLINE
(72) Tsai; Biochimica et Biophysica Acta 1991, V1080, P59 HCAPLUS
(73) Tsu; The Journal of Biochemical Chemistry 1994, V269(30), P19565 HCAPLUS
(74) Turkiewicz; Acta Biochimica Polonica 1986, V33(2), P87 HCAPLUS
(75) Turkiewicz; Comp Biochem Physiol 1991, V99B, P359 HCAPLUS
(76) Welgus; Biochemistry 1982, V21, P5183 HCAPLUS
(77) Welgus And Grant; Biochemistry 1983, V22, P2228
(78) Wormhoudt; Comp Biochem Physiol 1992, V103B(3), P675
(79) Zhailiev, D; Khirurgiia (Mosk) 1984, 1, P67 MEDLINE

IT **244097-30-1 244097-31-2 244097-32-3**
244097-36-7
RL: PRP (Properties)
(Unclaimed; acne treatment with krill-derived multifunctional enzyme)

RN 244097-30-1 HCAPLUS

CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-asparaginyl-L-.alpha.-glutamyl-L-valyl-L-threonyl-L-prolyl-L-histidyl-L-alanyl-L-tyrosyl-L-prolyl-L-tryptophyl-L-glutaminyl-L-valylglycyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





PAGE 2-B



PAGE 3-A



PAGE 4-A

RN 244097-31-2 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-methionyl-L-.alpha.-glutamyl-L-valyl-L-threonyl-L-prolyl-L-histidyl-L-alanyl-L-tyrosyl-L-prolyl-L-tryptophyl-L-glutaminyl-L-valylglycyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





PAGE 2-B



PAGE 3-A



PAGE 4-A

RN 244097-32-3 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-valyl-L-.alpha.-glutamyl-L-alanyl-L-threonyl-L-prolyl-L-histidyl-L-seryl-L-tryptophyl-L-prolyl-L-histidyl-L-glutaminyl-L-alanyl-L-alanyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 244097-36-7 HCAPLUS
CN L-Phenylalanine, L-isoleucyl-L-valylglycylglycyl-L-valyl-L-.alpha.-glutamyl-L-alanyl-L-valyl-L-prolyl-L-asparaginyl-L-seryl-L-tryptophyl-L-prolyl-L-histidyl-L-glutaminyl-L-alanyl-L-alanyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



L90 ANSWER 8 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:528979 HCAPLUS
DN 131:165747
TI Inotropic and diuretic effects of exendin, glucagon-like peptide-1[7-36]amide, or their agonists
IN Young, Andrew A.; Vine, Will; Beeley, Nigel R. A.; Prickett, Kathryn
PA Amylin Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A01N037-18
CC 2-6 (Mammalian Hormones)
Section cross-reference(s): 1, 34
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940788	A1	19990819	WO 1999-US2554	19990205 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2320371	AA	19990819	CA 1999-2320371	19990205 <--
	AU 9926596	A1	19990830	AU 1999-26596	19990205 <--
	EP 1054594	A1	20001129	EP 1999-906762	19990205 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002509078	T2	20020326	JP 2000-531064	19990205 <--
PRAI	US 1998-75122P	P	19980213 <--		
	WO 1999-US2554	W	19990205		

OS MARPAT 131:165747

AB Methods for increasing urine flow are disclosed, comprising administration of an effective amt. of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concn. are also disclosed. The methods are useful for treating conditions or disorders assocd. with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amt. of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compns. for use in the methods of the invention are also disclosed.

ST inotropic diuretic exendin insulinotropin agonist prepn

IT **Lung, disease**
(**edema**; exendin, glucagon-like peptide-1[7-36]amide, or agonists for treating conditions or disorders assocd. with toxic hypervolemia, such as renal **failure** and congestive heart **failure**)

IT Cirrhosis
(exendin, glucagon-like peptide-1[7-36]amide, or agonists for treating conditions or disorders assocd. with toxic hypervolemia, such as renal failure and congestive heart failure)

IT **Kidney, disease**
(**failure**; exendin, glucagon-like peptide-1[7-36]amide, or agonists for treating conditions or disorders assocd. with toxic hypervolemia, such as renal **failure** and congestive heart **failure**)

IT Heart, disease
(failure; exendin, glucagon-like peptide-1[7-36]amide, or agonists for treating conditions or disorders assocd. with toxic hypervolemia, such as renal failure, and congestive heart failure)

IT Kidney
(glomerulus, filtration rate; increasing renal plasma flow and glomerular filtration rate using an exendin, glucagon-like peptide-1[7-36]amide, or agonists)

IT Blood
(hypervolemia; exendin, glucagon-like peptide-1[7-36]amide, or agonists for treating conditions or disorders assocd. with toxic hypervolemia, such as renal failure and congestive heart failure)

IT Diuretics
Inotropics
(inotropic and diuretic effects of exendin, glucagon-like peptide-1[7-36]amide, or agonists)

IT Diuretics
(natriuretics; inotropic and diuretic effects of exendin, glucagon-like peptide-1[7-36]amide, or agonists)

IT **Kidney, disease**
(**nephrotic syndrome**; exendin, glucagon-like peptide-1[7-36]amide, or agonists for treating conditions or disorders assocd. with toxic hypervolemia, such as renal **failure** and congestive heart **failure**)

IT Surgery
(ocular and neuro-; prepg. a patient for surgical procedure by administering exendin, glucagon-like peptide-1[7-36]amide, or agonists)

IT Drug delivery systems
(pharmaceutical compns. contg. exendin, glucagon-like peptide-1[7-36]amide, of agonists as diuretics or inotropics)

IT Surgery
(prepg. a patient for surgical procedure by administering exendin, glucagon-like peptide-1[7-36]amide, or agonists)

IT Circulation
(renal; increasing renal plasma flow and glomerular filtration rate

using an exendin, glucagon-like peptide-1[7-36]amide, or agonists)
IT Preeclampsia
(treating pre-eclampsia or eclampsia of pregnancy using an exendin, glucagon-like peptide-1[7-36]amide, or agonists)
IT Edema
(treatment; inotropic and diuretic effects of exendin, glucagon-like peptide-1[7-36]amide, or agonists)
IT 165338-05-6P, 1-31-Exendin 4 (Heloderma suspectum) 210712-28-0P, 1-30-Exendin 4 (Heloderma suspectum) 210712-29-1P 210712-30-4P
210712-31-5P 210712-33-7P 210712-34-8P 210712-35-9P 210712-36-0P
210712-37-1P 210712-38-2P 210712-39-3P 210712-40-6P 210712-41-7P
210712-42-8P 210712-43-9P 210712-44-0P 210712-45-1P 210712-46-2P
210712-47-3P 210712-48-4P 210712-49-5P 210712-50-8P 210712-51-9P
210712-52-0P 210712-53-1P 210712-54-2P 210712-55-3P 210712-56-4P
210712-57-5P 210712-58-6P 210712-59-7P 210712-60-0P 210712-61-1P
210712-62-2P 210712-63-3P 210712-64-4P 210712-65-5P 210712-67-7P
210712-68-8P 210824-14-9P 210824-35-4P 210824-60-5P 210824-78-5P
210828-61-8P 210828-91-4P 210828-92-5P 210829-01-9P 210829-03-1P
210829-07-5P 210829-08-6P 210829-11-1P 210829-12-2P 210829-35-9P
210829-36-0P 210829-38-2P 210829-53-1P 210829-57-5P 210829-60-0P
238091-49-1P 238091-54-8P **238091-55-9P** 238091-56-0P
238091-57-1P 238091-58-2P 238091-59-3P 238091-60-6P 238091-61-7P
238091-62-8P 238091-63-9P 238091-64-0P 238091-65-1P 238091-66-2P
238091-67-3P 238091-68-4P 238091-69-5P 238091-70-8P 238091-71-9P
238091-72-0P 238091-73-1P 238091-74-2P 238091-75-3P 238091-76-4P
238091-77-5P 238091-78-6P 238091-79-7P 238091-80-0P 238091-81-1P
238091-82-2P 238091-83-3P 238091-84-4P 238091-85-5P 238091-86-6P
238091-87-7P 238091-88-8P 238091-89-9P 238091-90-2P 238091-91-3P
238091-92-4P 238091-93-5P 238091-94-6P 238410-89-4P
238410-90-7P 238411-00-2P 238411-01-3P 238411-02-4P 238411-03-5P
238411-04-6P 238411-05-7P 238411-06-8P 238411-07-9P 238411-08-0P
238411-10-4P 238748-48-6P 239091-09-9P 239091-51-1P 239091-53-3P
239091-57-7P 239091-60-2P 239091-62-4P 239091-64-6P 239100-19-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inotropic and diuretic effects and synthesis of exendin, glucagon-like peptide-1[7-36]amide, and agonists)
IT 118549-37-4, Insulinotropin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inotropic and diuretic effects and synthesis of exendin, glucagon-like peptide-1[7-36]amide, and agonists)
IT 130391-54-7, Exendin 3 141732-76-5, Exendin 4 213190-65-9, Exendin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inotropic and diuretic effects of exendin, glucagon-like peptide-1[7-36]amide, or agonists)
IT 7440-09-7, Potassium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(urinary potassium concn. using exendin, glucagon-like peptide-1[7-36]amide, or agonists)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Chen; US 5512549 A 1996 HCAPLUS
(2) Eng; US 5424286 A 1995 HCAPLUS
IT **238091-55-9P 238091-92-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inotropic and diuretic effects and synthesis of exendin, glucagon-like peptide-1[7-36]amide, and agonists)

RN 238091-55-9 HCAPLUS

CN L-Aspartamide, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-leucyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-phenylalanyl-L-leucyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 238091-92-4 HCAPLUS
CN L-Asparagine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-leucyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-phenylalanyl-L-leucyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



L90 ANSWER 9 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:175673 HCAPLUS
DN 130:222133
TI Peptides and compounds that bind to the IL-1 receptor
IN Barrett, Ronald W.; Yanofsky, Stephen D.
PA Affymax Technologies N.V., UK
SO U.S., 120 pp., Cont.-in-part of U.S. 5,767,234.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K038-00
ICS A61K038-04

NCL 514015000
CC **15-5** (Immunochemistry)
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5880096	A	19990309	US 1995-463076	19950605 <--
	US 5608035	A	19970304	US 1994-190788	19940202 <--
	US 5767234	A	19980616	US 1995-383474	19950201 <--
PRAI	US 1994-190788		19940202 <--		
	US 1995-383474		19950201 <--		

AB Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amt. of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ1 W where Z1 is L, I, A, or Q (SEQ ID NO:2); (2) XXQZ5YZ6XX where Z5 is P or Aze where Aze is azetidine; and Z6 is S, A, V, or L (SEQ ID NO:1); and (3) Z23NZ24SZ25Z26Z27Z28Z29Z30L where Z23 is D or Y; Z24 is D or S; Z25 is S or W; Z26 is S or Y; Z27 is D or V; Z28 is S or W; Z29 is F or L; and Z30 is D or L (SEQ ID NO:27); and where each amino acid is indicated by std. one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids. Also provided are peptides which bind to the IL-1RtI, which are 11 to 40 amino acids in length, which comprise the core sequence of amino acids: Z31XWZ32Z33Z34Z35Z36QZ37Z38 where each letter represents the std. one letter abbreviation for an amino acid or an analog thereof; X is selected from the group of natural or unnatural amino acids; Z37 is a natural or unnatural cyclic amino acid; Z31 is selected from phenylalanine and acetylated phenylalanine; Z32 is a natural or unnatural amino acid; Z33 is selected from proline and pipecolic acid; Z34 is selected from glycine, d-alanine, d-valine, sarcosine and aminoisobutyric acid; Z35 is a natural or unnatural amino acid and Z36 is selected from tyrosine, phosphotyrosine, phenylalanine and tryptophan; and Z38 is selected from tyrosinamide and substituted tyrosinamide (SEQ ID NO:392). These peptides are useful for inhibiting binding of IL-1 and IL-1 receptor, for screening IL-1 receptor agonist or antagonist, for assaying IL-1, and may be conjugated with cytotoxic agent or other therapeutic agent for treating diseases involving improper prodn. of or response to IL-1, e.g. **inflammatory** responses to infection and tissue injury.

ST interleukin 1 receptor binding peptide; **inflammation** infection injury IL1 receptor antagonist

IT Selectins
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(E-; interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Drug delivery systems
(carriers; interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Labels
(detectable; interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Immunity
(disorder, IL-1-related; interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Epidermal growth factor receptors
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(down regulation; interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Organ, animal
Organ, animal
(injury; interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Cytotoxic agents
Drugs
Infection
Inflammation
Protein sequences
(interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Interleukin 1 receptors
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Interleukin 1
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT Interleukin 1 receptor antagonist
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT 171491-67-1 171491-78-4 171491-79-5 171491-80-8 171491-81-9
171492-03-8 171492-12-9 171492-13-0 171492-14-1 171492-15-2
171492-16-3 171492-18-5 178696-05-4 186250-91-9 186250-92-0
186250-93-1 186250-94-2 186250-95-3 186250-96-4 186250-98-6
186251-00-3 186251-04-7 186251-06-9 186251-07-0 186251-08-1
186251-10-5 186251-11-6 186251-12-7 186251-13-8 186251-14-9
186251-15-0 186251-16-1 186251-17-2 186251-18-3 186251-21-8
186251-22-9 186251-24-1 186251-25-2 186251-26-3 186251-27-4
186252-03-9 186252-06-2 186252-07-3 186252-08-4 186252-09-5
186252-10-8 **186252-12-0** 186252-13-1 **186252-14-2**
186252-15-3 186252-16-4 186252-17-5 186252-18-6 186252-19-7
186252-20-0 186252-21-1 186252-22-2 186252-23-3 221107-63-7
221107-64-8 221107-65-9 221107-66-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

IT 363-24-6, Prostaglandin E2
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(response; interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Adams; US 5039790 1991 HCAPLUS
(2) Anon; WO 9100742 1991 HCAPLUS
(3) Anon; WO 9108285 1991 HCAPLUS
(4) Anon; WO 9117184 1991 HCAPLUS
(5) Auron; US 5077219 1991 HCAPLUS
(6) Bender; Ann Rep Med Chem 1989, V25, P185
(7) Cwirla; Proc Natl Acad Sci USA 1990, V87, P6378 HCAPLUS
(8) Dinarello; Blood 1991, V77(8), P1627 HCAPLUS
(9) Dower; US 4968607 1990 HCAPLUS
(10) Dower; Immunol Today 1987, V8(2), P46 HCAPLUS
(11) Dower; J Clin Immunol 1990, V10(6), P289 HCAPLUS
(12) Evans; J Biol Chem 1995, V270(19), P11477 HCAPLUS
(13) Fodor; Science 1991, V251, P767 HCAPLUS
(14) Hannum; US 5075222 1991 HCAPLUS
(15) Hannum; Nature 1990, V343, P336 HCAPLUS
(16) Krueger; US 5075288 1991 HCAPLUS
(17) Labriola, T; Proc Natl Acad Sci USA 1991, V88, P11182
(18) Larrick; Immunol Todya 1989, V10(2), P61 HCAPLUS
(19) McMahan; EMBO J 1991, V10(10), P2821 HCAPLUS

IT **186252-12-0 186252-14-2**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 1 receptor-binding peptides and their conjugates with cytotoxic or therapeutic agent or label for treating or diagnosing diseases involving improper prodn. of or response to IL-1)

RN 186252-12-0 HCAPLUS

CN L-Tyrosine, L-seryl-L-prolyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-asparaginyl-L-threonyl-L-alanyl-L-tryptophyl-L-tyrosyl-L-.alpha.-glutamyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B



RN 186252-14-2 HCAPLUS

CN L-Tyrosine, L-threonyl-L-prolyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-asparaginyl-L-threonyl-L-alanyl-L-tryptophyl-L-tyrosyl-L-.alpha.-glutamyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B



L90 ANSWER 10 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:81635 HCAPLUS
DN 130:152119
TI Cancer-associated nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications
IN Old, Lloyd J.; Scanlan, Matthew J.; Stockert, Elisabeth; Gure, Ali; Chen, Yao-Tseng; Gout, Ivan; O'Hare, Michael; Obata, Yuichi; Pfreundschuh, Michael; Tureci, Ozlem; Sahin, Ugur
PA Ludwig Institute for Cancer Research, USA; et al.
SO PCT Int. Appl., 789 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM G01N033-574
CC 14-1 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 3, 6, 9, **15**, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9904265	A2	19990128	WO 1998-US14679	19980715	<--
	WO 9904265	A3	19990826			
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	US 6218521	B1	20010417	US 1997-896164	19970717	<--
	US 6043084	A	20000328	US 1997-948705	19971010	<--
	US 6403373	B1	20020611	US 1998-102322	19980622	<--
	AU 9885715	A1	19990210	AU 1998-85715	19980715	<--
	EP 996857	A2	20000503	EP 1998-936860	19980715	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	JP 2001516009	T2	20010925	JP 2000-503425	19980715	<--
	US 2002037541	A1	20020328	US 2001-835992	20010417	<--
PRAI	US 1997-896164	A	19970717	<--		

US 1997-61599P P 19971010 <--
US 1997-61765P P 19971010 <--
US 1997-948705 A 19971010 <--
GB 1997-21697 A 19971011 <--
US 1998-102322 A 19980622 <--
WO 1998-US14679 W 19980715

AB The present invention involves the cloning and sequencing of cDNAs encoding human cancer-assocd. antigen precursors identified by immunoscreening with autologous antisera of subjects having cancer of the breast, colon, gastric, renal, lung, and prostate tissues. Some of the clones are considered completely novel as no nucleotide or amino acid homologies to coding regions were found in the databases searched, whereas other clones are novel but have some homol. to sequences deposited in databases (mainly EST sequences). Several hundred nucleotide and deduced amino acid sequences are provided. Also identified are 86 HLA-binding peptides found in the lung SEREX clones. The invention also discloses diagnostic and therapeutic methods based upon these mols.

ST cancer assocd cDNA antigen sequence human; breast cancer assocd cDNA antigen human; colon cancer assocd cDNA antigen human; stomach cancer assocd cDNA antigen human; kidney cancer assocd cDNA antigen human; lung cancer assocd cDNA antigen human; prostate cancer assocd cDNA antigen human

IT Histocompatibility antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA, complexes with cancer-assocd. proteins; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT Interleukins
Saponins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvant; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT **Antitumor agents**
Cytotoxic agents
Immunization
Kidney, neoplasm
Lung, neoplasm
Molecular cloning
Stomach, neoplasm
(cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT **Antibodies**
RL: ARG (Analytical reagent use); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT mRNA
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT Diagnosis
(cancer; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT **Antibodies**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(chimeric; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT **Intestine, neoplasm**
(colon; cancer-assocd. nucleic acids and antigens from human tissues

and their diagnostic and therapeutic applications)

IT Toxins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates of antitumor agents and; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT **Antibodies**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(conjugates; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT Neoplasm
(diagnosis; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT cDNA sequences
(for cancer-assocd. antigens from human tissues)

IT **Antibodies**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(humanized; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT **Antibodies**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT Mammary gland
Prostate gland
(neoplasm; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT Protein sequences
(of cancer-assocd. antigens from human tissues)

IT Proliferation inhibition
(proliferation inhibitors; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT Antigens
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(tumor-assocd.; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT 219808-42-1 219808-43-2 219808-44-3 219808-46-5 219808-47-6
219808-48-7 219808-49-8 219808-50-1 219808-51-2 219808-52-3
219808-53-4 219808-54-5 219808-55-6 219808-56-7 219808-57-8
219808-58-9 219808-59-0 219808-60-3 219808-62-5 219808-63-6
219808-64-7 219808-65-8 219808-66-9 219808-67-0 219808-68-1
219808-69-2 219808-70-5 219808-71-6 219808-72-7 219808-73-8
219808-74-9 219808-75-0 219808-76-1 219808-77-2 219808-78-3
219808-79-4 219808-80-7 219808-81-8 **219808-82-9**
219808-83-0 219808-84-1 219808-85-2 219808-86-3 219808-87-4
219808-88-5
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(HLA-binding peptide in lung cancer-assocd. protein; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT 83869-56-1, GM-CSF
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvant; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT 80700-94-3 98726-82-0 101463-15-4, Lamin C (human clone 7 precursor protein moiety) 113256-31-8, Phosphoprotein P 1 (human clone pT7P1

protein moiety reduced) 115470-57-0 134548-66-6, Protein (human clone pNM23-H2S gene nm23-H2 reduced) 141639-49-8, Histone H 1t (human) 147173-01-1 147339-19-3, .alpha.-Crystallin (human U-373MG cell B-chain) 148325-79-5 152990-73-3, Protein Shb (human reduced) 152990-86-8 153550-84-6, Protein DAD 1 (human reduced) 153553-15-2 154009-52-6, Annexin XI (human clone .lambda.ZV5 reduced) 155871-08-2 157546-56-0, Syntaxin (human clone pBS1.3 reduced) 160405-11-8 165526-85-2 170086-04-1 170679-66-0 171658-26-7, Rabaptin-5 (human) 172020-64-3 175279-46-6 175525-50-5 176898-80-9 177934-91-7 178740-94-8 179467-40-4 182938-65-4 183213-22-1 184379-70-2 189704-65-2 194304-81-9 200014-97-7, Protein (human gene DNJ3/CPR3) 200761-69-9, Protein (human testis gene BRDT reduced) 203812-13-9 205767-74-4 210568-51-7, Dynamin-like protein (human) 220127-88-8 220128-45-0 220128-46-1 220128-47-2 220128-48-3 220128-49-4 220128-50-7 220128-51-8 220128-52-9 220128-53-0 220128-54-1 220128-55-2 220128-56-3 220128-57-4 220128-58-5 220128-59-6 220128-60-9 220128-61-0 220128-62-1 220128-63-2 220128-65-4 220128-66-5 220128-67-6 220128-68-7 220128-69-8 220128-70-1 220128-71-2 220128-72-3 220128-75-6 220128-76-7 220128-82-5 220128-84-7 220128-85-8 220128-87-0 220129-16-8 220129-18-0 220129-20-4 220129-22-6 220129-24-8 220129-26-0 220129-27-1 220129-28-2 220129-30-6 220129-31-7 220129-33-9 220129-35-1 220129-37-3 220129-39-5 220129-41-9 220129-42-0 220129-45-3 220129-76-0 220129-83-9 220129-89-5 220130-00-7 220130-02-9 220130-04-1 220130-06-3 220171-35-7 220171-64-2 220171-75-5 220173-35-3 220197-79-5 220197-80-8 220197-82-0 220230-53-5 220232-26-8 220232-48-4 220232-64-4 220232-79-1 220232-90-6 220232-97-3 220233-03-4 220233-05-6 220233-06-7 220233-08-9 220233-09-0 220233-11-4 220233-13-6 220233-15-8 220233-16-9 220233-76-1 220235-90-5 220235-92-7 220235-93-8 220236-12-4 220236-16-8 220236-18-0 220274-02-2

RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT 139803-08-0 139808-51-8 140025-93-0 140026-88-6 140061-98-9 140079-04-5 142361-67-9 145885-80-9 147565-45-5 148450-65-1 150574-81-5 151973-87-4 153518-64-0 154210-82-9 165150-94-7 165526-84-1 167712-89-2 169733-95-3 170319-38-7, DNA (human rabaptin-5 cDNA plus flanks) 170681-21-7 171712-85-9 175826-07-0 176893-12-2 178659-41-1 178836-57-2 179790-41-1 180008-73-5 182093-26-1 182114-13-2 186580-68-7 187261-86-5 196024-82-5 196420-09-4 199066-25-6 205457-42-7 208554-20-5 208554-22-7 208554-24-9 208554-26-1 208554-27-2 208554-28-3 208554-29-4 208554-30-7 208554-31-8 208554-32-9 220100-92-5 220100-93-6 220100-94-7 220100-95-8 220100-96-9 220100-97-0 220100-98-1 220100-99-2 220127-90-2 220127-91-3 220128-15-4 220128-16-5 220128-17-6 220128-18-7 220128-19-8 220128-20-1 220128-21-2 220128-22-3 220128-23-4 220128-24-5 220128-25-6 220128-26-7 220128-27-8 220128-28-9 220128-29-0 220128-30-3 220128-31-4 220128-32-5 220128-33-6 220128-34-7 220128-35-8 220128-36-9 220128-37-0 220128-38-1 220128-39-2 220128-40-5 220128-41-6 220128-42-7 220128-43-8 220128-44-9 220128-77-8 220128-83-6 220128-86-9 220128-88-1 220129-17-9 220129-19-1 220129-21-5 220129-23-7 220129-25-9 220129-29-3 220129-32-8 220129-34-0 220129-36-2 220129-38-4 220129-40-8 220129-43-1 220129-44-2 220129-69-1 220129-75-9 220129-79-3 220129-98-6 220130-01-8 220130-03-0 220130-05-2 220130-07-4 220130-08-5 220130-09-6 220130-10-9 220130-11-0 220130-12-1 220130-13-2 220130-14-3 220130-15-4 220130-16-5 220130-17-6 220130-18-7 220130-19-8 220130-20-1 220130-21-2 220130-22-3 220130-23-4 220130-24-5

220130-63-2 220130-66-5 220130-68-7 220130-73-4 220130-78-9
220130-81-4 220130-82-5 220130-85-8 220130-86-9 220131-07-7
220131-09-9 220131-10-2 220131-11-3 220131-12-4 220131-13-5
220131-14-6 220131-15-7 220131-16-8 220131-17-9 220131-18-0
220131-20-4 220131-21-5 220131-23-7 220131-27-1 220131-28-2
220131-29-3 220131-31-7 220131-33-9 220131-34-0 220131-35-1
220131-36-2 220131-37-3 220131-38-4 220131-39-5 220131-71-5
220131-72-6 220131-73-7 220131-74-8 220131-75-9 220131-76-0
220131-77-1 220131-78-2 220131-79-3 220131-80-6 220131-87-3
220131-88-4 220131-89-5 220131-90-8 220131-91-9 220131-92-0
220131-93-1 220131-94-2 220131-95-3 220131-96-4 220131-97-5
220131-99-7 220132-00-3 220132-01-4 220132-02-5 220132-03-6
220132-04-7 220132-05-8 220132-06-9 220132-07-0 220132-08-1
220132-09-2 220132-14-9 220132-15-0 220132-16-1 220132-17-2
220132-18-3 220132-19-4 220132-20-7 220132-21-8 220132-22-9
220132-23-0 220132-24-1 220132-25-2 220132-26-3 220132-27-4
220132-28-5 220132-29-6 220132-31-0 220132-32-1 220132-33-2
220132-34-3 220132-37-6 220132-38-7 220132-39-8 220132-40-1
220132-41-2 220132-42-3 220132-43-4 220132-44-5 220132-45-6
220132-46-7 220132-47-8 220132-48-9 220132-49-0 220132-50-3
220132-51-4 220132-56-9 220132-60-5 220132-63-8 220132-64-9

RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT 220167-74-8 220167-77-1 220191-54-8 220191-55-9 220191-56-0
220191-59-3 220191-61-7 220191-62-8 220191-63-9 220191-64-0
220191-65-1 220191-66-2 220191-67-3 220191-68-4 220191-69-5
220191-70-8 220191-71-9 220191-72-0 220191-73-1 220191-75-3
220191-77-5 220191-78-6 220191-79-7 220191-80-0 220191-81-1
220191-82-2 220191-83-3 220191-84-4 220192-04-1 220192-05-2
220192-06-3 220192-07-4 220192-08-5 220192-09-6 220192-10-9
220192-11-0 220192-12-1 220192-13-2 220192-16-5 220192-18-7
220192-19-8 220192-20-1 220192-21-2 220192-22-3 220192-23-4
220192-24-5 220192-25-6 220192-26-7 220192-27-8 220192-28-9
220192-29-0 220192-30-3 220192-31-4 220192-43-8 220193-36-2
220193-37-3 220193-40-8 220193-41-9 220193-42-0 220193-43-1
220193-53-3 220193-86-2 220193-92-0 220193-93-1 220193-94-2
220193-95-3 220193-96-4 220193-97-5 220193-98-6 220193-99-7
220194-00-3 220194-01-4 220194-35-4 220194-36-5 220194-37-6
220194-38-7 220194-43-4 220194-51-4 220194-54-7 220194-55-8
220194-56-9 220194-58-1 220194-59-2 220194-60-5 220194-61-6
220194-62-7 220194-63-8 220194-64-9 220194-65-0 220194-66-1
220194-67-2 220194-68-3 220194-69-4 220194-70-7 220194-71-8
220194-72-9 220194-83-2 220194-93-4 220195-02-8 220195-03-9
220195-04-0 220195-05-1 220195-06-2 220195-07-3 220195-08-4
220195-09-5 220195-10-8 220195-11-9 220195-12-0 220195-13-1
220195-14-2 220195-15-3 220195-16-4 220195-20-0 220195-21-1
220195-22-2 220195-24-4 220195-31-3 220195-32-4 220195-33-5
220195-36-8 220195-37-9 220195-38-0 220195-39-1 220195-40-4
220195-41-5 220195-42-6 220195-43-7 220195-44-8 220195-45-9
220195-46-0 220195-47-1 220195-55-1 220195-57-3 220195-58-4
220195-59-5 220195-60-8 220195-61-9 220195-62-0 220195-63-1
220195-78-8 220195-79-9 220195-80-2 220195-85-7 220195-86-8
220195-87-9 220195-88-0 220195-89-1 220195-90-4 220195-91-5
220195-92-6 220195-93-7 220195-94-8 220195-95-9 220195-96-0
220195-97-1 220195-98-2 220195-99-3 220196-00-9 220196-01-0
220196-02-1 220196-03-2 220196-04-3 220196-06-5 220196-15-6
220196-21-4 220196-22-5 220196-23-6 220196-24-7 220196-25-8
220196-31-6 220196-35-0 220196-36-1 220196-37-2 220196-38-3
220196-46-3 220196-53-2 220196-54-3 220196-55-4 220196-56-5

220196-59-8 220196-61-2 220196-67-8 220196-68-9 220196-69-0
220196-70-3 220196-71-4 220196-72-5 220196-73-6 220196-74-7
220196-75-8 220196-76-9 220196-77-0 220196-78-1 220196-79-2
220196-81-6 220196-82-7 220196-83-8 220196-84-9 220196-85-0
220196-86-1 220196-87-2 220196-88-3 220196-89-4 220196-90-7
220197-05-7 220197-08-0 220197-10-4 220197-11-5 220197-12-6
220197-13-7 220197-16-0 220197-24-0 220197-44-4 220197-45-5
220197-46-6 220197-47-7 220197-48-8 220197-49-9 220197-50-2
220197-51-3 220197-52-4 220197-53-5 220197-54-6 220197-55-7
220197-56-8 220197-57-9 220197-58-0 220197-59-1 220197-62-6
220197-63-7 220197-64-8
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(nucleotide sequence; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT 220197-65-9 220197-66-0 220197-67-1 220197-68-2 220197-69-3
220197-70-6 220197-71-7 220197-72-8 220197-73-9 220197-74-0
220197-75-1 220197-76-2 220197-77-3 220197-78-4 220197-81-9
220231-30-1 220232-35-9 220232-58-6 220232-71-3 220232-85-9
220232-98-4 220233-04-5 220233-10-3 220233-12-5 220233-17-0
220233-77-2 220233-78-3 220233-87-4 220233-91-0 220233-98-7
220234-04-8 220234-11-7 220234-15-1 220234-16-2 220234-17-3
220234-21-9 220234-24-2 220234-26-4 220234-27-5 220234-59-3
220234-60-6 220234-62-8 220234-63-9 220234-64-0 220234-68-4
220234-69-5 220234-70-8 220234-71-9 220234-72-0 220234-73-1
220234-74-2 220234-75-3 220234-76-4 220234-77-5 220234-80-0
220234-81-1 220234-82-2 220234-83-3 220234-84-4 220234-85-5
220234-86-6 220234-87-7 220234-88-8 220234-89-9 220234-90-2
220234-91-3 220234-94-6 220234-95-7 220234-96-8 220234-97-9
220234-98-0 220234-99-1 220235-01-8 220235-06-3 220235-11-0
220235-13-2 220235-14-3 220235-15-4 220235-18-7 220235-19-8
220235-23-4 220235-26-7 220235-27-8 220235-28-9 220235-29-0
220235-30-3 220235-31-4 220235-32-5 220235-33-6 220235-34-7
220235-35-8 220235-36-9 220235-37-0 220235-38-1 220235-39-2
220235-40-5 220235-41-6 220235-42-7 220235-43-8 220235-44-9
220235-45-0 220235-46-1 220235-47-2 220235-48-3 220235-49-4
220235-50-7 220235-51-8 220235-53-0 220235-55-2 220235-56-3
220235-57-4 220235-58-5 220235-59-6 220235-82-5 220235-84-7
220235-85-8 220235-86-9 220235-87-0 220235-88-1 220235-89-2
220235-95-0 220235-96-1 220235-97-2 220235-98-3 220235-99-4
220236-04-4 220236-05-5 220236-06-6 220236-07-7 220236-09-9
220236-10-2 220236-11-3 220236-13-5 220236-14-6 220236-17-9
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(nucleotide sequence; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

IT **219808-82-9**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(HLA-binding peptide in lung cancer-assocd. protein; cancer-assocd. nucleic acids and antigens from human tissues and their diagnostic and therapeutic applications)

RN 219808-82-9 HCAPLUS
CN L-Valine, L-tyrosylglycyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-leucyl-L-.alpha.-aspartyl-L-seryl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L90 ANSWER 11 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:682301 HCAPLUS
DN 129:314983
TI Anti-peptide **antibody** against human cytochrome P450 3A4
IN Lu, Anthony Y. H.; Wang, Regina W.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K038-04
ICS A61K038-16; C07K016-40; C12P021-08
CC **15-3** (Immunochemistry)
Section cross-reference(s): 1, 7
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9844939	A1	19981015	WO 1998-US7165	19980409 <--
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1011708	A1	20000628	EP 1998-919741	19980409 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000513742	T2	20001017	JP 1998-543138	19980409 <--
	US 6300476	B1	20011009	US 1998-57897	19980409 <--
PRAI	US 1997-43230P	P	19970410 <--		
	WO 1998-US7165	W	19980409 <--		

AB The author discloses an anti-peptide **antibodies** recognizing human cytochrome P 450 3A4. The **antibody** was raised against a 21 amino acid portion (residues 253-273) and effectively inhibits both testosterone and midazolam hydroxylase activities.
ST peptide **antibody** cytochrome P450; testosterone hydroxylase peptide **antibody**
IT **Immunoglobulins**

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(G; **antibodies** to human cytochrome P 450 3A4 peptide inhibits its enzymic activity)

IT Epitopes
(**antibodies** to human cytochrome P 450 3A4 peptide inhibits its enzymic activity)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(conjugates, with keyhole limpet hemocyanins; in prepn. of inhibitory **antibodies**)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(drug-metabolizing; **antibodies** to human cytochrome P 450 3A4 peptide inhibits its enzymic activity in relation to)

IT Hemocyanins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(keyhole limpet, conjugates with cytochrome P 450 3A4 peptides; in prepn. of inhibitory **antibodies**)

IT **Antibodies**
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(monoclonal; **antibodies** to human cytochrome P 450 3A4 peptide inhibits its enzymic activity)

IT 9035-51-2, Cytochrome P450, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(CYP3A4; inhibitory **antibodies** to)

IT 9075-83-6, Testosterone 6.beta.-hydroxylase 122653-76-3, Midazolam 1'-hydroxylase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**antibodies** to human cytochrome P 450 3A4 peptide inhibits its enzymic activity)

IT 214691-66-4 214691-67-5 214691-68-6 214691-69-7 214691-70-0
214691-71-1 214691-72-2 214691-73-3 214691-74-4 214691-75-5
214691-76-6 214691-78-8 214691-79-9 214691-80-2 214691-81-3
214691-82-4 214691-83-5 214691-84-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**antibodies** to human cytochrome P 450 3A4 peptide inhibits its enzymic activity)

IT 214691-52-8 214691-54-0 214691-55-1 214691-56-2 214691-57-3
214691-58-4 214691-59-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(as epitope for inhibitory **antibodies** to human cytochrome P 450 3A4)

IT 193544-51-3 214691-51-7 214691-53-9 214691-60-8 214691-61-9
214691-62-0 214691-63-1 214691-64-2 214691-65-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(in prepn. of inhibitory **antibodies** to human cytochrome P 450 3A4)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bork; J Biol Chem 1989, V264(2), P910 HCAPLUS
(2) Komori; J Biochem 1988, V104(6), P912 HCAPLUS
(3) Sumitomo Chemical Company Limited; EP 0644267 A2 1995 HCAPLUS
(4) Watkins; Proc Natl Acad Sci USA 1985, V82, P6310 HCAPLUS

IT **214691-82-4**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**antibodies** to human cytochrome P 450 3A4 peptide inhibits its enzymic activity)
RN 214691-82-4 HCAPLUS
CN L-Aspartic acid, L-isoleucyl-L-leucyl-L-.alpha.-glutamyl-L-lysyl-L-valyl-L-lysyl-L-.alpha.-glutamyl-L-histidyl-L-glutaminyl-L-.alpha.-glutamyl-L-seryl-L-methionyl-L-.alpha.-aspartyl-L-methionyl-L-asparaginyl-L-asparaginyl-L-prolyl-L-glutaminyl-L-.alpha.-aspartyl-L-phenylalanyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B

PAGE 2-C



L90 ANSWER 12 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:408503 HCAPLUS
DN 129:148010
TI T cell epitopes in Japanese cedar (Cryptomeria japonica) pollen allergens: choice of major T cell epitopes in Cry j 1 and Cry j 2 toward design of the peptide-based immunotherapeutics for the management of Japanese cedar pollinosis
AU Sone, Toshio; Morikubo, Keiko; Miyahara, Michinori; Komiyama, Naoki; Shimizu, Kimiko; Tsunoo, Hajime; Kino, Kohsuke
CS Department of Pharmaceutical Research, Meiji Inst. of Health Science, Kanagawa, Japan
SO Journal of Immunology (**1998**), 161(1), 448-457
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
CC 15-9 (Immunochemistry)
AB Japanese cedar pollinosis is caused by exposure to Japanese cedar (C. japonica) pollen, of which 2 components, Cry j 1 and Cry j2, are believed to be the major allergens. T cell lines specific to either Cry j 1 or rCry j 2 were reactive to various portions of each panel of overlapping peptides derived from Cry j 1 or Cry j 2. Two peptides, p211-225 and p108-120, from among 6 major T cell epitopes identified in Cry j 1 sequence, and 3 peptides, p182-200, p344-355, and p66-80, from among 5 in Cry j 2, were chosen to design an artificial polypeptide (named Cry-consensus) based on a difference among the types of the restriction

mols. capable of presenting these peptides. After construction of a DNA encoding these peptides in order, Cry-consensus was expressed in Escherichia coli. Five of 6 T cell epitopes, except for Cry j 2 p344-355, in Cry-consensus were recognized by the T cell clones specific to each peptide. PBMC from allergic patients induced higher proliferation under stimulation from Cry-consensus than individual peptides. Eight-eight percent of the PBMC (15 of 17) showed proliferation under the Cry-consensus stimulation. Thus, several major T cell epitopes from Cry j 1 and Cry j 2 can be chosen in the design of peptide-based immunotherapeutics for the management of Japanese cedar pollinosis in subjects having various types of HLA class II mols.

ST T cell epitope Cryptomeria pollen allergen; Japanese cedar allergen epitope mapping

IT Allergens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Cry j 1; T cell epitope mapping in Japanese cedar in relation to design of peptide-based immunotherapeutics for management of Japanese cedar pollinosis)

IT Allergens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Cry j 2; T cell epitope mapping in Japanese cedar in relation to design of peptide-based immunotherapeutics for management of Japanese cedar pollinosis)

IT **Allergy inhibitors**
Cryptomeria japonica
Hay fever
Pollen
T cell (lymphocyte)
(T cell epitope mapping in Japanese cedar in relation to design of peptide-based immunotherapeutics for management of Japanese cedar pollinosis)

IT Epitopes
(mapping; T cell epitope mapping in Japanese cedar in relation to design of peptide-based immunotherapeutics for management of Japanese cedar pollinosis)

IT

165325-98-4	165325-99-5	165326-00-1	165326-01-2	165326-03-4
175700-94-4	175700-95-5	175700-96-6	175700-97-7	175700-98-8
175700-99-9	175701-00-5	175701-01-6	175701-02-7	175701-03-8
175701-04-9	175701-05-0	175701-06-1	175701-07-2	175701-08-3
175701-09-4	175701-10-7	175701-11-8	175701-12-9	175701-13-0
175701-14-1	175701-15-2	175701-16-3	175701-17-4	175701-18-5
175701-19-6	175701-20-9	175701-21-0	**175701-22-1**	
175701-23-2	175701-24-3	175701-25-4	175701-26-5	
175701-27-6	175701-28-7	175701-29-8	175701-30-1	175701-31-2
175701-32-3	175701-33-4	175701-34-5	175701-35-6	175701-36-7
175701-37-8	175701-38-9	175701-39-0	175701-40-3	175701-41-4
175701-46-9	207977-35-3	207977-43-3	207977-45-5	207977-53-5
207977-57-9	210973-82-3	210973-83-4	210973-84-5	210973-85-6
210973-86-7	210973-87-8	210973-88-9	210973-90-3	210973-91-4
210973-92-5	210973-93-6	210973-96-9	210973-97-0	210973-98-1
210973-99-2	210974-00-8	210974-02-0	210974-03-1	210974-04-2
210974-05-3	210974-07-5	210974-08-6	210974-09-7	210974-10-0
210974-11-1	210974-13-3	210974-14-4	210974-15-5	210974-16-6
210974-18-8	210974-19-9	210974-20-2	210974-21-3	210974-22-4
210974-23-5	210974-24-6	210974-25-7	210974-27-9	210974-28-0
210974-29-1	210974-30-4	210974-31-5	210974-33-7	210974-34-8
210974-35-9	210974-36-0	210974-37-1	210974-39-3	210974-40-6
210974-41-7	210974-42-8	210974-43-9	210974-44-0	210974-46-2
210974-47-3	210974-48-4	210974-49-5	210974-50-8	210974-51-9
210974-53-1	210974-54-2	210974-56-4	210974-57-5	210974-59-7
210974-60-0	210974-61-1	210974-63-3	210974-64-4	210974-65-5
210974-66-6	210974-67-7	210974-70-2	210974-71-3	210974-72-4
210974-73-5	210974-75-7	210974-76-8	210974-77-9	210974-79-1

210974-80-4 210974-82-6 210974-83-7 210974-84-8 210974-86-0
RL: PRP (Properties)
(T cell epitope mapping in Japanese cedar in relation to design of peptide-based immunotherapeutics for management of Japanese cedar pollinosis)

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bousquet, J; J Allergy Clin Immunol 1994, V94, P1 MEDLINE
(2) Briner, T; Proc Natl Acad Sci USA 1993, V90, P7608 HCAPLUS
(3) Chicz, R; J Exp Med 1993, V178, P27 HCAPLUS
(4) Collins, D; J Immunol 1991, V147, P4054 MEDLINE
(5) Cookson, W; Lancet 1989, Vi, P1292
(6) Ebner, C; J Immunol 1993, V150, P1047 HCAPLUS
(7) Ebner, C; J Immunol 1995, V154, P1932 HCAPLUS
(8) Frew, A; Clin Exp Allergy 1994, V24, P416 MEDLINE
(9) Fujisao, S; Hum Immunol 1996, V45, P131 HCAPLUS
(10) Gaur, A; Science 1992, V258, P1491 HCAPLUS
(11) Ghosh, P; Nature 1995, V378, P457 HCAPLUS
(12) Griffith, I; J Allergy Clin Immunol 1993, V91, P339
(13) Hashimoto, M; Clin Exp Allergy 1995, V25, P848 MEDLINE
(14) Hashimoto, M; Tissue Antigens 1994, V44, P166 MEDLINE
(15) Higgins, J; J Allergy Clin Immunol 1992, V90, P749 MEDLINE
(16) Hoyne, G; Immunology 1994, V83, P190 HCAPLUS
(17) Hoyne, G; J Exp Med 1993, V178, P1783 HCAPLUS
(18) Ikagawa, S; J Allergy Clin Immunol 1996, V97, P53 HCAPLUS
(19) Ito, H; Allergology Int 1996, V45, P181
(20) Kimura, A; HLA 1991 1992, V1, P397
(21) Kobayashi, H; Immunogenetics 1996, V44, P366 HCAPLUS
(22) Komiyama, N; Biochem Biophys Res Commun 1994, V201, P1021 HCAPLUS
(23) Liebers, V; Clin Exp Allergy 1996, V26, P494 MEDLINE
(24) Marsh, D; Science 1994, V264, P1152 HCAPLUS
(25) Marshall, K; J Immunol 1994, V152, P4946 HCAPLUS
(26) Matsunaga, Y; FEBS Lett 1993, V324, P325 HCAPLUS
(27) Matsushita, S; J Immunol 1987, V138, P109 HCAPLUS
(28) Muto, M; Adv Allergy Immunol 1992, V1, P161
(29) Namba, M; FEBS Lett 1994, V353, P124 HCAPLUS
(30) Norman, P; Int Arch Allergy Immunol 1997, V113, P224 HCAPLUS
(31) O'Brien, R; Immunology 1995, V86, P176 HCAPLUS
(32) O'Brien, R; J Allergy Clin Immunol 1994, V93, P628 HCAPLUS
(33) O'Hehir, R; J Allergy Clin Immunol 1993, V92, P105 MEDLINE
(34) O'Sullivan, D; J Immunol 1990, V145, P1799 HCAPLUS
(35) Rammensee, H; Immunogenetics 1995, V41, P178 HCAPLUS
(36) Rogers, B; Mol Immunol 1994, V31, P955 HCAPLUS
(37) Ruffilli, A; Allergy 1997, V52, P256 MEDLINE
(38) Sakaguchi, M; Allergy 1990, V45, P309 HCAPLUS
(39) Shirakawa, T; Nat Genet 1994, V7, P125 HCAPLUS
(40) Simons, F; Int Immunol 1996, V8, P1937 HCAPLUS
(41) Sone, T; Biochem Biophys Res Commun 1994, V199, P619 HCAPLUS
(42) Spiegelberg, H; J Immunol 1994, V152, P4706 HCAPLUS
(43) Stern, L; Nature 1994, V368, P215 HCAPLUS
(44) Sugimura, K; Allergy 1996, V51, P732 HCAPLUS
(45) Ukai, K; Arerugi 1994, V43, P101 MEDLINE
(46) van Neerven, R; J Immunol 1993, V151, P2326 HCAPLUS
(47) van Neerven, R; J Immunol 1994, V152, P4203 HCAPLUS
(48) van Noort, J; Eur J Immunol 1991, V21, P1989 HCAPLUS
(49) Wallner, B; Allergy 1994, V49, P302 MEDLINE
(50) Walls, E; Lymphocytes:A Practical Approach 1987, P149
(51) Yasueda, H; J Allergy Clin Immunol 1983, V71, P77 HCAPLUS

IT **175701-22-1 175701-23-2**
RL: PRP (Properties)
(T cell epitope mapping in Japanese cedar in relation to design of peptide-based immunotherapeutics for management of Japanese cedar pollinosis)

RN 175701-22-1 HCAPLUS
CN L-Asparagine, L-seryl-L-tyrosyl-L-valyl-L-histidyl-L-valyl-L-asparaginylglycyl-L-alanyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 175701-23-2 HCAPLUS
CN L-Lysine, L-asparaginylglycyl-L-alanyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-glutaminyl-L-asparaginylglycyl-L-leucyl-L-arginyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

L90 ANSWER 13 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:79825 HCAPLUS
DN 128:291752
TI Molecular mimicry in diabetes mellitus. The homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B-like enteroviruses and binds to the diabetes associated HLA-DR3 molecule
AU Vreugdenhil, G. R.; Geluk, A.; Ottenhoff, T. H. M.; Melchers, W. J. G.; Roep, B. O.; Galama, J. M. D.
CS Dep. Medical Microbiology, Univ. Nijmegen, Nijmegen, 6500 HB, Neth.
SO Diabetologia (**1998**), 41(1), 40-46
CODEN: DBTGAJ; ISSN: 0012-186X
PB Springer-Verlag
DT Journal
LA English
CC 6-3 (General Biochemistry)
Section cross-reference(s): 14, 15
AB It was proposed that mol. mimicry between protein 2C (p2C) of coxsackie virus B4 and the autoantigen glutamic acid decarboxylase (GAD65) plays a role in the pathogenesis of insulin-dependent diabetes mellitus (IDDM). The amino acid sequence of p2C which shares homol. with a sequence in GAD65 (PE-VKEK), is highly conserved in coxsackie virus B4 isolates as well as in different viruses of the subgroup of coxsackie B-like enteroviruses. These are the most prevalent enteroviruses and therefore exposure to the mimicry motif will be a frequent event throughout life. Presentation of the homologous peptides by HLA mols. is essential for T-cell reactivity. Therefore, the authors tested whether the PEVKEK motif can bind to the IDDM-assocd. HLA-DR1, -DR3 and -DR4 mols. Synthetic peptides with sequences derived from p2C and GAD65 did bind to HLA-DR3 but

not to HLA-DR1 or -DR4. Replacement of amino acids within the motif showed that the PEVKEK motif binds specifically to HLA-DR3. Moreover, both p2C and GAD65 peptides bind in the same position within the peptide binding groove of the DR3 mol. which is an essential requirement for T-cell cross-reactivity. The results support mol. mimicry between p2C of coxsackie B-like enteroviruses and GAD65. However, this mol. mimicry may be limited to the HLA-DR3 pos. sub-population of IDDM patients.

ST diabetes mol mimicry CVB2C GAD65 HLADR; coxsackie B2C HLADR antigen binding; islet autoantigen GAD65 CVB2C antigen binding; protein sequence GAD65 CVB2C

IT Histocompatibility antigens
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(HLA-DR1; homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65, highly conserved in the coxsackie B-like enteroviruses, binding to HLA-DR3 in diabetes mellitus)

IT Histocompatibility antigens
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(HLA-DR3; homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65, highly conserved in the coxsackie B-like enteroviruses, binding to HLA-DR3 in diabetes mellitus)

IT Histocompatibility antigens
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(HLA-DR4; homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65, highly conserved in the coxsackie B-like enteroviruses, binding to HLA-DR3 in diabetes mellitus)

IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(P2-X; homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65, highly conserved in the coxsackie B-like enteroviruses, binding to HLA-DR3 in diabetes mellitus)

IT Structure-activity relationship
(antigen-binding; protein 2C and islet autoantigen GAD65, highly conserved in the coxsackie B-like enteroviruses, binding to HLA-DR3 in diabetes mellitus)

IT Protein sequences
(homol.; The homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B-like enteroviruses and binds to the diabetes assocd. HLA-DR3 mol.)

IT Human coxsackievirus B
(homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65, highly conserved in the coxsackie B-like enteroviruses, binding to HLA-DR3 in diabetes mellitus)

IT **Diabetes mellitus**
(insulin-dependent; homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65, highly conserved in the coxsackie B-like enteroviruses, binding to HLA-DR3 in diabetes mellitus)

IT 9024-58-2, Glutamic acid decarboxylase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(GAD65; homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65, highly conserved in the coxsackie B-like enteroviruses, binding to HLA-DR3 in diabetes mellitus)

IT 206067-91-6
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 12-mer peptide CVB3p2C binding to HLA-DR

antigen)
IT 206067-90-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 12-mer peptide CVB4p2C binding to HLA-DR antigen)
IT 206067-96-1
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 12-mer peptide GAD65 binding to HLA-DR antigen)
IT 206067-92-7
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 12-mer peptide PV3p2C binding to HLA-DR antigen)
IT 206067-93-8
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 12-mer peptide p2CE2.fwdarw.D binding to HLA-DR antigen)
IT 206067-94-9
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 12-mer peptide p2CE2.fwdarw.V binding to HLA-DR antigen)
IT 206067-88-1
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 20-mer peptide CVB3p2C binding to HLA-DR antigen)
IT 206067-95-0
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 20-mer peptide GAD65 binding to HLA-DR antigen)
IT **206067-89-2**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 20-mer peptide PV3p2C binding to HLA-DR antigen)
IT 206067-87-0
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(eidamino acid sequences of 20-mer peptide CVB4p2C binding to HLA-DR antigen)
IT **206067-89-2**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequences of 20-mer peptide PV3p2C binding to HLA-DR antigen)
RN 206067-89-2 HCAPLUS
CN L-Valine, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-tryptophyl-L-leucyl-L-arginyl-L-.alpha.-glutamyl-L-arginyl-L-isoleucyl-L-isoleucyl-L-prolyl-L-glutaminyl-L-alanyl-L-arginyl-L-.alpha.-aspartyl-L-lysyl-L-leucyl-L-.alpha.-glutamyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L90 ANSWER 14 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:65923 HCAPLUS
DN 128:128291
TI Preparation of compounds (peptides) capable of binding to MDM2 for inhibition of the binding of MDM2 to p53 protein
IN Lane, David; Bottger, Volker; Bottger, Angelika; Picksley, Stephen; Hochkeppel, Heinz-Kurt; Garcia-Echeverria, Carlos; Chene, Patrick; Furet, Pascal
PA Novartis A.-G., Switz.; Cancer Research Campaign Technology Ltd.; Lane, David; Bottger, Volker; Bottger, Angelika; Picksley, Stephen; Hochkeppel, Heinz-Kurt; Garcia-Echeverria, Carlos; Chene, Patrick; Furet, Pascal
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K014-00
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9801467	A2	19980115	WO 1997-EP3549	19970704 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,

GN, ML, MR, NE, SN, TD, TG

CA	2259149	AA	19980115	CA	1997-2259149	19970704 <--
AU	9738479	A1	19980202	AU	1997-38479	19970704 <--
EP	958305	A2	19991124	EP	1997-935511	19970704 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
NZ	333609	A	20000825	NZ	1997-333609	19970704 <--
JP	2001500365	T2	20010116	JP	1998-504775	19970704 <--
US	2001018511	A1	20010830	US	1999-214371	19990326 <--
PRAI GB	1996-14197	A	19960705 <--			
GB	1997-7041	A	19970407 <--			
WO	1997-EP3549	W	19970704 <--			

OS MARPAT 128:128291

AB The present invention relates to compds. capable of binding to the oncogene protein MDM2, processes for the prepn. of such compds., pharmaceutical prepns. comprising such compds., and uses of said compds., e.g. in the therapeutic (including prophylactic) treatment of an animal or esp. of the human body (no data given). The title compds. R1XFXR2R3WXXR4 (R1 = Pro, Leu, Glu, Cys, Gln; X = natural amino acid; F = Phe; R2 = Arg, His, Glu, Cys, Ser, preferably Asp; R3 = His, Phe, preferably Tyr; W = Trp; R4 = Phe, Gln, preferably Leu) and their derivs. were prepd. on Milligen 9050 automated peptide synthesizer by using the std. Boc and Fmoc chem.

ST peptide prepn antitumor agent; peptidyl inhibition MDM2 binding protein p53; MDM2 binding site peptide mimic prepn

IT **Antitumor agents**
(prepn. of peptides as inhibitors of the binding interaction between MDM2 and protein p53)

IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of the binding interaction between MDM2 and protein p53)

IT Mdm2 protein
p53 (protein)
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(prepn. of peptides as inhibitors of the binding interaction between MDM2 and protein p53)

IT 201984-53-4P 201984-56-7P 201984-59-0P 201984-69-2P 201984-75-0P 201984-80-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of peptides as inhibitors of the binding interaction between MDM2 and protein p53)

IT 201984-20-5P 201984-22-7P 201984-24-9P 201984-27-2P 201984-29-4P
201984-31-8P 201984-34-1P 201984-36-3P 201984-38-5P
201984-39-6P 201984-41-0P 201984-43-2P 201984-45-4P
201984-47-6P 201984-49-8P 201984-51-2P 201984-55-6P 201984-58-9P
201984-61-4P 201984-63-6P 201984-65-8P 201984-68-1P 201984-71-6P
201984-78-3P 201984-82-9P 201984-85-2P 201984-89-6P 201984-90-9P
201984-91-0P 201984-93-2P 201984-94-3P 201984-95-4P 201984-97-6P
201984-98-7P 201984-99-8P 201985-00-4P 202075-45-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of the binding interaction between MDM2 and protein p53)

IT 86636-92-2 126705-22-4
RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of peptides as inhibitors of the binding interaction between MDM2 and protein p53)

IT **201984-39-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptides as inhibitors of the binding interaction between MDM2 and protein p53)

RN 201984-39-6 HCAPLUS

CN L-Phenylalaninamide, N-acetyl-L-valyl-L-glutaminyl-L-asparaginyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-tyrosyl-L-tryptophyl-L-threonyl-L-glutaminyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



L90 ANSWER 15 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:15774 HCAPLUS
DN 128:74317
TI Synthetic T cell epitope peptides of Japanese cypress pollen allergens for diagnosis and treatment of hay fever
IN Kino, Kohsuke; Dairiri, Kazuo
PA Meiji Milk Products Co., Ltd., Japan; Kino, Kohsuke; Dairiri, Kazuo
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM C07K014-415
ICS C07K007-08; A61K038-02; A61K039-36; G01N033-53
CC 15-9 (Immunochemistry)
Section cross-reference(s): 34

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9747648	A1	19971218	WO 1997-JP2031	19970612 <--
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2258125	AA	19971218	CA 1997-2258125	19970612 <--
	CN 1227566	A	19990901	CN 1997-197087	19970612 <--
	EP 960887	A1	19991201	EP 1997-927371	19970612 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	KR 2000016619	A	20000325	KR 1998-710215	19981212 <--
PRAI	JP 1996-153527	A	19960614 <--		
	WO 1997-JP2031	W	19970612 <--		

AB The T cell epitopes on a Japanese cypress (hinoki) pollen allergen mols. Cha o 1 and Cha o 2 have been identified by stimulating a T cell line established from a patient suffering from Japanese cypress pollen allergy with an overlap peptide covering the allergen domain. primary structure of the Japanese cypress pollen allergen. The peptide is useful for immunotherapy for or diagnosis of hay fever caused by Japanese cypress, Japanese cedar, and other spring trees that exhibit the common antigen.

ST Japanese cypress allergen Chao1 Chao2 pollinosis; synthetic T cell epitope Chao1 Chao2; hay fever diagnosis immunotherapy

IT Allergens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Chao1 and Chao2; synthetic T cell epitope peptides of Japanese cypress pollen allergens for diagnosis and treatment of hay fever)

IT Chamaecyparis
Cryptomeria japonica
Tree
(allergy caused by spring trees; synthetic T cell epitope peptides of Japanese cypress pollen allergens for diagnosis and treatment of hay fever)

IT T cell (lymphocyte)
(regulation of; synthetic T cell epitope peptides of Japanese cypress pollen allergens for diagnosis and treatment of hay fever)

IT Diagnosis
Hay fever
Immunotherapy
(synthetic T cell epitope peptides of Japanese cypress pollen allergens for diagnosis and treatment of hay fever)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthetic T cell epitope peptides of Japanese cypress pollen allergens for diagnosis and treatment of hay fever)

IT 155176-95-7P 200720-96-3P 200720-97-4P 200720-98-5P 200720-99-6P
200721-00-2P 200721-01-3P 200721-02-4P 200721-03-5P 200721-04-6P
200721-05-7P 200721-06-8P 200721-07-9P 200721-08-0P 200721-09-1P
200721-10-4P 200721-11-5P 200721-12-6P 200721-13-7P 200721-14-8P
200721-15-9P 200721-16-0P 200721-17-1P 200721-18-2P 200721-19-3P
200721-20-6P 200721-21-7P 200721-22-8P 200721-23-9P 200721-24-0P
200721-25-1P 200721-26-2P 200721-27-3P 200721-28-4P 200721-29-5P
200721-30-8P 200721-31-9P 200721-32-0P 200721-33-1P 200721-34-2P
200721-35-3P 200721-36-4P 200721-37-5P 200721-38-6P 200721-39-7P
200721-40-0P 200721-41-1P 200721-42-2P **200721-43-3P**
200721-44-4P 200721-45-5P 200721-46-6P 200721-47-7P
200721-48-8P 200721-49-9P 200721-50-2P 200721-51-3P 200721-52-4P
200721-53-5P 200721-54-6P 200721-55-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthetic T cell epitope peptides of Japanese cypress pollen allergens for diagnosis and treatment of hay fever)

IT **200721-43-3P 200721-44-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthetic T cell epitope peptides of Japanese cypress pollen allergens for diagnosis and treatment of hay fever)

RN 200721-43-3 HCAPLUS

CN Glycine, L-arginyl-L-alanyl-L-.alpha.-glutamyl-L-valyl-L-seryl-L-histidyl-L-valyl-L-histidyl-L-valyl-L-asparaginyl-L-arginyl-L-alanyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-glutaminyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





PAGE 2-B



PAGE 3-A

RN 200721-44-4 HCAPLUS
CN L-Serine, L-arginyl-L-alanyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-glutaminyl-L-asparaginylglycyl-L-leucyl-L-arginyl-L-

isoleucyl-L-lysyl-L-threonyl-L-tryptophyl-L-glutaminylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L90 ANSWER 16 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:514446 HCAPLUS
DN 127:174897
TI Degradation of C1-inhibitor by plasmin: implications for the control of **inflammatory** processes
AU Wallace, Eleanor M.; Perkins, Stephen J.; Sim, Robert B.; Willis, Anthony C.; Feighery, Con; Jackson, John
CS Department of Immunology, St. James' Hospital, Dublin, 8, Ire.
SO Molecular Medicine (New York) (**1997**), 3(6), 385-396
CODEN: MOMEF3; ISSN: 1076-1551
PB Springer
DT Journal
LA English
CC 14-11 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 7
AB A correct balance between protease and inhibitor activity is crit. in the maintenance of homeostasis; excessive activation of enzyme pathways is frequently assocd. with **inflammatory** disorders. Plasmin is an enzyme ubiquitously activated in **inflammatory** disorders, and C1-inhibitor (C1-Inh) is a pivotal inhibitor of protease activity, which is particularly important in the regulation of enzyme cascades generated in plasma. The nature of the interaction between plasmin and C1-Inh is poorly understood. C1-Inh was immunoadsorbed from the plasma of normal individuals, from that of patients with systemic lupus erythematosus or adult respiratory distress syndrome, and from the plasma and synovial fluid of patients with rheumatoid arthritis. As plasmin is a putative enzyme responsible for C1-Inh degrdn., the interaction between plasmin and C1-Inh was examd. using SDS-PAGE. In addn., peptides cleaved from C1-Inh by plasmin were isolated and sequenced and the precise cleavage sites detd. from the known primary sequence of C1-Inh. Homol. models of C1-Inh were then constructed. Increased levels of cleaved and inactivated C1-Inh

were found in each of the **inflammatory** disorders examd. Through SDS-PAGE anal. it was shown that plasmin rapidly degraded C1-Inh in vitro. The pattern of C1-Inh cleavage seen in vivo in patients with **inflammatory** disorders and that produced in vitro following incubation with plasmin were very similar. Homol. models of C1-Inh indicate that the majority of the plasmin cleavage sites are adjacent to the reactive site of the inhibitor. This study suggests that local C1-Inh degrdn. by plasmin may be a central and crit. event in the loss of protease inhibition during **inflammation**. These findings have important implications for the authors' understanding of pathogenic mechanisms in **inflammation** and for the development of more effectively targeted therapeutic regimes. These findings may also explain the efficacy of anti-plasmin agents in the treatment of C1-Inh deficiency states, as they may diminish plasmin-mediated C1-Inh degrdn.

ST plasmin C1 inhibitor degrdn peptide **inflammation**

IT **Respiratory distress syndrome**
(adult; degrdn. of C1-inhibitor by human plasmin in health and in **inflammatory** disorders)

IT Blood plasma
Conformation
Inflammation
Protein motifs
Rheumatoid arthritis
Synovial fluid
(degrdn. of C1-inhibitor by human plasmin in health and in **inflammatory** disorders)

IT **Lupus erythematosus**
(systemic; degrdn. of C1-inhibitor by human plasmin in health and in **inflammatory** disorders)

IT 9001-90-5, Plasmin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(degrdn. of C1-inhibitor by human plasmin in health and in **inflammatory** disorders)

IT 194091-17-3 194091-19-5 194091-20-8 194091-21-9 194091-22-0
194091-23-1 194091-24-2 194091-26-4 194091-28-6
194091-30-0
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(degrdn. of C1-inhibitor by human plasmin in health and in **inflammatory** disorders)

IT 80295-38-1, C1 Inhibitor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(degrdn. of C1-inhibitor by human plasmin in health and in **inflammatory** disorders)

IT 9049-68-7, Antiplasmin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(degrdn. of C1-inhibitor by human plasmin in health and in **inflammatory** disorders)

IT **194091-23-1**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(degrdn. of C1-inhibitor by human plasmin in health and in **inflammatory** disorders)

RN 194091-23-1 HCAPLUS

CN L-Glutamine, L-lysyl-L-tyrosyl-L-prolyl-L-valyl-L-alanyl-L-histidyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

L90 ANSWER 17 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:215797 HCAPLUS
DN 126:198553
TI The H-Y antigen
IN Goulmy, Els A. J. M.; Hunt, Donald F.; Engelhard, Victor H.
PA Rijksuniversiteit Te Leiden, Neth.; Goulmy, Els A. J. M.; Hunt, Donald F.; Engelhard, Victor H.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K014-705
ICS C07K016-28; A61K038-17
CC **15-2** (Immunochemistry)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9705168	A1	19970213	WO 1996-NL307	19960729 <--

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,

SD, SE
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM
CA 2224894 AA 19970213 CA 1996-2224894 19960729 <--
AU 9666317 A1 19970226 AU 1996-66317 19960729 <--
AU 723937 B2 20000907
EP 840749 A1 19980513 EP 1996-926013 19960729 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI
JP 11511129 T2 19990928 JP 1996-507499 19960729 <--
US 6521598 B1 20030218 US 1998-217 19980626 <--
PRAI EP 1995-202067 A 19950727 <--
WO 1996-NL307 W 19960729 <--

AB H-Y is a transplantation antigen that can lead to rejection of HLA-matched male organ and bone marrow grafts by female recipients, and may play a role in pregnancy and spermatogenesis. We show that one human H-Y peptide antigen presented by HLA-B7 is an 11 residue peptide derived from SMCY gene, an evolutionarily conserved Y chromosomal protein. A homologous gene on the X chromosome, SMCX, differs by two residues in the same region. We also show a peptide antigen recognized by two HLA-A2.1 restricted T cell clones, which is also encoded by SMCY. The identification of H-Y offers prospects for improvements in transplantation outcome, prenatal diagnosis and fertilization strategies.

ST minor histocompatibility HY antigen transplant rejection

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-B7, epitope; minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)

IT B cell (lymphocyte)
T cell (lymphocyte)
(anti-idiotypic; minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)

IT **Transplant and Transplantation**
(graft-vs.-host reaction; minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)

IT Immune tolerance
Protein sequences
Transplant rejection
(minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)

IT **Antibodies**
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)

IT TCR (T cell receptors)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(minor, H-Y; minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)

IT 169312-12-3 **187941-55-5**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)

IT **187941-55-5**

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(minor histocompatibility antigen H-Y and **antibody** for treating transplant rejection and graft vs. host disease)
RN 187941-55-5 HCAPLUS
CN L-Valine, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-seryl-L-tyrosyl-L-isoleucyl-L-cysteinyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L90 ANSWER 18 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:113361 HCAPLUS
DN 126:117068
TI Peptides and compounds that bind to the interleukin 1 (IL-1) receptor
IN Barrett, Ronald W.; Yanofsky, Stephen D.; Baldwin, David; Jacobs, Jeff W.; Bovy, Philippe R.; Leahy, Ellen M.; Pottorf, Richard S.; Dharanipragada, Ramalinga; Tomlinson, Ronald C.

PA Affymax Technologies N.V., UK; Barrett, Ronald W.; Yanofsky, Stephen D.; Baldwin, David; Jacobs, Jeff W.; Bovy, Philippe R.; Leahy, Ellen M.; Pottorf, Richard S.; Dharanipragada, Ramalinga; Tomlinson, Ronald C.

SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K038-10
ICS A61K038-02; C07K005-00; C07K007-00
CC **15-5** (Immunochemistry)
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9639165	A1	19961212	WO 1996-US9835	19960605 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	US 5861476	A	19990119	US 1995-464538	19950605 <--
	AU 9663820	A1	19961224	AU 1996-63820	19960605 <--
	EP 833654	A1	19980408	EP 1996-923258	19960605 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1995-464538 19950605 <--
US 1994-190788 19940202 <--
US 1995-383474 19950201 <--
WO 1996-US9835 19960605 <--

AB Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amt. of IL-1R, or an IL-1R agonist or antagonist that is useful for treatment of interleukin 1-mediated **inflammatory** responses or diseases to infection, tissue injury, rheumatoid arthritis, osteoarthritis, psoriasis, **inflammatory** bowel disease, encephalitis, glomerulonephritis and respiratory distress syndrome. Also provided are peptides which bind to the IL-1RtI, which are 11 to 40 amino acids in length.

ST interleukin 1 receptor type I peptide

IT **Kidney, disease**
(**glomerulonephritis, inflammation** due to; peptides and compds. that bind to the interleukin 1 receptor)

IT **Encephalitis**
Infection
Injury
Osteoarthritis
Psoriasis
Rheumatoid arthritis
(**inflammation** due to; peptides and compds. that bind to the interleukin 1 receptor)

IT **Intestine, disease**
(**inflammatory, inflammation** due to; peptides and compds. that bind to the interleukin 1 receptor)

IT **Respiratory distress syndrome**
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(newborn, **inflammation** due to; peptides and compds. that bind to the interleukin 1 receptor)

IT Cytotoxic agents
Inflammation
Protein sequences
(peptides and compds. that bind to the interleukin 1 receptor)

IT Interleukin 1 receptor antagonist
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL

(Biological study); USES (Uses)
(peptides and compds. that bind to the interleukin 1 receptor)

IT Peptides, biological studies
RL: ARU (Analytical role, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptides and compds. that bind to the interleukin 1 receptor)

IT Interleukin 1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peptides and compds. that bind to the interleukin 1 receptor)

IT Interleukin 1 receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(type I; peptides and compds. that bind to the interleukin 1 receptor)

IT 171492-13-0 186250-91-9 186250-92-0 186250-93-1 186250-94-2
186250-95-3 186250-96-4 186250-97-5 186250-98-6 186251-00-3
186251-02-5 186251-04-7 186251-06-9 186251-07-0 186251-08-1
186251-09-2 186251-10-5 186251-11-6 186251-12-7 186251-13-8
186251-14-9 186251-15-0 186251-16-1 186251-17-2 186251-18-3
186251-19-4 186251-20-7 186251-21-8 186251-22-9 186251-23-0
186251-24-1 186251-25-2 186251-26-3 186251-27-4 186251-28-5
186251-29-6 186251-30-9 186251-31-0 186251-32-1 186251-33-2
186251-34-3 186251-35-4 186251-36-5 186251-37-6 186251-38-7
186251-39-8 186251-40-1 186251-41-2 186251-42-3 186251-43-4
186251-44-5 186251-45-6 186251-46-7 186251-47-8 186251-48-9
186251-49-0 186251-50-3 186251-52-5 186251-53-6 186251-54-7
186251-55-8 186251-56-9 186251-57-0 186251-58-1 186251-59-2
186251-60-5 186251-61-6 186251-62-7 186251-64-9 186251-66-1
186251-68-3 186251-70-7 186251-72-9 186251-73-0 186251-75-2
186251-77-4 186251-78-5 186251-79-6 186251-80-9 186251-81-0
186251-82-1 186251-83-2 186251-84-3 186251-85-4 186251-86-5
186251-87-6 186251-88-7 186251-89-8 186251-90-1 186251-91-2
186251-92-3 186251-93-4 186251-94-5 186251-95-6 186251-96-7
186251-97-8 186251-98-9 186251-99-0 186252-00-6 186252-01-7
186252-02-8 186252-03-9 186252-04-0 186252-05-1 186252-06-2
186252-07-3 186252-08-4 186252-09-5 186252-10-8 186252-11-9
186252-12-0 186252-13-1 **186252-14-2** 186252-15-3
186252-16-4 186252-17-5 186252-18-6 186252-19-7 186252-20-0
186252-21-1 186252-22-2 186252-23-3 186252-24-4
RL: ARU (Analytical role, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptides and compds. that bind to the interleukin 1 receptor)

IT **186252-12-0 186252-14-2**
RL: ARU (Analytical role, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptides and compds. that bind to the interleukin 1 receptor)

RN 186252-12-0 HCAPLUS

CN L-Tyrosine, L-seryl-L-prolyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-asparaginyl-L-threonyl-L-alanyl-L-tryptophyl-L-tyrosyl-L-.alpha.-glutamyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B



RN 186252-14-2 HCAPLUS
CN L-Tyrosine, L-threonyl-L-prolyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-asparaginyl-L-threonyl-L-alanyl-L-tryptophyl-L-tyrosyl-L-.alpha.-glutamyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B



L90 ANSWER 19 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:658758 HCAPLUS
DN 126:1457
TI Distribution of pre-pro-thyrotropin-releasing hormone-connecting peptide, pre-pro-TRH (178-199)
AU Mitsuma, Terunori; Rhue, Nebi; Kayama, Masato; Adachi, Koshin; Yokoi, Yasutada; Mori, Yuichi; Takasu, Sinobu; Ping, Jing; Hirooka, Yoshifumi; Nogimori, Tsuyoshi
CS 4th Dep. Intern. Med., Aichi Med. Univ., Aichi, 480-11, Japan
SO Aichi Ika Daigaku Igakkai Zasshi (**1996**), 24(2), 329-335

CODEN: AIDZAC; ISSN: 0301-0902
PB Aichi Ika Daigaku Igakkai
DT Journal
LA English
CC 2-5 (Mammalian Hormones)
AB Pre-pro-TSH-releasing hormone (TRH) (178-199), one of pre-pro-TRH-connecting peptide, was identified immunohistochem. in rat tissues using anti-pre-pro-TRH (178-199) antiserum. Anti-pre-pro-TRH (178-199) was raised in New Zealand white rabbits immunized with a conjugate of synthetic pre-pro-TRH (178-199) with bovine serum albumin. Immunohistochem. anal. was performed by the ABC method. Pre-pro-TRH (178-199) immunoreactivity was visualized in the central nervous system, retina, anterior pituitary, mucosa of the stomach, Auerbach's nervous branch and Meissner's nervous branch of gastrointestinal tract, adrenal gland, testis and pancreas, corresponding to distribution of TRH. Significant staining was detected in neural perikarya, axon and dendrite. When using antiserum preincubated with synthetic pre-pro-TRH (178-199), no significantly stained cells in the anterior pituitary were detected. These findings suggest that pre-pro-TRH (178-199) is widely distributed in the rat organs corresponding to TRH distribution.
ST preproTRH connecting peptide distribution organ
IT Pituitary gland, anterior lobe
(Auerbach's nervous branch, Meissner's nervous branch; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(amygdaloid body; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(basal ganglia; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(cerebellum; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(cerebral cortex; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Adrenal medulla
Pancreatic islet of Langerhans
Spinal cord
Testis
(distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(hippocampus; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(hypothalamus; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Ganglion
(internal submucosal, stomach, small intestine and colon; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(medulla oblongata; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(midbrain; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Ganglion
(myenteric; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Nervous system
(olfactory system; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(pons; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Eye
(retina; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(septal nucleus; distribution of pre-pro-TRH (178-199) in rat tissues)
IT Brain
(thalamus; distribution of pre-pro-TRH (178-199) in rat tissues)
IT **122018-92-2**

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(distribution of pre-pro-TRH (178-199) in rat tissues)

IT **122018-92-2**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(distribution of pre-pro-TRH (178-199) in rat tissues)

RN 122018-92-2 HCAPLUS

CN L-Glutamic acid, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-tryptophyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-lysyl-L-.alpha.-glutamylglycyl-L-.alpha.-glutamylglycyl-L-valyl-L-leucyl-L-methionyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



L90 ANSWER 20 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:425655 HCAPLUS
DN 125:76429
TI Use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities
IN Steinert, Peter M.; Goldman, Robert D.; Digiovanna, John J.
PA United States of America, USA
SO U.S., 9 pp.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K038-10
ICS A61K038-18
NCL 514012000
CC 1-12 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5527773	A	19960618	US 1993-112784	19930825 <--

PRAI US 1993-112784 19930825 <--

AB Synthetic peptides corresponding to different regions of the human keratin 1 chain can disassemble preformed keratin intermediate filaments or inhibit filament assembly both in vitro and in vivo. The disruption of keratin filaments may have therapeutic applications in the treatment of epithelial abnormalities. Synthetic peptides corresponding to the H1,

beginning of 1A, and full-length 1A regions inhibited keratin filament assembly and stimulated keratin filament diassembly in vitro. These peptides, when microinjected into cells, also disrupted the filaments. Recovery occurred after .apprx.3-4 h. The peptides were specific for intermediate filaments and did not disrupt any other cytoskeletal elements including microtubules and microfilaments.

ST keratin peptide epithelium disease treatment

IT Skin
(cornification of, treatment of genetic diseases of; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT Epithelium
(diseases of, treatment of; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT Genitourinary tract
(treatment of lesions of; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT **Psoriasis**
Wart
(treatment of; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT Keratins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(1, peptides of H1 or 1A regions of; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT Skin, neoplasm
(inhibitors, use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT Cytoskeleton
(intermediate filament, use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT **Intestine, neoplasm**
(**polyp**, treatment of; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT **Neoplasm inhibitors**
(skin, use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT **178888-05-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(keratin 1 1A domain fragment; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT 178900-78-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(keratin 1 1A domain; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT 178900-75-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(keratin 1 H1 domain; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

IT **178888-05-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(keratin 1 1A domain fragment; use of keratin 1-derived peptides to disrupt the cytoskeleton and treat epithelial abnormalities)

RN 178888-05-6 HCAPLUS

CN L-Valine, L-arginyl-L-.alpha.-glutamyl-L-glutaminyl-L-isoleucyl-L-lysyl-L-seryl-L-leucyl-L-asparaginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-alanyl-L-seryl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A



L90 ANSWER 21 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:363501 HCAPLUS
DN 125:26938
TI Corticotropin release inhibiting factor and methods of using same
IN Redei, Eva; Aird, Fraser
PA Trustees of the University of Pennsylvania, USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K038-06
ICS A61K038-00; C07K005-08; C07K014-575; C07K016-00; C07H021-04; G01N033-53
CC 2-5 (Mammalian Hormones)
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9608265	A1	19960321	WO 1995-US11455	19950908 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2199734	AA	19960321	CA 1995-2199734	19950908 <--
	AU 9535093	A1	19960329	AU 1995-35093	19950908 <--
	AU 704838	B2	19990506		
	EP 781140	A1	19970702	EP 1995-931786	19950908 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI	US 1994-304383	A	19940912 <--		
	WO 1995-US11455	W	19950908 <--		

AB The invention features a substantially pure prepn. of a peptide having ACTH release inhibiting factor (CRIF) activity comprising at least three contiguous amino acids contained within the amino acid sequence positioned between the fourth and fifth TSH releasing hormone (TRH) sequence on a prepro-TRH protein. The CRIF peptide further comprises the fourth uncleaved TRH portion of prepro-TRH positioned at the amino terminus of CRIF. Compns., methods of diagnosis and methods of treating CRIF related diseases are also included in the invention.

ST ACTH release inhibiting factor sequence treatment
IT Blood analysis
(ACTH release-inhibiting factor detn. in blood)
IT Mouse
Protein sequences
Rat
(ACTH release-inhibiting factor sequence and pharmacol. uses thereof)
IT Transformation, genetic
(ACTH release-inhibiting factor sequence and pharmacol. uses thereof

and cDNA transfection)

IT **Antibodies**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**antibody** binding to ACTH release-inhibiting factor and pharmacol. uses)

IT **Inflammation inhibitors**
(**inflammatory** disease treatment by ACTH release-inhibiting factor and thyroid hormones)

IT Thyroid hormones
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**inflammatory** disease treatment by ACTH release-inhibiting factor and thyroid hormones)

IT Deoxyribonucleic acid sequences
(complementary, ACTH release-inhibiting factor sequence and pharmacol. uses thereof)

IT 148937-30-8, Corticotropin release-inhibiting factor
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ACTH release-inhibiting factor sequence and pharmacol. uses thereof)

IT **122018-92-2**, Rat CRIF 147023-71-0, Human CRIF
177716-51-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACTH release-inhibiting factor sequence and pharmacol. uses thereof)

IT 50-23-7, Cortisol 9002-60-2, ACTH, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ACTH release-inhibiting factor sequence and pharmacol. uses thereof)

IT 51-48-9, Thyroxine, biological studies 6893-02-3, L-T3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**inflammatory** disease treatment by ACTH release-inhibiting factor and thyroid hormones)

IT 177730-90-4 177730-91-5 177730-92-6 177730-93-7 177730-94-8
177730-95-9
RL: BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; ACTH release-inhibiting factor sequence and pharmacol. uses thereof and cDNA transfection and pharmacol. uses)

IT **122018-92-2**, Rat CRIF **177716-51-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACTH release-inhibiting factor sequence and pharmacol. uses thereof)

RN 122018-92-2 HCAPLUS

CN L-Glutamic acid, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-tryptophyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-lysyl-L-.alpha.-glutamylglycyl-L-.alpha.-glutamylglycyl-L-valyl-L-leucyl-L-methionyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

CO_2H

RN 177716-51-7 HCAPLUS
CN L-Glutamic acid, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-tryptophyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-threonyl-L-.alpha.-glutamylglycyl-L-.alpha.-glutamyl-L-.alpha.-glutamylglycylglycyl-L-leucyl-L-methionyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L90 ANSWER 22 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:248631 HCAPLUS
DN 124:315051
TI Epitopes of Japanese cedar pollen allergen Cry j II for therapeutics and prophylactics
IN Sone, Toshio; Komyama, Naoki; Kii, Kosuke
PA Meiji Milk Prod Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C12N015-09
ICS C07K007-08; C07K014-415
ICA A61K039-36; C12Q001-68; G01N033-53
CC 15-2 (Immunochemistry)
Section cross-reference(s): 1, 11
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08047392	A2	19960220	JP 1994-297840	19941107 <--
PRAI	JP 1993-276773		19931105 <--		
	JP 1994-134868		19940526 <--		

AB A cDNA sequence encoding allergen Cry j II is isolated from a cDNA library of Japanese cedar (sugi or Cryptomeria japonica) and its amino acid sequence deduced. T-cell epitopes derived from the Cry j II allergen are provided which can be used for the prevention, diagnosis, and treatment of Japanese cedar pollinosis.
ST Japanese cedar allergen Cryj II epitope; hay fever diagnosis therapeutic Cryj II
IT Cryptomeria japonica
(T-cell epitope derived from Japanese cedar pollen allergen Cry j II and its use for therapeutics and prophylactics)
IT Gene, plant
RL: MSC (Miscellaneous)
(cloning of cDNA for Japanese cedar pollen allergen Cry j II and its use for therapeutics and prophylactics)
IT **Hay fever**
(cloning of cDNA for Japanese cedar pollen allergen Cry j II and its use for therapeutics and prophylactics for)
IT Allergens
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(epitopes of Japanese cedar pollen allergen Cry j II for therapeutics and prophylactics)

IT Protein sequences
(of Japanese cedar pollen allergen Cry j II)

IT Deoxyribonucleic acid sequences
(complementary, for Japanese cedar pollen allergen Cry j II)

IT 175700-94-4 175700-95-5 175700-96-6 175700-97-7 175700-98-8
175700-99-9 175701-00-5 175701-01-6 175701-02-7 175701-03-8
175701-04-9 175701-05-0 175701-06-1 175701-07-2 175701-08-3
175701-09-4 175701-10-7 175701-11-8 175701-12-9 175701-13-0
175701-14-1 175701-15-2 175701-16-3 175701-17-4 175701-18-5
175701-19-6 175701-20-9 175701-21-0 **175701-22-1**
175701-23-2 175701-24-3 175701-25-4 175701-26-5
175701-27-6 175701-28-7 175701-29-8 175701-30-1 175701-31-2
175701-32-3 175701-33-4 175701-34-5 175701-35-6 175701-36-7
175701-37-8 175701-38-9 175701-39-0 175701-40-3 175701-41-4
175701-42-5 175701-43-6 175701-44-7 175701-45-8 175701-46-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-cell epitope derived from Japanese cedar pollen allergen Cry j II and its use for therapeutics and prophylactics)

IT 157154-58-0 163547-05-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; cloning of cDNA for Japanese cedar pollen allergen Cry j II and its use for therapeutics and prophylactics)

IT 163547-07-7 175705-66-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; cloning of cDNA for Japanese cedar pollen allergen Cry j II and its use for therapeutics and prophylactics)

IT **175701-22-1 175701-23-2**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-cell epitope derived from Japanese cedar pollen allergen Cry j II and its use for therapeutics and prophylactics)

RN 175701-22-1 HCAPLUS

CN L-Asparagine, L-seryl-L-tyrosyl-L-valyl-L-histidyl-L-valyl-L-asparaginylglycyl-L-alanyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

RN 175701-23-2 HCAPLUS
CN L-Lysine, L-asparaginylglycyl-L-alanyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-glutaminyl-L-asparaginylglycyl-L-leucyl-L-arginyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

NH_2

L90 ANSWER 23 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:410557 HCAPLUS
DN 123:136567
TI Polypeptides that interact with other proteins and that include conformation-constraining groups flanking a protein-protein interaction site
IN Evans, Herbert J.; Kini, R. Manjunatha
PA USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K007-06
ICS A61K037-02; C07K003-08; C07K001-00
CC 6-3 (General Biochemistry)
Section cross-reference(s): 1, 2, 7
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9425482	A1	19941110	WO 1994-US4294	19940421 <--
	W: AU, BR, CA, JP, KR, NZ, US, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2161108	AA	19941110	CA 1994-2161108	19940421 <--
	AU 9467707	A1	19941121	AU 1994-67707	19940421 <--
	US 5965698	A	19991012	US 1996-532818	19960503 <--
	US 6100044	A	20000808	US 1997-934224	19970919 <--
	US 6258550	B1	20010710	US 1999-413492	19991006 <--
PRAI	US 1993-51741	A	19930423 <--		
	US 1993-143364	A	19931029 <--		
	WO 1994-US4294	W	19940421 <--		
	US 1996-532818	A3	19960503 <--		
	US 1997-934224	A3	19970919 <--		

AB Homologs and analogs of naturally-occurring polypeptides that contain one or more interaction sites of the natural counterpart with the interaction sites flanked by conformation-constraining moieties, such as proline or cysteine, are described for use as therapeutics or as investigative tools. These peptides may also contain non-protein groups that restrict free rotation. A series of derivs. of the RGD peptide were shown to inhibit collagen- or ADP-induced platelet aggregation.
ST conformationally constrained peptide therapeutic uses; platelet aggregation inhibitor conformationally constrained peptide
IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CP-10, conformationally-constrained analogs of peptides of, as chemotactic peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT Macrophage
(activators of, conformationally-constrained peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT Analgesics
Appetite depressants
Immunostimulants
(conformationally constrained analogs of peptides as; peptides contg.

conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Fibrinogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analogs of peptides of; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Antihypertensives
Cardiotonics
Chemotactic factors
Fibrinolytics
Immunomodulators
(conformationally constrained peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Blood coagulation
(conformationally constrained peptides for induction of; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Peptides, biological studies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conformationally constrained; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Sweetening agents
(conformationally-constrained analogs of peptides of thaumatins, monellins, and mabinlins as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Enkephalins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as analgesics; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Monellins
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as sweetening agents; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT **Neoplasm inhibitors**
(conformationally-constrained peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Mitogens
(for lymphocytes, conformationally constrained peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Staphylococcus aureus
(mitogen of, conformationally-constrained analogs of peptides of, as lymphocyte mitogen; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphocyte
(mitogens for, conformationally constrained peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Fertility
Inflammation
(peptides affecting, conformationally constrained analogs of; peptides

contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Hypoglycemia
(potentiators for, conformationally constrained analogs of peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Blood
(proteins of, conformationally constrained analogs of peptides of; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Fibrinogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma.-chain, conformationally-constrained analogs of peptides of, as **inflammation** inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Mental disorder
(Alzheimer's disease, peptides assocd. with, conformationally constrained analogs of; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphocyte
(B-cell, differentiating peptides for, conformationally constrained analogs of peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LAPP (leech antiplatelet protein), conformationally-constrained analogs of peptides of, as platelet inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LH-releasing factor, conformationally-constrained analogs of peptides of, as antifertility agents; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LZ-8 (Lingzhi, 8), conformationally-constrained analogs of peptides of, as immunomodulators; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiotensin II AT2, conformationally-constrained analogs of peptides of, as inhibitors of premature labor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Animal growth regulators
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(blood platelet-derived growth factors, conformationally-constrained analogs of peptides of, as clotting inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ciliary neurotrophic factors, conformationally constrained analogs of peptides of, as growth promoter; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Proteins, specific or class
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(curculins, conformationally-constrained analogs of peptides of, as sweetening agents; peptides contg. conformation-constraining groups

that interact with other proteins and their therapeutic uses)

IT Parturition
(disorder, premature, conformationally-constrained analogs of peptides of angiotensin receptors as inhibitors of; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Hemopoietins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hematopoietic cell growth factors KL, conformationally-constrained analogs of peptides of, as hemopoietic factors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Fertility
(inhibitors, conformationally-constrained analogs of peptides of LHRH receptor, as antifertility agents; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 10, conformationally-constrained analogs of peptides of, as immunomodulators; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 3, conformationally-constrained analogs of peptides of, as chemotactic peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 4, conformationally-constrained analogs of peptides of, as immunomodulators; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 8, conformationally-constrained analogs of peptides of, as chemotactic peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphokine and cytokine receptors
Receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 8, conformationally-constrained analogs of peptides of, as **inflammation** inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(leukemia-inhibiting factor, conformationally-constrained analogs of peptides of, as neoplasm inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT **Neoplasm inhibitors**
(lung small-cell carcinoma, conformationally-constrained analog of peptide of gastrin-releasing peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Proteins, specific or class
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(mabinlins, conformationally-constrained analogs of peptides of, as sweetening agents; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(migration-inhibiting factor, conformationally-constrained analogs of

peptides of, as **inflammation** inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Glycoproteins, specific or class
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(miraculins, conformationally-constrained analogs of peptides of, as sweetening agents; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT **Antibodies**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, to fibrinogen .alpha. chain, conformationally-constrained analogs of peptides of, as platelet inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(moubatins, conformationally-constrained analogs of peptides of, as platelet inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuroglia-derived neurotrophic factors, conformationally-constrained analogs of peptides of, as neurotropic factor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pleiotrophins, conformationally constrained analogs of peptides of, as growth promoter; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT **Lung, neoplasm**
(**small-cell carcinoma**, inhibitors,
conformationally-constrained analog of peptide of gastrin-releasing peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Proteins, specific or class
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(thaumatins, conformationally-constrained analogs of peptides of, as sweetening agents; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Integrins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.IIb, conformationally constrained analogs of peptides of; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma., conformationally-constrained analogs of peptides of, as macrophage-activating peptides; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9013-93-8, Phospholipase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CM-IV, of Naja nigricollis, conformationally-constrained analogs of peptides of, as clotting inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161501-99-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained CP-10 peptide analog as chemoattractant; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 125850-12-6 129058-85-1 161501-79-7 161501-80-0 161501-81-1
161501-82-2 161501-83-3 161501-84-4 161501-85-5 161501-86-6
161501-87-7 161501-88-8
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained RGD peptide analog as platelet aggregation inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161501-89-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained adrenomedullin peptide analog as hypotensive; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161503-05-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained calciseptin peptide analog as platelet aggregation inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-00-7
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained interleukin 8 peptide analog as chemoattractant; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161501-90-2 161501-91-3
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained maxadilan peptide analog as hypotensive; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161501-92-4 161501-93-5 161501-94-6 161501-95-7
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained staphylokinase peptide analog as hypotensive; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161501-96-8 161501-97-9 161501-98-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained streptokinase peptide analog as hypotensive; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-01-8 161502-02-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, conformationally constrained .alpha.-1 proteinase inhibitor analog as chemoattractant; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9041-92-3D, conformationally-constrained analogs of peptides of
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as chemoattractants; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9002-01-1D, Streptokinase, conformationally-constrained analogs of peptides of 9040-61-3D, Staphylokinase, conformationally-constrained

analogs of peptides of
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as fibrinolytics; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 143011-72-7D, Granulocyte colony-stimulating factor, conformationally-constrained analogs of peptides of
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as growth promoters; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 134710-25-1D, Calciseptin, conformationally constrained peptide analogs from 135374-80-0D, Maxadilan, conformationally-constrained analogs of peptides of 154835-90-2D, Adrenomedullin, conformationally-constrained analogs of peptides of
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as hypotensives; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 7440-70-2, Calcium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(blood lowering agents, conformationally constrained analogs of peptides as; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-18-7 161502-19-8 161502-20-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analog of peptide of Streptococcus pyogenes mitogen, as lymphocyte mitogen; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-16-5 161502-17-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analog of peptide of glial cell line-derived neurotropic factor, as neurotropic factor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-07-4 161502-08-5 161502-09-6 161502-10-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analog of peptide of granulocyte colony-stimulating factor, as growth promoter; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-11-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analog of peptide of interleukin-3, as growth promoter; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-12-1 161502-13-2 161502-14-3
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analog of peptide of stem cell factor, as hemopoietic factor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-15-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analog of peptide of vascular permeability factor, as hemopoietic factor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-05-2 161502-06-3
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analogs of peptides of ciliary

neurotropic factor, as growth promoter; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-03-0 161502-04-1 161503-06-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally constrained analogs of peptides of pleiotrophin, as growth promoter; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 52-90-4P, Cysteine, biological studies 147-85-3P, Proline, biological studies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conformationally constrained peptides contg.; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-99-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide for lowering kidney vessel resistance; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161536-66-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of B-cell differentiating peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-64-3 161502-65-4 161502-66-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of LHRH receptor, as antifertility agent; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-21-2 **161502-22-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of Ling-Zhi 8, as immunomodulator; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-73-4 161502-74-5 161502-75-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of PDGF, as inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-67-6 161502-68-7 161536-64-7
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of angiotensin II receptor, as inhibitor of premature labor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-35-8
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of anthopleurin A, as cardiotonics; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161536-62-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of anthopleurin B, as cardiotonics; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-34-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of botrocetin, as clot-inducer; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 151992-27-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of calcitonin, as hypocalcemic agent; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161502-49-4
RL: FFD (Food or feed use); PRP (Properties); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of curculin, as taste-modifying agent; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161502-96-1 161502-97-2
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of enkephalin, as analgesic; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161502-88-1 161502-89-2 161502-90-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of factor IXa, as clotting inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161502-76-7 161502-77-8
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of factor V, as inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161502-78-9 161502-79-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of factor VIII, as inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161502-91-6 161502-92-7 161502-93-8
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of factor VIIa, as clotting inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161502-85-8 161502-86-9 161502-87-0 161536-65-8
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of factor Xa, as clotting inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161502-72-3
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of fibrinogen .gamma.-chain, as **inflammation** inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)
IT 161503-03-3
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of gastrin-releasing

peptide, for treatment of small cell lung cancer; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-98-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of human growth hormone, as hypoglycemic potentiator; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161536-63-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of interferon .gamma., as macrophage-activating peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-23-4 161502-24-5 161502-25-6 161536-61-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of interleukin 4, as immunomodulator; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-69-8 161502-70-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of interleukin 8 receptor , as **inflammation** inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-26-7 161502-27-8 161502-28-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of interleukin-10, as immunomodulator; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-58-5 161502-59-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of leech antiplatelet protein, as platelet inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-54-1 161502-55-2 161502-56-3 161502-57-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of leukemia inhibitory factor, as neoplasm inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-42-7 161502-43-8 161502-44-9 161502-45-0 161502-46-1
RL: FFD (Food or feed use); PRP (Properties); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of mabinlin, as sweetening agent; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-71-2
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of macrophage migration-inhibiting factor, as **inflammation** inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-47-2 161502-48-3
RL: FFD (Food or feed use); PRP (Properties); BIOL (Biological study);

USES (Uses)
(conformationally-constrained analog of peptide of miraculin, as taste-modifying agent; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-41-6
RL: FFD (Food or feed use); PRP (Properties); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of monellin, as sweetening agent; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-62-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of monoclonal **antibody** to fibrinogen .alpha. chain, as platelet inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-60-9 161502-61-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of moubatin, as platelet inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-51-8 161502-52-9 161502-53-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of oncostatin M, as neoplasm inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-80-3 161502-81-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of phospholipase CM-IV, as clotting inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-95-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of platelet glycoprotein IIb, as platelet inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-82-5 161502-83-6 161502-84-7
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of prothrombin, as clotting inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-50-7 161514-31-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of relaxin, as contraction-inhibiting peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161503-02-2
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of somatostatin, for control of growth hormone and glucagon secretion; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-29-0 161502-30-3 161502-31-4 161502-32-5 161502-33-6

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of staphylocoagulase, as clot-inducer; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-36-9 161502-37-0 161502-38-1 161502-39-2 161502-40-5
RL: FFD (Food or feed use); PRP (Properties); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of thaumatin, as sweetening agent; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161503-00-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of thymopoietin, as immunostimulant; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161503-01-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of thymosin .alpha.1, as immunostimulant; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-94-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of von Willebrand factor, as platelet inhibitor; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 161502-63-2
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptide of growth-inhibiting factor, for treatment of Alzheimer's disease; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9011-97-6, Cholecystokinin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as appetite suppressant; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 62079-80-5, Anthopleurin A (Anthopleura xanthogrammica reduced)
72067-68-6, Anthopleurin B (Anthopleura xanthogrammica reduced)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as cardiotonics; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 127464-60-2, Vascular permeability factor
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as chemotactic peptide; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9001-13-2, Staphylocoagulase 85537-36-6, Botrocetin 161503-04-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as clot-inducers; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9007-12-9, Calcitonin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as hypocalcemic agent; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 60529-76-2, Thymopoietin 69521-94-4, Thymosin .alpha.1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as immunostimulant; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 106956-32-5, Oncostatin M
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, as neoplasm inhibitors; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 157857-80-2, Growth-inhibiting factor (human reduced)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analogs of peptides of, for treatment of Alzheimer's disease; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9002-69-1DP, Relaxin, conformationally-constrained analogs of
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9001-24-5D, Blood-coagulation factor V, conformationally-constrained analogs of peptides of 9002-05-5D, Blood-coagulation factor Xa, conformationally-constrained analogs of peptides of 37316-87-3D, Blood-coagulation factor IXa, conformationally-constrained analogs of peptides of 51110-01-1D, Somatostatin, conformationally-constrained analogs of peptides of 65312-43-8D, Blood-coagulation factor VIIa, conformationally-constrained analogs of peptides of 80043-53-4D, Gastrin-releasing peptide, conformationally-constrained analogs of peptides of 109319-16-6D, conformationally-constrained analogs of peptides of 113189-02-9D, Blood-coagulation factor VIII, conformationally-constrained analogs of peptides of
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT 9001-26-7, Prothrombin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proteins of, conformationally constrained analogs of peptides of; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

IT **161502-22-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of Ling-Zhi 8, as immunomodulator; peptides contg. conformation-constraining groups that interact with other proteins and their therapeutic uses)

RN 161502-22-3 HCAPLUS

CN L-Valine, glycyl-L-asparaginyl-L-prolyl-L-asparaginyl-L-asparaginyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-valyl-L-threonyl-L-phenylalanyl-L-prolyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L90 ANSWER 24 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:362667 HCAPLUS
DN 122:282262
TI Endothelin antagonist peptides
IN Cody, Wayne L.; Depue, Patricia; Doherty, Annette M.; He, John X.; Taylor, Michael D.
PA Warner-Lambert Co., USA
SO U.S., 32 pp. Cont.-in-part of U.S. Ser. No. 809, 746, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K037-02
ICS C07K007-06

NCL 514017000
CC 1-12 (Pharmacology)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5382569	A	19950117	US 1992-995480	19921221 <--
	CA 2108754	AA	19921117	CA 1992-2108754	19920424 <--
	ES 2151888	T3	20010116	ES 1992-923584	19920424 <--
	CA 2146874	AA	19940707	CA 1993-2146874	19931217 <--
	WO 9414843	A1	19940707	WO 1993-US12377	19931217 <--
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9458280	A1	19940719	AU 1994-58280	19931217 <--
	AU 679712	B2	19970710		
	EP 675902	A1	19951011	EP 1994-904089	19931217 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08504823	T2	19960528	JP 1993-515347	19931217 <--
	US 5641752	A	19970624	US 1994-316533	19940930 <--
	US 5773414	A	19980630	US 1997-813625	19970307 <--
PRAI	US 1991-701274	B2	19910516 <--		
	US 1991-809746	B2	19911218 <--		
	US 1992-995480	A	19921221 <--		
	WO 1993-US12377	W	19931217 <--		
	US 1994-316533	A3	19940930 <--		

OS MARPAT 122:282262

AB Novel antagonist peptides (Markush included) of endothelin are described, as well as methods for the prepn. and pharmaceutical compns. of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinol., neurol. disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes. More than 300 specific peptides are claimed. Prepn. of peptides is described, and activities (rat heart ventricle binding assay, inositol phosphate accumulation, arachidonic acid release assay) are included for selected peptides.

ST endothelin antagonist peptide therapeutic

IT Antiarrhythmics
Antidiabetics and Hypoglycemics
Antihypertensives
Ischemia
Neoplasm inhibitors
Toxemia of pregnancy
(endothelin antagonist peptides for therapeutic use)

IT Blood vessel, disease
(Raynaud's phenomenon, endothelin antagonist peptides for therapeutic use)

IT Heart, disease
(angina pectoris, endothelin antagonist peptides for therapeutic use)

IT Artery
(angioplasty, percutaneous transluminal coronary; endothelin antagonist peptides for therapeutic use)

IT **Bronchodilators**
(**antiasthmatics**, endothelin antagonist peptides for therapeutic use)

IT Antiarteriosclerotics
(antiatherosclerotics, endothelin antagonist peptides for therapeutic use)

IT Endocrine system
Nervous system
(disease, endothelin antagonist peptides for therapeutic use)

IT Meninges

(diseases, subarachnoid hemorrhage, endothelin antagonist peptides for therapeutic use)

IT Animal metabolism
(disorder, endothelin antagonist peptides for therapeutic use)

IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(endothelin 1, endothelin antagonist peptides for therapeutic use)

IT Shock
(endotoxin, endothelin antagonist peptides for therapeutic use)

IT Heart, disease
Kidney, disease
(**failure**, endothelin antagonist peptides for therapeutic use)

IT Heart, disease
(infarction, endothelin antagonist peptides for therapeutic use)

IT **Intestine, disease**
(**ischemia**, endothelin antagonist peptides for therapeutic use)

IT Stomach, disease
(mucosa, protection; endothelin antagonist peptides for therapeutic use)

IT Hypertension
(pulmonary, endothelin antagonist peptides for therapeutic use)

IT Heart, disease
(restenosis, endothelin antagonist peptides for therapeutic use)

IT 116243-73-3, Endothelin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; endothelin antagonist peptides for therapeutic use)

IT 160480-79-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bendothelin antagonist peptides for therapeutic use)

IT 148002-21-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endohelin antagonist peptides for therapeutic use)

IT 143037-35-8P 148001-45-0P 148001-46-1P 148001-47-2P 148001-48-3P
148001-49-4P 148001-50-7P 148001-51-8P 148001-52-9P 148001-53-0P
148001-56-3P 148001-57-4P 148001-58-5P 148001-59-6P 148001-60-9P
148001-66-5P 148001-72-3P 148029-27-0P 150343-95-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(endothelin antagonist peptides for therapeutic use)

IT 138831-83-1 143037-31-4 143037-33-6 143037-34-7 143037-36-9
148001-62-1 148001-75-6 148001-89-2 148002-42-0 148003-16-1
148003-31-0 148003-41-2 148029-66-7 148029-82-7 148029-98-5
150297-16-8 150297-21-5 150297-22-6 150344-00-6 150344-02-8
150344-05-1 150344-11-9 150344-12-0 151078-85-2 151078-86-3
160480-71-7 160480-74-0 160480-75-1 160480-76-2 160480-77-3
160480-78-4 160480-80-8 160480-81-9 160480-82-0 160480-84-2
160480-85-3 160480-86-4 160480-87-5 160480-88-6 160480-89-7
160480-91-1 160480-92-2 160480-93-3 160480-94-4 160480-95-5
160480-96-6 160480-97-7 160480-98-8 160480-99-9 160481-00-5
160481-01-6 160481-02-7 163112-40-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin antagonist peptides for therapeutic use)

IT 148001-55-2P 148001-61-0P 151039-33-7P 163112-39-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(endothelin antagonist peptides for therapeutic use)

IT 148001-65-4 148001-67-6 148001-68-7 148001-70-1 148001-71-2
148001-73-4 148001-76-7 148001-77-8 148001-78-9 148001-79-0
148001-87-0 148001-99-4 148002-00-0 148002-01-1 148002-02-2
148002-03-3 148002-04-4 148002-05-5 148002-06-6 148002-07-7
148002-08-8 148002-09-9 148002-10-2 **148002-11-3**
148002-12-4 148002-13-5 148002-14-6
148002-15-7 148002-16-8 **148002-17-9** 148002-18-0
148002-19-1 148002-20-4 148002-22-6 148002-23-7 148002-24-8
148002-25-9 148002-26-0 148002-27-1 148002-28-2 148002-29-3
148002-30-6 148002-31-7 148002-32-8 148002-33-9 148002-34-0
148002-35-1 148002-36-2 148002-37-3 148002-38-4 148002-39-5
148002-40-8 148002-41-9 148002-43-1 148002-44-2 148002-45-3
148002-46-4 148002-47-5 148002-48-6 148002-49-7 148002-50-0
148002-51-1 148002-52-2 148002-53-3 148002-54-4 148002-55-5
148002-56-6 148002-57-7 148002-58-8 148002-59-9 148002-60-2
148002-61-3 148002-62-4 148002-63-5 148002-64-6 148002-65-7
148002-66-8 148002-67-9 148002-68-0 148002-69-1 148002-70-4
148002-71-5 148002-72-6 148002-73-7 148002-74-8 148002-75-9
148002-76-0 148002-77-1 148002-78-2 148002-79-3 148002-80-6
148002-81-7 148002-82-8 148002-83-9 148002-84-0 148002-85-1
148002-86-2 148002-87-3 148002-88-4 148002-89-5 148002-90-8
148002-91-9 148002-92-0 148002-93-1 148002-94-2 148002-95-3
148002-96-4 148002-97-5 148002-98-6 148002-99-7 148003-00-3
148003-01-4 148003-02-5 148003-03-6 148003-04-7 148003-05-8
148003-06-9 148003-07-0 148003-08-1 148003-09-2 148003-10-5
148003-11-6 148003-12-7 148003-13-8 148003-14-9 148003-15-0
148003-17-2 148003-18-3 148003-19-4 148003-20-7 148003-21-8
148003-22-9 148003-23-0 148003-24-1 148003-25-2 148003-26-3
148003-27-4 148003-28-5 148003-29-6 148003-30-9 148003-32-1
148003-33-2 148003-34-3 148003-35-4 148003-36-5 148003-37-6
148003-38-7 148003-39-8 148003-40-1 148003-42-3 148003-43-4
148003-44-5 148003-45-6 148003-46-7 148003-47-8 148003-48-9
148003-49-0 148003-50-3 148003-51-4 148003-52-5 148003-53-6
148003-54-7 148003-55-8 148003-56-9 148003-57-0 148003-58-1
148003-59-2 148003-60-5 148003-61-6 148003-62-7 148003-63-8
148003-64-9 148003-65-0 148003-66-1 148003-67-2 148003-68-3
148003-69-4 148003-70-7 148003-71-8 148003-72-9 148003-73-0
148003-74-1 148003-75-2 148003-76-3 148003-77-4 148023-27-2
148023-28-3 148029-28-1 148029-29-2 148029-30-5 148029-31-6
148029-32-7 148029-33-8 148029-34-9 148029-35-0 148029-36-1
148029-37-2 148029-38-3 148029-39-4 148029-40-7 148029-41-8
148029-42-9 148029-43-0 148029-45-2 148029-46-3 148029-47-4
148029-48-5 148029-49-6 148029-50-9 148029-51-0 148029-52-1
148029-53-2 148029-54-3 148029-55-4 148029-56-5 148029-57-6
148029-58-7 148029-59-8 148029-60-1 148029-63-4 148029-64-5
148029-65-6 148029-69-0 148029-95-2 148030-00-6 148030-01-7
148030-02-8 148030-03-9 148030-04-0 148030-05-1 148030-06-2
148030-07-3 148030-08-4 148030-09-5 148030-10-8 148030-11-9
148030-12-0 148030-13-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin antagonist peptides for therapeutic use)

IT 148030-14-2 148030-15-3 148035-19-2 148051-12-1 148051-13-2
148051-14-3 160480-65-9 160480-66-0 160480-67-1 160480-68-2
160480-69-3 160480-70-6 160480-72-8 160480-73-9 160480-83-1
160480-90-0 160481-03-8 163112-38-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin antagonist peptides for therapeutic use)

IT **148002-08-8 148002-11-3 148002-12-4**
148002-13-5 148002-14-6 148002-15-7
148002-17-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin antagonist peptides for therapeutic use)

RN 148002-08-8 HCAPLUS

CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-D-phenylalanyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148002-11-3 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-D-tyrosyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 148002-12-4 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-O-methyl-D-tyrosyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 148002-13-5 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-O-ethyl-D-tyrosyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 148002-14-6 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[N-acetyl-3-(2-naphthalenyl)-D-alanyl]-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 148002-15-7 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[N-acetyl-3-(1-naphthalenyl)-D-alanyl]-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 148002-17-9 HCAPLUS

CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-3-[1,1'-biphenyl]-4-yl-D-alanyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L90 ANSWER 25 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:314153 HCAPLUS
DN 122:106542
TI Preparation of peptide endothelin antagonists.
IN Cody, Wayne Livingston; Depue, Patricia; Doherty, Annette Marian; He, John Xiaoqiang; Taylor, Michael Douglas
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K007-06
ICS A61K037-43
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9414843	A1	19940707	WO 1993-US12377	19931217 <--
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5382569	A	19950117	US 1992-995480	19921221 <--
	AU 9458280	A1	19940719	AU 1994-58280	19931217 <--
	AU 679712	B2	19970710		
	EP 675902	A1	19951011	EP 1994-904089	19931217 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08504823	T2	19960528	JP 1993-515347	19931217 <--
PRAI	US 1992-995480	A	19921221 <--		
	US 1991-701274	B2	19910516 <--		
	US 1991-809746	B2	19911218 <--		
	WO 1993-US12377	W	19931217 <--		

OS MARPAT 122:106542
GI



AB A1A2A3A4A5A6 [I; A1 = RCH[(CH2)nR2]CO, Q1, etc.; n = 0-6; R = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, fluorenylmethyl, NR3R4, OR3, CO2R3, etc.; R2 = H, alkyl, trityl, NR3R4, etc.; R3, R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, fluorenylmethyl; A2-A5 = null, NR11CH[(CH2)nR10]CO, Q2, Q3, etc.; q = 0-4; R10 = H, alkyl, aryl, cycloalkyl, alkenyl, alkynyl, OR3, NR3R4, CONR3R4, etc.; R11 = H, alkyl, aryl; A6 = NR11CH[(CH2)nR12]R13, Q4, etc.; R12 = aryl, heteroaryl, heterocycloalkyl; R13 = (CH2)nCO2H, (CH2)nOH, (CH2)nCONR3R4, etc.; with provisos], were prepd. I are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinol., neurol. disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes. Thus, Ac-D-Dip-Leu-Asp-Ile-Ile-Trp-OH (Dip = 3,3-diphenylalanyl) (prepd. by solid phase synthesis) at 1.0 .mu.M/kg i.v. in rats significantly attenuated systemic depressor response to endothelin-1 but had no effect on pressor responses.

ST peptide prepn endothelin antagonist; drug prepn peptide endothelin antagonist

IT Antiarrhythmics
Antidiabetics and Hypoglycemics
Antihypertensives
Neoplasm inhibitors
Nervous system agents
(prepn. of peptide endothelin antagonists)

IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide endothelin antagonists)

IT Ischemia
Toxemia of pregnancy
(treatment; prepn. of peptide endothelin antagonists)

IT Blood vessel, disease
(Raynaud's phenomenon, treatment; prepn. of peptide endothelin antagonists)

IT Heart, disease

(angina pectoris, treatment; prepn. of peptide endothelin antagonists)
IT Artery
(angioplasty, prepn. of peptide endothelin antagonists for treatment of percutaneous transluminal coronary angioplasty)
IT **Bronchodilators**
(**antiasthmatics**, prepn. of peptide endothelin antagonists)
IT Antiarteriosclerotics
(antiatherosclerotics, prepn. of peptide endothelin antagonists)
IT Endocrine system
(disease, treatment; prepn. of peptide endothelin antagonists)
IT Meninges
(diseases, subarachnoid hemorrhage, treatment; prepn. of peptide endothelin antagonists)
IT Animal metabolism
(disorder, treatment; prepn. of peptide endothelin antagonists)
IT Shock
(endotoxin, treatment; prepn. of peptide endothelin antagonists)
IT Heart, disease
Kidney, disease
(**failure**, treatment; prepn. of peptide endothelin antagonists)
IT Heart, disease
(infarction, treatment; prepn. of peptide endothelin antagonists)
IT Heart, disease
(restenosis, treatment; prepn. of peptide endothelin antagonists)
IT 138831-83-1P 143037-31-4P 143037-32-5P 143037-33-6P 143037-34-7P
143037-35-8P 143037-36-9P 148001-45-0P 148001-46-1P 148001-47-2P
148001-48-3P 148001-49-4P 148001-50-7P 148001-51-8P 148001-52-9P
148001-53-0P 148001-54-1P 148001-55-2P 148001-56-3P 148001-57-4P
148001-58-5P 148001-59-6P 148001-60-9P 148001-61-0P 148001-62-1P
148001-65-4P 148001-66-5P 148001-67-6P 148001-68-7P 148001-69-8P
148001-70-1P 148001-71-2P 148001-72-3P 148001-73-4P 148001-75-6P
148001-76-7P 148001-77-8P 148001-78-9P 148001-79-0P 148001-80-3P
148001-81-4P 148001-82-5P 148001-83-6P 148001-84-7P 148001-85-8P
148001-86-9P 148001-87-0P 148001-88-1P 148001-89-2P 148001-90-5P
148001-91-6P 148001-92-7P 148001-93-8P 148001-94-9P 148001-95-0P
148001-96-1P 148001-97-2P 148001-99-4P 148002-00-0P 148002-01-1P
148002-02-2P 148002-03-3P 148002-04-4P 148002-05-5P 148002-06-6P
148002-07-7P **148002-08-8P** 148002-09-9P 148002-10-2P
148002-11-3P 148002-12-4P 148002-13-5P
148002-14-6P 148002-15-7P 148002-16-8P
148002-17-9P 148002-18-0P 148002-19-1P 148002-20-4P
148002-21-5P 148002-22-6P 148002-23-7P 148002-24-8P 148002-25-9P
148002-26-0P 148002-27-1P 148002-28-2P 148002-29-3P 148002-30-6P
148002-31-7P 148002-32-8P 148002-33-9P 148002-34-0P 148002-35-1P
148002-36-2P 148002-37-3P 148002-38-4P 148002-39-5P 148002-40-8P
148002-41-9P 148002-42-0P 148002-43-1P 148002-44-2P 148002-45-3P
148002-46-4P 148002-47-5P 148002-48-6P 148002-49-7P 148002-50-0P
148002-51-1P 148002-52-2P 148002-53-3P 148002-54-4P 148002-55-5P
148002-56-6P 148002-57-7P 148002-58-8P 148002-59-9P 148002-60-2P
148002-61-3P 148002-62-4P 148002-63-5P 148002-64-6P 148002-65-7P
148002-66-8P 148002-67-9P 148002-68-0P 148002-69-1P 148002-70-4P
148002-71-5P 148002-72-6P 148002-73-7P 148002-74-8P 148002-75-9P
148002-76-0P 148002-77-1P 148002-78-2P 148002-79-3P 148002-80-6P
148002-81-7P 148002-82-8P 148002-83-9P 148002-84-0P 148002-85-1P
148002-86-2P 148002-87-3P 148002-88-4P 148002-89-5P 148002-90-8P
148002-91-9P 148002-92-0P 148002-93-1P 148002-94-2P 148002-95-3P
148002-96-4P 148002-97-5P 148002-98-6P 148002-99-7P 148003-00-3P
148003-01-4P 148003-02-5P 148003-03-6P 148003-04-7P 148003-05-8P
148003-06-9P 148003-07-0P 148003-08-1P 148003-09-2P 148003-10-5P
148003-11-6P 148003-12-7P 148003-13-8P 148003-14-9P 148003-15-0P
148003-16-1P 148003-17-2P 148003-18-3P 148003-19-4P 148003-20-7P
148003-21-8P 148003-22-9P 148003-23-0P 148003-24-1P 148003-25-2P

148003-26-3P 148003-27-4P 148003-28-5P 148003-29-6P 148003-30-9P
148003-31-0P 148003-32-1P 148003-33-2P 148003-34-3P 148003-35-4P
148003-36-5P 148003-37-6P 148003-38-7P 148003-39-8P 148003-40-1P
148003-41-2P 148003-42-3P 148003-43-4P 148003-44-5P 148003-45-6P
148003-46-7P 148003-47-8P 148003-48-9P 148003-49-0P 148003-50-3P
148003-51-4P 148003-52-5P 148003-53-6P 148003-54-7P 148003-55-8P
148003-56-9P 148003-57-0P 148003-58-1P 148003-59-2P 148003-60-5P
148003-61-6P 148003-62-7P 148003-63-8P 148003-64-9P 148003-65-0P
148003-66-1P 148003-67-2P 148003-68-3P 148003-69-4P 148003-70-7P
148003-71-8P 148003-72-9P 148003-73-0P 148003-74-1P 148003-75-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide endothelin antagonists)

IT 148003-76-3P 148003-77-4P 148023-27-2P 148023-28-3P 148029-27-0P
148029-28-1P 148029-29-2P 148029-30-5P 148029-31-6P 148029-32-7P
148029-33-8P 148029-34-9P 148029-35-0P 148029-36-1P 148029-37-2P
148029-38-3P 148029-39-4P 148029-40-7P 148029-41-8P 148029-42-9P
148029-43-0P 148029-44-1P 148029-45-2P 148029-46-3P 148029-47-4P
148029-48-5P 148029-49-6P 148029-50-9P 148029-51-0P 148029-52-1P
148029-53-2P 148029-54-3P 148029-55-4P 148029-56-5P 148029-57-6P
148029-58-7P 148029-59-8P 148029-60-1P 148029-61-2P 148029-62-3P
148029-63-4P 148029-64-5P 148029-65-6P 148029-66-7P 148029-67-8P
148029-68-9P 148029-69-0P 148029-70-3P 148029-71-4P 148029-72-5P
148029-73-6P 148029-74-7P 148029-75-8P 148029-76-9P 148029-77-0P
148029-78-1P 148029-79-2P 148029-80-5P 148029-81-6P 148029-82-7P
148029-83-8P 148029-84-9P 148029-85-0P 148029-86-1P 148029-87-2P
148029-88-3P 148029-89-4P 148029-90-7P 148029-91-8P 148029-92-9P
148029-93-0P 148029-94-1P 148029-95-2P 148029-96-3P 148029-97-4P
148029-98-5P 148029-99-6P 148030-00-6P 148030-01-7P 148030-02-8P
148030-03-9P 148030-04-0P 148030-05-1P 148030-06-2P 148030-07-3P
148030-08-4P 148030-09-5P 148030-10-8P 148030-11-9P 148030-12-0P
148030-13-1P 148030-14-2P 148030-15-3P 148035-19-2P 148051-12-1P
148051-13-2P 148051-14-3P 150297-16-8P 150297-21-5P 150297-22-6P
150343-95-6P 150344-00-6P 150344-02-8P 150344-05-1P 150344-11-9P
150344-12-0P 151039-33-7P 151078-85-2P 151078-86-3P 160480-64-8P
160480-65-9P 160480-66-0P 160480-67-1P 160480-68-2P 160480-69-3P
160480-70-6P 160480-71-7P 160480-72-8P 160480-73-9P 160480-74-0P
160480-75-1P 160480-76-2P 160480-77-3P 160480-78-4P 160480-79-5P
160480-80-8P 160480-81-9P 160480-82-0P 160480-83-1P 160480-84-2P
160480-85-3P 160480-86-4P 160480-87-5P 160480-88-6P 160480-89-7P
160480-90-0P 160480-91-1P 160480-92-2P 160480-93-3P 160480-94-4P
160480-95-5P 160480-96-6P 160480-97-7P 160480-98-8P 160480-99-9P
160481-00-5P 160481-01-6P 160481-02-7P 160481-03-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide endothelin antagonists)

IT 116243-73-3, Endothelin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of peptide endothelin antagonists)

IT 7536-58-5 13139-15-6 13139-16-7 18942-49-9 47355-10-2D, resin bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of peptide endothelin antagonists)

IT **148002-08-8P 148002-11-3P 148002-12-4P**
148002-13-5P 148002-14-6P 148002-15-7P
148002-17-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide endothelin antagonists)

RN 148002-08-8 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-D-phenylalanyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148002-11-3 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-D-tyrosyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 148002-12-4 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-O-methyl-D-tyrosyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 148002-13-5 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-O-ethyl-D-tyrosyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 148002-14-6 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[N-acetyl-3-(2-naphthalenyl)-D-alanyl]-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 148002-15-7 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[N-acetyl-3-(1-naphthalenyl)-D-alanyl]-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 148002-17-9 HCAPLUS

CN L-Tryptophan, N-[N-[N-[N-[N-(N-acetyl-3-[1,1'-biphenyl]-4-yl-D-alanyl)-L-isoleucyl]-L-.alpha.-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L90 ANSWER 26 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1992:147518 HCAPLUS
DN 116:147518
TI Synthetic peptides of human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33, and 56, useful in immunoassay for diagnostic purposes
IN Dillner, Joakim; Dillner, Lena; Cheng, Hwee Ming
PA Medscand AB, Swed.
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM G01N033-569
ICS C07K007-04
CC 9-10 (Biochemical Methods)
Section cross-reference(s): **15**
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9118294	A1	19911128	WO 1991-SE335	19910513 <--
	W: AU, CA, FI, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2040849	AA	19921020	CA 1991-2040849	19910419 <--
	CA 2082658	AA	19911112	CA 1991-2082658	19910513 <--
	AU 9178890	A1	19911210	AU 1991-78890	19910513 <--
	AU 668499	B2	19960509		
	JP 06501542	T2	19940217	JP 1991-509789	19910513 <--
	EP 594613	A1	19940504	EP 1991-909813	19910513 <--
	EP 594613	B1	19971105		
	R: AT, BE, DE, DK, FR, GB, IT, LU, NL, SE				
	AT 160020	E	19971115	AT 1991-909813	19910513 <--
	US 5932412	A	19990803	US 1997-934915	19970922 <--

PRAI SE 1990-1705 19900511 <--
WO 1991-SE335 19910513 <--
US 1993-949836 19930222 <--

AB The title peptides are provided for diagnosis of infection with human papillomavirus (hPV) and of hPV-carrying tumors, esp. cervix cancer and condyloma, using an immunoassay. Synthetic peptide sequences are presented. All peptides were tested by ELISA for reactivity with IgA, **IgG**, or IgM **antibodies** in human sera. The major immunoreactive peptides were also tested in IgA and **IgG** ELISAs with cervical secretions from 30 women with cervical intraepithelial neoplasia (CIN) or with a history of CIN. Peptides which were most immunoreactive with serum were those which were most reactive with cervical secretions.

ST peptide human papillomavirus immunoassay; diagnosis human papillomavirus peptide; tumor human papillomavirus diagnosis peptide; cervical intraepithelial neoplasia diagnosis peptide

IT Human papillomavirus 1
Human papillomavirus 11
Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 31
Human papillomavirus 33
Human papillomavirus 5
Human papillomavirus 56
Human papillomavirus 6
Human papillomavirus 8
(diagnosis of infection with, and related diseases, peptides for)

IT Wart
(diagnosis of, human papillomavirus peptides for)

IT Neoplasm
(human papilloma virus-carrying, immunodiagnosis of, peptides for)

IT Blood analysis
(human papillomavirus immunodiagnosis in, peptides for)

IT Immunoassay
(human papillomavirus infection diagnosis with, peptides for)

IT Bovine papillomavirus
(human papillomavirus-derived peptides prodn. of **antibodies** to)

IT Human papillomavirus
(infection with, immunodiagnosis of, peptides for)

IT Protein sequences
(of human papillomavirus immunodiagnostic peptides)

IT Peptides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(of human papillomavirus proteins, for immunodiagnosis)

IT **Antibodies**
RL: ANST (Analytical study)
(to human papillomavirus proteins or peptides, human papillomavirus or related disease immunodiagnosis in relation to)

IT **Immunoglobulins**
RL: ANT (Analyte); ANST (Analytical study)
(A, to human papillomavirus proteins or peptides, human papillomavirus or related disease immunodiagnosis in relation to)

IT Transcription factors
RL: ANT (Analyte); ANST (Analytical study)
(E2, peptides from, of human papillomavirus, for diagnosis)

IT Proteins
RL: ANT (Analyte); ANST (Analytical study)
(E5, peptides from, of human papillomavirus, for diagnosis)

IT Proteins
RL: ANT (Analyte); ANST (Analytical study)
(E6, peptides from, of human papillomavirus, for diagnosis)

IT Transcription factors
RL: ANT (Analyte); ANST (Analytical study)
(E7, peptides from, of human papillomavirus, for diagnosis)
IT **Immunoglobulins**
RL: ANT (Analyte); ANST (Analytical study)
(G, to human papillomavirus proteins or peptides, human papillomavirus or related disease immunodiagnosis in relation to)
IT Proteins
RL: ANT (Analyte); ANST (Analytical study)
(L1, peptides from, of human papillomavirus, for diagnosis)
IT Proteins
RL: ANT (Analyte); ANST (Analytical study)
(L2, peptides from, of human papillomavirus, for diagnosis)
IT **Immunoglobulins**
RL: ANT (Analyte); ANST (Analytical study)
(M, to human papillomavirus proteins or peptides, human papillomavirus or related disease immunodiagnosis in relation to)
IT Reproductive tract
(acuminate wart, diagnosis of, human papillomavirus peptides for)
IT Uterus, neoplasm
(cervix, diagnosis of, human papillomavirus peptides for)
IT Uterus
(cervix, secretions of, human papillomavirus immunodiagnosis in, peptides for)
IT Immunoassay
(enzyme-linked immunosorbent assay, human papillomavirus infection diagnosis with, peptides for)
IT Immunoassay
(fluorescence, human papillomavirus infection diagnosis with, peptides for)
IT Proteins
RL: ANT (Analyte); ANST (Analytical study)
(gene E1, peptides from, of human papillomavirus, for diagnosis)
IT Proteins
RL: ANT (Analyte); ANST (Analytical study)
(gene E4, peptides from, of human papillomavirus, for diagnosis)
IT Immunoassay
(immunohistochem., human papillomavirus infection diagnosis with, peptides for)
IT Carcinoma
(squamous cell, diagnosis of, human papillomavirus peptides for)
IT 139727-91-6
RL: ANT (Analyte); ANST (Analytical study)
(amino acid sequence and immunoreactivity of, immunodiagnosis of human papillomavirus and related diseases in relation to)
IT 133453-90-4 133453-94-8 133453-95-9 133453-97-1 133454-00-9
133454-15-6 133454-19-0 133454-20-3 133454-23-6 133454-24-7
133454-29-2 133454-30-5 133454-31-6 133454-32-7 133454-33-8
133454-34-9 **133454-35-0** 133483-74-6 133483-75-7
139727-93-8 139727-94-9 139727-95-0 139727-96-1
139727-97-2 139727-98-3 139727-99-4 139728-00-0 139728-01-1
139728-02-2 139728-03-3 139728-04-4 139728-05-5 139728-06-6
139728-07-7 139728-08-8 139728-09-9 139728-10-2 139728-11-3
139728-12-4 139728-13-5 139744-70-0 139744-71-1 139744-72-2
139744-73-3 139744-74-4 139744-75-5 139744-76-6 139744-77-7
139744-78-8 139744-79-9 139744-80-2 139744-81-3 139744-82-4
139744-83-5 139744-84-6 139744-85-7 139744-86-8 139744-87-9
139744-88-0 139744-89-1 139744-90-4 139744-91-5 139744-92-6
139744-93-7 139744-94-8 139744-95-9 139744-96-0 139744-97-1
139744-98-2 139744-99-3 139745-00-9 139745-01-0 139745-02-1
139745-03-2 139745-04-3 139745-05-4 139745-10-1 139767-10-5
RL: PRP (Properties)
(amino acid sequence of, immunodiagnosis of human papillomavirus and

related diseases in relation to)
IT 139727-91-6D, immunoreactivity of
RL: ANT (Analyte); ANST (Analytical study)
(human papillomavirus diagnosis in relation to)
IT 139727-89-2
RL: ANT (Analyte); ANST (Analytical study)
(immunoreactivity of, cor. L1 protein-derived peptide sequence of human papillomavirus in relation to)
IT 129020-03-7 129045-50-7 139727-90-5 139745-06-5 139745-07-6 139745-08-7 139745-09-8
RL: ANT (Analyte); ANST (Analytical study)
(immunoreactivity of, human papillomavirus diagnosis in relation to)
IT 139727-92-7
RL: ANT (Analyte); ANST (Analytical study)
(immunoreactivity of, to bovine papillomavirus)
IT **133454-35-0 139727-93-8**
RL: PRP (Properties)
(amino acid sequence of, immunodiagnosis of human papillomavirus and related diseases in relation to)
RN 133454-35-0 HCAPLUS
CN L-Asparagine, glycyl-L-methionyl-L-leucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-alanyl-L-threonyl-L-valyl-L-prolyl-L-cysteinyl-L-tryptophyl-L-asparaginyl-L-tyrosyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-asparaginyl-L-leucyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



RN 139727-93-8 HCAPLUS
CN L-Cysteine, L-isoleucylglycyl-L-seryl-L-alanyl-L-arginyl-L-methionyl-L-leucyl-L-valyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-alanyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



L90 ANSWER 27 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1992:126812 HCAPLUS
DN 116:126812
TI Pasteurella haemolytica antigens, their recombinant production, and their use in vaccines against respiratory disease in animals
IN Acres, Stephen D.; Bariuk, Lorne A.; Potter, Andrew A.; Lawman, Michael J. P.
PA University of Saskatchewan, Can.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K039-102
ICS C12N015-31; A61K039-395
CC **15-2** (Immunochemistry)
Section cross-reference(s): 3
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9115237	A1	19911017	WO 1990-CA170	19900525	<--
	W: AU, FI, JP, KP, KR, NO					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE					
	AU 9056621	A1	19911030	AU 1990-56621	19900525	<--
	AU 642650	B2	19931028			
	EP 527724	A1	19930224	EP 1990-906831	19900525	<--
	EP 527724	B1	19970827			
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE					
	JP 05508301	T2	19931125	JP 1990-507689	19900525	<--
	AT 157258	E	19970915	AT 1990-906831	19900525	<--
	ES 2108693	T3	19980101	ES 1990-906831	19900525	<--
	NO 9203827	A	19921126	NO 1992-3827	19921001	<--
	US 5476657	A	19951219	US 1993-15537	19930209	<--

	US 5871750	A	19990216	US 1994-355919	19941214 <--
	US 5849531	A	19981215	US 1995-455510	19950531 <--
PRAI	US 1990-504850		19900405 <--		
	US 1989-335018		19890407 <--		
	WO 1990-CA170		19900525 <--		
	US 1993-15537		19930209 <--		
	US 1994-355919		19941214 <--		

OS MARPAT 116:126812

AB Proteins and subunit antigens from P. haemolytica are provided for stimulating immunity against respiratory diseases, e.g. pneumonia (including shipping fever pneumonia). The subunit antigens include immunogenic amino acid sequences of P. haemolytica fimbrial protein, P. haemolytica plasmin receptor protein, P. haemolytica 50-kDa outer membrane protein, and P. haemolytica leukotoxin. The antigens can be used alone or in combination in a vaccine compn. Vaccination protocols are described, as is recombinant prodn. of the antigens. Vaccination trials indicated e.g. that a recombinant leukotoxin-.beta.-galactosidase fusion protein, as well as authentic leukotoxin, were effective immunogens for the prevention of bovine pneumonic pasteurellosis. The predicted amino acid sequence of the fusion protein is included, as are nucleotide and predicted amino acid sequences for the structural gene (and flanking sequences) of leukotoxin 352 (98% homologous to authentic leukotoxin).

ST Pasteurella antigen vaccine; outer membrane protein Pasteurella vaccine; fimbrial protein Pasteurella vaccine; plasmin receptor Pasteurella vaccine; leukotoxin Pasteurella vaccine; cloning Pasteurella antigen DNA; fusion protein Pasteurella leukotoxin galactosidase; cattle pneumonic pasteurellosis vaccine; respiratory disease animal vaccine

IT Vaccines
(against respiratory disease of animal, Pasteurella haemolytica antigens for)

IT Pasteurella haemolytica
(antigenic proteins of, for vaccine)

IT Escherichia coli
(cloning in, of antigenic Pasteurella haemolytica polypeptide DNA)

IT Gene, microbial
RL: PROC (Process)
(for leukotoxin of Pasteurella haemolytica, cloning of, for vaccine)

IT **Pneumonia**
(in pasteurellosis, vaccine for prevention of, in bovine)

IT Deoxyribonucleic acid sequences
(leukotoxin 352 gene-specifying, of Pasteurella haemolytica, complete)

IT Molecular cloning
(of antigenic Pasteurella haemolytica polypeptide DNA)

IT Protein sequences
(of fusion protein of truncated leukotoxin of Pasteurella haemolytica with .beta.-galactosidase)

IT Protein sequences
(of leukotoxin 352 (recombinant), of Pasteurella haemolytica, complete)

IT Antigens
RL: BIOL (Biological study)
(of Pasteurella haemolytica, for vaccine)

IT Plasmid and Episome
(pAA101, for recombinant leukotoxin of Pasteurella haemolytica prodn.)

IT Plasmid and Episome
(pAA114, with leukotoxin gene of Pasteurella haemolytica)

IT Plasmid and Episome
(pAA352, for recombinant leukotoxin of Pasteurella haemolytica prodn.)

IT Cattle
(pneumonic pasteurellosis in, prevention of, vaccine for)

IT Pili
(proteins of, of Pasteurella haemolytica, for vaccine)

IT Ruminant
(respiratory disease in, vaccine for, Pasteurella haemolytica antigenic

polypeptides for)
IT Antiserums
(to Pasteurella haemolytica, antigenic polypeptides for prodn. of)
IT Deoxyribonucleic acids
RL: BIOL (Biological study)
(Pasteurella haemolytica antigenic polypeptide-encoding, cloning of)
IT Proteins, specific or class
RL: BIOL (Biological study)
(OMP (outer membrane protein), of Pasteurella haemolytica, for vaccine)
IT Respiratory tract
(disease, vaccine for, in ruminant, Pasteurella haemolytica antigenic polypeptides for)
IT Proteins, specific or class
RL: BIOL (Biological study)
(fusion products, of leukotoxin truncated form of Pasteurella haemolytica with .beta.-galactosidase, for vaccine)
IT Toxins
RL: BIOL (Biological study)
(leuko-, of Pasteurella haemolytica, for vaccine)
IT **Antibodies**
RL: BIOL (Biological study)
(monoclonal, to fimbriae of Pasteurella haemolytica)
IT Proteins, specific or class
RL: BIOL (Biological study)
(outer membrane, 50,000-mol.-wt., recombinant, of Pasteurella haemolytica, prodn. of, for vaccine)
IT Receptors
RL: BIOL (Biological study)
(plasmin, of Pasteurella haemolytica, for vaccine)
IT 139569-09-8
RL: BIOL (Biological study)
(amino acid sequence of and cloning of DNA for, vaccine polypeptide in relation to)
IT 139569-10-1P
RL: PREP (Preparation)
(amino acid sequence of and recombinant prodn. of, vaccine in relation to)
IT **134476-35-0**
RL: BIOL (Biological study)
(for vaccine against Pasteurella haemolytica)
IT 9031-11-2D, .beta.-Galactosidase, fusion proteins with truncated leukotoxin
RL: BIOL (Biological study)
(for vaccine to Pasteurella haemolytica)
IT 139569-97-4 139569-98-5
RL: PRP (Properties); BIOL (Biological study)
(nucleotide sequence and cloning of)
IT 9001-90-5, Plasmin
RL: BIOL (Biological study)
(receptor for, of Pasteurella haemolytica, for vaccine)
IT **134476-35-0**
RL: BIOL (Biological study)
(for vaccine against Pasteurella haemolytica)
RN 134476-35-0 HCAPLUS
CN Glycine, glycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartylglycylglycyl-L-lysylglycyl-L-asparaginyl-L-.alpha.-aspartyl-L-leucyl-L-leucyl-L-histidylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L90 ANSWER 28 OF 32 HCAPLUS COPYRIGHT 2003 ACS

AN 1991:423702 HCAPLUS
DN 115:23702
TI Vaccine compositions containing Pasteurella haemolytica proteins and treatments of pneumonia in animals
IN Acres, Stephen D.; Babiuk, Lorne A.; Potter, Andrew A.; Lawman, Michael J. P.
PA University of Saskatchewan, Can.
SO Can. Pat. Appl., 88 pp.
CODEN: CPXXEB
DT **Patent**
LA English
IC ICM C12N015-31
ICS C12N001-00; C12P021-02; C07K013-00; C07K007-04; A61K039-40; A61K039-102
CC 3-4 (Biochemical Genetics)
Section cross-reference(s): 63
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	CA 2014033	AA	19901007		CA 1990-2014033	19900406	<--
	CA 2014033	C	19930209				
	US 5476657	A	19951219		US 1993-15537	19930209	<--
	US 5871750	A	19990216		US 1994-355919	19941214	<--
	US 5849531	A	19981215		US 1995-455510	19950531	<--
PRAI	US 1989-335018		19890407	<--			
	US 1990-504850		19900405	<--			
	US 1993-15537		19930209	<--			
	US 1994-355919		19941214	<--			

OS MARPAT 115:23702
AB New proteins and subunit antigens of P. haemolytica A-1 to be used as vaccines against animal respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The subunit antigens are from the fimbrial protein, the plasmin receptor protein, the 50K outer membrane protein, and leukotoxin. Also disclosed are the methods of vaccination and of manufg. the subunit antigens. The protecting effect of leukotoxin and the additive effect of the 50k protein on calves infected by bovine herpes virus-1 and P. haemolytica A-1 was demonstrated.
ST vaccine respiratory disease Pasteurella; fimbrial protein Pasteurella pneumonia vaccine; membrane 50K protein Pasteurella vaccine; leukotoxin Pasteurella vaccine
IT Pasteurella haemolytica
(A-1, subunit antigens of, as vaccine against respiratory diseases)
IT Vaccines
(against respiratory diseases, Pasteurella haemolytica A-1 subunit antigens as)
IT Plasmid and Episome
(pAA101, leukotoxin lktA gene of Pasteurella haemolytica A-1 on, expression in Escherichia coli of)
IT Plasmid and Episome
(pAA352, epitope-encoding gene of Pasteurella haemolytica A-1 on, in vaccine against respiratory diseases prepn.)
IT Shipping fever
(pneumonia in, vaccine against, Pasteurella haemolytica A-1 subunit antigens as)
IT **Pneumonia**
(shipping fever-caused, vaccine against, Pasteurella haemolytica A-1 subunit antigens as)
IT Escherichia coli
(Pasteurella haemolytica A-1 subunit antigens manuf. with, as vaccine)
IT Proteins, specific or class
RL: BIOL (Biological study)
(50,000-mol.-wt., Pasteurella haemolytica A-1 outer membrane, as vaccine against respiratory diseases)

IT Respiratory tract
(disease, vaccine against, Pasteurella haemolytica A-1 subunit antigens as)
IT Pilins
RL: BIOL (Biological study)
(fimbrillins, Pasteurella haemolytica A-1, as vaccine against respiratory diseases)
IT Toxins
RL: BIOL (Biological study)
(leuko-, 352, of Pasteurella haemolytica A-1, as vaccine against respiratory diseases)
IT **134476-35-0**
RL: PRP (Properties)
(amino acid sequence of antigenic determinant of leukotoxin, of Pasteurella haemolytica A-1)
IT 9001-90-5, Plasmin
RL: PRP (Properties)
(receptor for, of Pasteurella haemolytica A-1, as vaccine against respiratory diseases)
IT 9031-11-2DP, .beta.-Galactosidase, fusion products with 50K membrane protein or leukotoxin of Pasteurella haemolytica A-1
RL: PREP (Preparation)
(recombinant prepn. of, as vaccine)
IT **134476-35-0**
RL: PRP (Properties)
(amino acid sequence of antigenic determinant of leukotoxin, of Pasteurella haemolytica A-1)
RN 134476-35-0 HCAPLUS
CN Glycine, glycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartylglycylglycyl-L-lysylglycyl-L-asparaginyl-L-.alpha.-aspartyl-L-leucyl-L-leucyl-L-histidylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L90 ANSWER 29 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1990:513688 HCAPLUS
DN 113:113688
TI Immunochemical method for detection of human papillomavirus **antibodies**, peptides useful in the method, and use of the method for diagnosis, especially of cervical carcinoma
IN Dillner, Joakim; Dillner, Lena
PA Medscand AB, Swed.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM G01N033-569
ICS C07K007-08
CC **15-1** (Immunochemistry)
Section cross-reference(s): 10
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9004790	A1	19900503	WO 1989-SE612	19891030 <--

W: AT, AU, BB, BG, BR, CH, DE, DK, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG

AU 8944815	A1	19900514	AU 1989-44815	19891030	<--
AU 639666	B2	19930805			
EP 440700	A1	19910814	EP 1989-911909	19891030	<--
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
JP 04506562	T2	19921112	JP 1989-511118	19891030	<--
JP 3117695	B2	20001218			
AT 100207	E	19940115	AT 1989-911909	19891030	<--
FI 97426	B	19960830	FI 1991-2050	19910426	<--
FI 97426	C	19961210			
US 5629146	A	19970513	US 1991-678974	19910625	<--
PRAI SE 1988-3870	A	19881028 <--			
EP 1989-911909	A	19891030 <--			
WO 1989-SE612	A	19891030 <--			

AB A method is provided for detection of human papillomavirus (HPV) for diagnosis, esp. for diagnosis of carcinoma or pre-stages thereof, or the risk of development of carcinoma. The method relies on detecting the presence of IgA, **IgG**, and IgM **antibodies** against papillomavirus virions in a body fluid, esp. a cervical secretion. The virions include individual virion proteins or peptides thereof. Thus, 66 peptides (20 amino acid residues each) with a 5 residue overlap to each other were synthesized according to the deduced amino acid sequences of the L1 and L2 open reading frames (encoding viral capsid proteins) for HPV16. The peptides were used in an ELISA testing sera from HPV16-carrying cervical neoplasia patients for reactivity with either IgA, **IgG**, or IgM. Reactivity for individual serum samples using individual peptides is shown. The 7 most immunoreactive peptides were also tested for IgA, **IgG**, and IgM reactivity in 60 control serum samples, derived from healthy donors or patients with irrelevant tumors. Most of these peptides showed significant immunoreactivity only with <10% of the control sera.

ST IgA human papillomavirus detection capsid peptide; IgM human papillomavirus detection capsid peptide; **IgG** human papillomavirus detection capsid peptide; cervix carcinoma diagnosis papillomavirus peptide; virus papilloma **antibody** detection capsid peptide

IT Animal tissue
Blood analysis
Body fluid
(papillomavirus-assocd. neoplasm diagnosis in, IgA and IgM and **IgG** to papillomavirus detection in, peptide derived from human papillomavirus 16 capsid protein for)

IT Neoplasm
(papillomavirus-assocd., diagnosis of, IgA and IgM and **IgG** to papillomavirus detection in, peptide derived from human papillomavirus 16 capsid protein for)

IT **Antibodies**
RL: BIOL (Biological study)
(to papillomavirus virion proteins, in neoplasm detection, peptides derived from human papilloma virus capsid protein in relation to)

IT Proteins, specific or class
RL: BIOL (Biological study)
(14,000-mol.-wt., of papillomavirus virion, **antibodies** to, detection of, for neoplasm detection, peptides derived from human papillomavirus capsid protein in relation to)

IT Proteins, specific or class
RL: BIOL (Biological study)
(28,000-mol.-wt., of papillomavirus virion, **antibodies** to, detection of, for neoplasm detection, peptides derived from human papillomavirus capsid protein in relation to)

IT Proteins, specific or class
RL: BIOL (Biological study)
(54,000-mol.-wt., of papillomavirus, IgA to, detection of, for neoplasm detection, peptides derived from human papillomavirus capsid protein in

relation to)
IT Proteins, specific or class
RL: BIOL (Biological study)
(64,000-mol.-wt., of papillomavirus, IgA to, detection of, for neoplasm detection, peptides derived from human papillomavirus capsid protein in relation to)
IT **Immunoglobulins**
RL: BIOL (Biological study)
(A, to papillomavirus proteins, in neoplasm detection, peptides derived from human papillomavirus capsid protein in relation to)
IT **Immunoglobulins**
RL: BIOL (Biological study)
(G, to papillomavirus proteins, in neoplasm detection, peptides derived from human papillomavirus capsid protein in relation to)
IT Proteins, specific or class
RL: BIOL (Biological study)
(L1, peptides derived from, in IgA and IgM and **IgG** to papillomavirus detection for cervical neoplasm diagnosis)
IT Proteins, specific or class
RL: BIOL (Biological study)
(L2, peptides derived from, in IgA and IgM and **IgG** to papillomavirus detection for cervical neoplasm diagnosis)
IT **Immunoglobulins**
RL: BIOL (Biological study)
(M, to papillomavirus proteins, in neoplasm detection, peptides derived from human papillomavirus capsid protein in relation to)
IT Uterus, neoplasm
(cervix, diagnosis of papillomavirus-assocd., peptide derived from human papillomavirus capsid protein for IgA and IgM and **IgG** detection in)
IT Virus, animal
(human papilloma, diagnosis of infection with, detection of IgA and IgM and **IgG** in, capsid-derived peptides for)
IT Virus, animal
(human papilloma 16, capsid protein of, peptides derived from, for detection of IgA and IgM and **IgG** to papillomavirus, cervical neoplasm diagnosis in relation to)
IT Virus, animal
(papilloma, diagnosis of infection with, IgA and **IgG** and IgM detection for, capsid-derived peptides in)
IT 129019-85-8 129019-86-9 129019-87-0 129019-88-1 129019-89-2
129019-90-5 129019-91-6 129019-92-7 129019-93-8 129019-94-9
129019-95-0 129019-96-1 129019-97-2 129019-98-3 129019-99-4
129020-00-4 129020-01-5 129020-02-6 129020-03-7 129020-04-8
129020-05-9 129020-06-0 129020-07-1 129020-08-2 129020-09-3
129020-10-6 129020-11-7 129020-12-8 129020-13-9 129020-14-0
129020-15-1 129020-16-2 129020-17-3 129020-18-4 129020-19-5
129020-20-8 129020-21-9 129020-22-0 **129020-23-1**
129020-24-2 129020-25-3 129020-26-4 129020-27-5 129020-28-6
129020-29-7 129020-30-0 129020-31-1 129020-32-2 129020-33-3
129020-34-4 129020-35-5 129020-36-6 129020-37-7 129020-38-8
129020-39-9 129020-40-2 129020-41-3 129020-42-4 129020-43-5
129045-46-1 129045-47-2 129045-48-3 129045-49-4 129045-50-7
129045-51-8 129045-52-9 129045-53-0
RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence of, peptide derived from human papillomavirus 16 capsid protein, in detection of IgA and **IgG** and IgM to human papillomavirus, for cervical carcinoma diagnosis)
IT **129020-23-1**
RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence of, peptide derived from human papillomavirus 16

capsid protein, in detection of IgA and **IgG** and IgM to human papillomavirus, for cervical carcinoma diagnosis)

RN 129020-23-1 HCAPLUS

CN L-Isoleucine, L-seryl-L-leucyl-L-valyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-threonyl-L-seryl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-alanylglycyl-L-alanyl-L-prolyl-L-threonyl-L-seryl-L-valyl-L-prolyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L90 ANSWER 30 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1990:512010 HCAPLUS
DN 113:112010
TI Polypeptide-induced monoclonal receptors to protein ligands
IN Niman, Henry Lee
PA Progenx, Inc., USA
SO PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM G01N033-53
ICS G01N033-577
CC 9-10 (Biochemical Methods)
Section cross-reference(s): 4, 14, **15**

FAN.CNT 4

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	WO 9001701	A1	19900222		WO 1989-US3403	19890811	<--
	W: JP						
	JP 04500122	T2	19920109		JP 1989-508832	19890811	<--
	AT 160877	E	19971215		AT 1989-308184	19890811	<--
	AU 8939902	A1	19900215		AU 1989-39902	19890814	<--
	AU 632490	B2	19930107				
	US 5786178	A	19980728		US 1994-300068	19940902	<--
	US 5733738	A	19980331		US 1995-418898	19950407	<--
PRAI	US 1988-232395	A	19880812	<--			
	US 1989-393267	A	19890809	<--			
	US 1983-524084	B2	19830817	<--			
	US 1985-701954	A2	19850215	<--			
	US 1985-736545	B1	19850521	<--			
	US 1987-39534	A2	19870416	<--			
	US 1987-118823	B2	19871109	<--			
	WO 1989-US3403	W	19890811	<--			
	US 1991-772702	B1	19911007	<--			
	US 1991-779143	B1	19911021	<--			

US 1992-925815 B1 19920804 <--

AB An assay method is described for the detection of the presence of an oncoprotein ligand in a body sample such as serum, a cell ext., amniotic fluid, urine or a urine conc. which comprises mixing the body sample with an anti-oncoprotein receptor and measuring the formation of a complex. The receptor is a monoclonal mol. raised to polypeptides whose amino acid residue sequences correspond to the sequences of oncoprotein ligands which also binds to the oncoprotein ligand.

ST oncoprotein detection immunoassay monoclonal **antibody**; cancer diagnosis carcinogen immunoassay; fetus sex detn

IT Adenoma
(colorectal, H-ras p21 protein in blood serum of human with)

IT Carcinogens
(detection of exposure to)

IT Neoplasm
(detection of, methods for)

IT Sex
(female, of fetus of humans, detection of)

IT Immunochemical analysis
(for oncoproteins, in biol. samples)

IT **Antibodies**
RL: ANST (Analytical study)
(in oncoproteins detection in biol. samples)

IT Hemocyanins
RL: ANST (Analytical study)
(keyhole limpet, synthetic peptides coupled to, for oncoprotein detection)

IT Peptides, biological studies
RL: BIOL (Biological study)
(monoclonal **antibodies** to, for oncoprotein detection)

IT Receptors
RL: ANST (Analytical study)
(oncogene-encoded, **antibodies** to, for detection of cross-reacting proteins in tissues of humans, diagnosis and carcinogen exposure detection in relation to)

IT Hodgkin's disease
Kidney, neoplasm
Leukemia
Lung, neoplasm
Lymphoma
Melanoma
Myeloma
Ovary, neoplasm
Stomach, neoplasm
Testis, neoplasm
(oncogene-related proteins in urine of humans with)

IT Amniotic fluid
Animal cell
Animal tissue
Blood analysis
Body fluid
Urine analysis
(oncoprotein detection in)

IT Newborn
(oncoprotein detection in, of human)

IT Foundries
(oncoprotein in blood serum of workers in)

IT Pregnancy
(oncoprotein in body fluid of human in)

IT Hybridoma
(prepn. of, for oncoproteins detection)

IT Proteins, specific or class
RL: ANT (Analyte); ANST (Analytical study)

(70,000-mol.-wt., detection of, by immunoassay)
IT Proteins, specific or class
RL: ANST (Analytical study)
(P68gag-v-ros, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(Wnt-1, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(adenylate cyclase-stimulating, guanine nucleotide-binding, Gs, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Animal growth regulators
RL: ANST (Analytical study)
(blood platelet-derived growth factors, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Animal growth regulators
RL: ANST (Analytical study)
(blood platelet-derived growth factors, 1, monoclonal **antibody** to)
IT Animal growth regulators
RL: ANST (Analytical study)
(blood platelet-derived growth factors, 2, monoclonal **antibody** to)
IT Animal growth regulators
RL: ANST (Analytical study)
(blood platelet-derived growth factors, p28v-sis, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Uterus, neoplasm
(cervix, oncogene-related proteins in urine of humans with)
IT **Intestine, neoplasm**
(colon, oncogene-related proteins in urine of humans with)
IT Glycophosphoproteins
RL: ANST (Analytical study)
(colony-stimulating factor 1-binding, gene c-fms, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Embryo
(fetus, female, detection of, of humans)
IT Phosphoproteins
RL: ANST (Analytical study)
(gene L-myc, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(gene A-raf, **antibodies** to, for detection of immunol. cross-reacting proteins in tissues and urine of humans, diagnosis and carcinogen exposure detection in relation to)
IT Phosphoproteins
RL: ANST (Analytical study)
(gene N-myc, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Phosphoproteins
RL: ANST (Analytical study)
(gene c-abl, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Glycophosphoproteins
RL: ANST (Analytical study)
(gene c-erbB2, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(gene c-fgr, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Ribonucleic acid formation factors
RL: ANST (Analytical study)
(gene c-fos, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(gene c-fps, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(gene c-mos, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Phosphoproteins
RL: ANST (Analytical study)
(gene c-myc, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Phosphoproteins
RL: ANST (Analytical study)
(gene c-raf, **antibodies** to, for detection of immunol. cross-reacting proteins in tissues and urine of humans, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(gene c-ros, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(gene c-src, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(gene c-syn, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)
IT Proteins, specific or class
RL: ANST (Analytical study)
(gene gag, **antibodies** to, for detection of immunol. cross-reacting proteins in tissues and urine of humans, diagnosis and carcinogen exposure detection in relation to)
IT Phosphoproteins
RL: ANST (Analytical study)
(gene met, **antibodies** to, for detection of immunol.

cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene pim-1, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-abl, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Glycophosphoproteins
RL: ANST (Analytical study)
(gene v-erbB, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-erbA, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-fes, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANT (Analyte); ANST (Analytical study)
(gene v-fgr, detection of, by immunoassay)

IT Glycoproteins, specific or class
RL: ANST (Analytical study)
(gene v-fms, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-kit, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-mil, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-mos, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-raf, **antibodies** to, for detection of immunol. cross-reacting proteins in tissues and urine of humans, diagnosis and carcinogen exposure detection in relation to)

IT Ribonucleic acid formation factors
RL: ANST (Analytical study)
(gene v-rel, **antibodies** to, for detection of immunol. cross-reacting proteins in tissues and urine of humans, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-src, **antibodies** to, for detection of immunol.

cross-reacting proteins in tissues and urine of humans, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(gene v-yes, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Immunochemical analysis
(immunoblotting, for oncoproteins, in biol. samples)

IT **Antibodies**
RL: ANST (Analytical study)
(monoclonal, in oncoproteins detection in biol. samples)

IT Bladder
Mammary gland
Prostate gland
(neoplasm, oncogene-related proteins in urine of humans with)

IT Lipoproteins
RL: ANST (Analytical study)
(p21c-Ha-ras1, 12-valine-, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Lipoproteins
RL: ANST (Analytical study)
(p21N-ras, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Phospholipoproteins
RL: ANST (Analytical study)
(p21v-Ha-ras, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Phospholipoproteins
RL: ANST (Analytical study)
(p21v-Ki-ras, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Ribonucleic acid formation factors
RL: ANST (Analytical study)
(p48v-myb, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANST (Analytical study)
(p85gag-v-fes, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Aromatic hydrocarbons, biological studies
RL: BIOL (Biological study)
(polycyclic, oncoprotein in blood serum of human exposed to)

IT Lipoproteins
RL: ANST (Analytical study)
(transducins, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT Proteins, specific or class
RL: ANT (Analyte); ANST (Analytical study)
(transforming, detection of, in biol. samples)

IT Animal growth regulators
RL: ANST (Analytical study)
(.beta.-transforming growth factors, **antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT 9001-88-1 51845-53-5 70431-11-7 80449-02-1

RL: ANST (Analytical study)
(**antibodies** to, for detection of immunol. cross-reacting proteins in urine and tissues of human, diagnosis and carcinogen exposure detection in relation to)

IT 62229-50-9, Epidermal growth factor
RL: ANT (Analyte); ANST (Analytical study)
(detection of, in body fluids of humans)

IT 87171-12-8 96425-34-2 97288-18-1 97288-19-2 97288-20-5
97288-21-6 97288-22-7 97288-23-8 97288-24-9 97288-25-0
97288-26-1 97288-27-2 97288-28-3 97288-29-4 97288-30-7
97288-32-9 97288-33-0 97288-36-3 97288-37-4 97288-42-1
97288-44-3 97288-45-4 97288-46-5 97288-47-6 97288-48-7
97307-80-7 97307-81-8 97307-83-0 97307-84-1 97307-85-2
100008-26-2 124676-43-3 126704-86-7 126704-87-8 126704-88-9
126704-89-0 126704-90-3 126704-91-4 126704-92-5 126704-93-6
126704-94-7 126704-95-8 126704-96-9 126704-97-0 126704-98-1
126704-99-2 126705-00-8 126705-01-9 126705-02-0 126705-03-1
126705-04-2 126705-05-3 126705-06-4 126705-07-5 126733-66-2
126733-67-3 126733-68-4 126777-53-5 129016-42-8 129016-43-9
129016-44-0 129016-45-1 129016-46-2 129016-47-3 129016-48-4
129016-49-5 129016-50-8 129016-51-9 129016-52-0 129016-53-1
129016-54-2 129016-55-3 129016-56-4 129016-57-5 129016-58-6
129016-59-7 129016-60-0 129016-61-1 129016-62-2 129016-63-3
129016-64-4 129016-65-5 129016-66-6 129016-67-7 129016-68-8
129016-69-9 129016-70-2 129016-71-3 129016-72-4 129016-73-5
129016-74-6 129016-75-7 129016-76-8 129016-77-9 129016-78-0
129016-79-1 129016-80-4 129016-81-5 129016-82-6 129016-83-7
129016-84-8 129016-85-9 129016-86-0 129016-87-1 129016-88-2
129016-89-3 129016-90-6 129016-91-7 129016-92-8 129016-93-9
129016-94-0 129016-95-1 129016-96-2 129016-97-3 129016-98-4
129016-99-5 129017-00-1 129017-01-2 129017-02-3 129017-03-4
129017-04-5 129017-05-6 129017-06-7 129017-07-8 129017-08-9
129017-09-0 129017-10-3 129017-11-4 129017-12-5 129017-13-6
129017-14-7 129017-15-8 129017-16-9 129017-17-0 129017-18-1
129017-19-2 129017-20-5 129017-21-6 129017-22-7 129017-23-8
129017-24-9 129017-25-0 129017-26-1 129017-27-2 129017-28-3
129017-29-4 129017-30-7 129017-31-8 129017-32-9 129017-33-0
129017-34-1 129017-35-2 129017-36-3 129017-37-4
129017-38-5 129017-39-6 129017-40-9 129017-41-0 129017-42-1
129017-43-2 129017-44-3 129017-45-4 129017-46-5 129017-47-6
129017-48-7 129017-49-8 129017-50-1 129017-51-2 129017-52-3
129017-53-4 129017-54-5 129017-55-6 129017-56-7 129017-57-8
129017-58-9 129017-59-0 129017-60-3 129017-61-4 129017-62-5
129017-63-6 129017-64-7 129017-65-8 129017-66-9 129044-58-2
129044-59-3 129044-60-6 129044-61-7 129044-62-8 129044-63-9
129044-64-0 129044-65-1 129044-66-2 129044-67-3 129044-68-4
129044-69-5 129044-70-8 129044-71-9 129044-72-0 129044-73-1
129044-74-2 129044-75-3 129044-76-4 129044-77-5 129044-78-6
129044-79-7 129044-80-0 129044-81-1
RL: BIOL (Biological study)
(in hybridoma prepn. for oncoprotein detn. in biol. samples)

IT 92-52-4D, 1,1'-Biphenyl, chloro derivs.
RL: ANST (Analytical study)
(serum screening of workers exposed to)

IT **129017-34-1**
RL: BIOL (Biological study)
(in hybridoma prepn. for oncoprotein detn. in biol. samples)

RN 129017-34-1 HCAPLUS

CN L-Lysine, L-lysyl-L-phenylalanyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-threonyl-L-seryl-L-isoleucyl-L-isoleucyl-L-leucyl-L-phenylalanyl-L-leucyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A

PAGE 2-B



L90 ANSWER 31 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1989:587854 HCAPLUS

DN 111:187854
TI Processing of thyrotropin-releasing hormone prohormone (pro-TRH) in the adult rat pancreas: identification and localization of pro-TRH-related peptides in .beta.-cells of pancreatic islets
AU Leduque, Patrick; Bulant, Marc; Dubois, Paul M.; Nicolas, Pierre; Vaudry, Hubert
CS Lab. Endocrinol. Mol., Univ. Rouen, Mont-Saint-Aignan, 76134, Fr.
SO Endocrinology (**1989**), 125(3), 1492-7
CODEN: ENDOAO; ISSN: 0013-7227
DT Journal
LA English
CC 2-5 (Mammalian Hormones)
AB Rat TRH prohormone (pro-TRH) contains 5 sep. copies of the TRH progenitor sequence, Gln-His-Pro-Gly. All 5 sequences are flanked by paired basic amino acid cleavage sites and linked together by connecting sequences. RIAs to synthetic TRH and prepro-TRH-(178-199) were used to investigate pro-TRH processing in the endocrine pancreas of adult rats. HPLC anal. of adult rat pancreatic exts. showed the presence of a major immunoreactive peptide eluting at the position of prepro-TRH-(178-199). An addnl. peak coeulting with [<Glu172]prepro-TRH-(172-199) (<Glu = pyroglutamyl) revealed the presence of a C-terminally extended form of TRH. Quantification of TRH in pancreatic exts. indicated the presence of 22 mol TRH/mol prepro-TRH-(178-199) and 17 mol TRH/mol [<Glu172]prepro-TRH-(172-199). Treatment of rats with streptozotocin markedly reduced the pancreatic content of both immunoreactive TRH (-84%) and immunoreactive prepro-TRH-(178-199) (-62%). Light microscopic immunocytochem. showed that prepro-TRH-(178-199)-like immunoreactivity was exclusively located within insulin-contg. cells of the pancreatic islets. At the electron microscopic level, prepro-TRH-(178-199) immunoreactivity appeared to be concd. in secretory granules. Apparently, processing of pro-TRH generates both non-TRH- and TRH-related peptides in the adult rat pancreas, and .beta.-cells of the endocrine pancreas are the major source of TRH- and pro-TRH-derived peptides.
ST TRH prohormone metab pancreas; pancreatic islet beta proTRH peptide
IT **Pancreatic islet of Langerhans**
(.beta.-cell, pro-TRH-related peptides of, localization of)
IT **122018-92-2 123404-49-9**
RL: BIOL (Biological study)
(as pro-TRH metabolite, of pancreatic islet .beta.-cells)
IT 24305-27-9, TRH
RL: PROC (Process)
(of pancreatic islet .beta.-cells, localization of)
IT 98616-54-7
RL: BIOL (Biological study)
(peptides formation from, in pancreatic islet .beta.-cells)
IT **122018-92-2 123404-49-9**
RL: BIOL (Biological study)
(as pro-TRH metabolite, of pancreatic islet .beta.-cells)
RN 122018-92-2 HCAPLUS
CN L-Glutamic acid, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-tryptophyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-lysyl-L-.alpha.-glutamylglycyl-L-.alpha.-glutamylglycyl-L-valyl-L-leucyl-L-methionyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

CO_2H

RN 123404-49-9 HCAPLUS
CN L-Glutamic acid, 5-oxo-L-prolyl-L-histidyl-L-prolylglycyl-L-arginyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-tryptophyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-lysyl-L-.alpha.-glutamylglycyl-L-.alpha.-glutamylglycyl-L-valyl-L-leucyl-L-methionyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



L90 ANSWER 32 OF 32 HCAPLUS COPYRIGHT 2003 ACS
AN 1989:490746 HCAPLUS
DN 111:90746
TI Pro-TRH-connecting peptides in the rat pancreas during ontogenesis
AU Dutour, Anne; Bulant, Marc; Giraud, Pierre; Nicolas, Pierre; Vaudry, Hubert; Oliver, Charles
CS Lab. Neuroendocrinol. Exp., Fac. Med. Nord, Marseille, 13326, Fr.
SO Peptides (New York, NY, United States) (**1989**), 10(3), 523-7
CODEN: PPTDD5; ISSN: 0196-9781
DT Journal
LA English
CC 2-5 (Mammalian Hormones)
AB Rat TRH prohormone (pro-TRH) is a protein contg. 5 copies of TRH, sepd. by connecting peptides. RIAs to synthetic peptides corresponding to prepro-TRH(160-169) and prepro-TRH(178-199) were used to investigate the ontogenesis of pro-TRH-derived peptides in the rat pancreas. Reverse-phase HPLC anal. of pancreatic exts. from 2-day-old rats showed the presence of 2 major immunoreactive peptides exhibiting the same retention time as synthetic prepro-TRH(160-169) and prepro-TRH(178-199). The concns. of TRH and pro-TRH cryptic peptides in the rat pancreas rose rapidly after birth, reached a max. at day 2-4, and decreased gradually afterwards. Streptozotocin treatment of newborn rats induced a marked decrease of TRH (96%), prepro-TRH(160-169) (97%), and prepro-TRH(178-199) (94%) content in pancreatic exts. Apparently, the evolution of TRH and pro-TRH-derived peptides follows the same pattern during the postnatal period. In addn. .beta.-cells are probably the only source of

pro-TRH-derived peptides in the rat pancreas.
ST pancreas TRH prohormone development; beta cell pancreas TRH prohormone
IT Development, mammalian
(TRH prohormone of pancreas in)
IT **Pancreatic islet of Langerhans**
(.beta.-cell, TRH prohormone-derived peptides of)
IT 24305-27-9, TRH
RL: BIOL (Biological study)
(of pancreas, in development)
IT 122018-91-1 **122018-92-2**
RL: BIOL (Biological study)
(of pancreas, in development, TRH in relation to)
IT **122018-92-2**
RL: BIOL (Biological study)
(of pancreas, in development, TRH in relation to)
RN 122018-92-2 HCAPLUS
CN L-Glutamic acid, L-phenylalanyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-tryptophyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-lysyl-L-.alpha.-glutamylglycyl-L-.alpha.-glutamylglycyl-L-valyl-L-leucyl-L-methionyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D